Studies on cyclic AMP phosphodiesterases by Erdogan, Suat
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
STUDIES ON CYCLIC AMP 
PHOSPHODIESTERASES
A thesis subm itted  to the University of Glasgow 
for the degree of D octor of Philosophy in 
the Faculty  of Science
by
SUAT ERDOGAN BVSc, MSc
Division of B iochem istry and  M olecular Biology 
Institu te  of Biomedical and  Life Science (IBLS) 
U niversity  of Glasgow
A ugust 1997
© Suat Erdogaii
ProQuest Number: 10391366
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10391366
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
s
I
This thesis is dedicated to
my parents
CONTENTS
List of Tables 
List o f Figures 
List of Abbreviations 
A cknow ledgem ents 
Abstract
Page
viii
ix
x iii
x v i
xvii
CHAPTER 1 
INTRODUCTION 1-54
1
1.1
1,1.2
1.1.3
1.1.4
1.1.5
1 . 1.6 
1.1.7
Introduction 1
Adenosine-3',5'-cyclic monophosphate (cAMP) signalling 2 
Generation of cAMP 2
G-proteins 4
Adenylate cyclases 5
cAMP-dependent protein kinase 8
Protein kinase A anchoring proteins 9
The nuclear response to cAMP 10
1.2 The effects of cAMP in the immune system 11
1.3
1.3.1
1.3.2
1.3.3
1.3.4
1.3.5
The effects of cAMP in various systems
cAMP in the central neiTous system (CNS)
cAMP in platelets
cAMP in the heart
cAMP in smooth muscle
cAMP as a hormonal second messenger
14
14
14
15
15
16
1.4 Degradation of cAMP 17
1.5 Cyclic nucleotide phosphodiesterases (PDEs)
1.5.1 Nomenclature
1.5.2 Primary structure of PDEs
1.5.3 PDE1 : Ca2+ /  calmodulin-stimulated PDEs
1.5.4 PDE2: cyclic GMP-stimulated PDEs (cGS-PDE)
1.5.6 PDE3: cyclic GMP-inhibited PDEs (cGI-PDE)
1.5.7 PDE4: cyclic AMP-specific PDEs (cAMP PDE)
1.5.7.1 Background
17
20
20
22
25
27
30
30
ui
1.5.7.2 Molecular cloning of PDE4 isoforms 32
1.5.7.3 The structural features of the PDE4 isoforms 32
1.5.7.4 PDE4A 36
1.5.7.5 PDE4B 41
1.5.7.6 PDE4C 43
1.5.7.7 PDE4D 44
1.5.7.8 Regulation of PDE4 enzymes 45
1.5.7.9 Phosphorylation of PDE4 isoforms 45
1.5.7.10 Regulation of PDE4 expression 46
1.5.7.11 Regulation of PDE4 by phosphatidic acid 47
1.5.7.12 Interaction of PDE4 with SH3 domains 48
1.5.7.13 Therapeutic role of PDE4 inhibitors 49
1.5.8 PDE5: cyclic GMP-specific PDEs (cGMP PDE) 50
1.5.9 PDE6: photoreceptor PDEs 52
1.5.10 PDE7 : cAMP-specifîc rolipram-insensitive PDEs 5 3
CHAPTER 2
MATERIAL AND METHODS 55-86
2.1 Materials 56
2.1.1 Radiochemicals 5 6
2.1.2 Tissue culture plastic ware 56
2.1.3 Tissue culture medium 56
2.1.4 General reagents 57
2.1.4.1 Chemical compounds 57
2.1.4.2 Biochemical reagents 58
2.1.5 Molecular Biology reagents 60
2.1.6 Equipment 60
2.1.7 Cell lines 61
2.1.7.1 COS7 cells 61
2.1.7.2 Human leukaemic T-cell line Jurkat (J6) 61
2.2 Methods 62
2.2.1 Treatment of Jurkat T-cells with vehicles 62
2.2.1.1 Deteimination of cell number and viability 62
2.2.1.2 Cell lysis and homogenisation of Jurkat T-cells 63
2.2.2 Antibody preparation 64
2.2.3 SDS-PAGE electrophoresis 64
IV
j:,|
 : -Mnt
2.2.4 Western blotting 65
2.2.5 Cyclic AMP phosphodiesterase assay 66
2.2.5.1 Preparation of reagents 68
2.2.5.2 Assay procedure 69
2.2.5.3 Calculation of specific activities 69
2.2.6 Determination of kinetic constants 70
2.2.7 Determination of IC50 values 70
2.2.8 Relative Fmax determinations 71
2.2.9 Cyclic AMP determination 71
2.2.9.1 Assay principle 71
2.2.9.2 Preparation of cyclic AMP binding protein 72
2.2.9.3 Assessing intracellular cAMP concentrations 72
2.2.9.4 Preparation of reagents for assay 73
2.2.9.5 Assay procedure 73
2.2.10 Protein determination 74
2.2.11 Immunoprécipitation 75
2.2.12 Expression of the PDE cDNAs in COS7 cells 75
2.2.12.1 DEAE dextran method of transient transfection 75
2.2.12.2 Disruption of transfected COS7 cells 76
2.2.12.3 Subcellular fractionation 76
2.2.12.4 Treatment of membranes with high salt concentration 77
2.2.12.5 Solubilisation of membranes with Triton X-100 77
2.2.13 Lactate dehydrogenase assay 77
2.2.14 Precipitation of oligonucleotides 78
2.2.14.1 Quantitation of oligonucleotides 78
2.2.15 RNA extraction by Tri-Reagent 79
2.2.15.1 Determination of RNA concentration 80
2.2.16 First-strand cDNA synthesis 80
2.2.17 The Polymerase Chain Reaction (PCR) 80
2.2.18 Agarose gel electrophoresis 81
2.2.19 Purification of DNA from PCR products 81
2.2.20 Competent cell preparation 82
2.2.21 Transformation of plasmid vector into competent cells 83
2.2.22 Storage of E. coli cells 83
2.2.23 Plasmid DNA purification 83
2.2.24 Estimation of DNA concentration 84
2.2.25 S torage of plasmid DN A 85
2.2.26 Analysis of data and statistics 85
CHAPTER 3
INVESTIGATION OF TH E EFFECT OF cAMP 
ELEVATING AGENTS ON PHOSPHODIESTERASE 
A CTIV ITIES IN HUMAN JU RK A T T-CELLS 87-147
3.1 Introduction 88
3.1.1 Aim of the study 93
3.2 Results 93
3.2.1 Characterisation of the phosphodiesterase isoforms of
Jurkat T-cells 93
3.2.2 Effect of cyclic AMP-elevating agents on phosphodiesterases
of Jurkat T-cells 97
3.2.3. Determination of PDE4 subtype gene expressions and the
effect of elevated cyclic AMP 102
3.3 Conclusions and Discussion 107
CHAPTER 4
CHARACTERISATION OF FIVE HUMAN PDE4D 
ISO FO RM S 148-195
4.1 Introduction 149
4.1.1 Aim of the study 151
4.2 Results 151
4.2.1 Expression and subcellular distribution of human
PDE4D1, PDE4D2, PDE4D3, PDE4D4 andPDE4D5 
cDNAs in COS7 cells 151
4.2.2 Immunological detection of human PDE4D1, PDE4D2, 
PDE4D3, PDE4D4 and PDE4D5 cDNAs expressed in
COS7 cells 152
4.2.3 Solubilisation of particulate fractions of the human 
PDE4D3, PDE4D4 and PDE4D5 by Triton X-100
andNaCl 154
4.2.4 Kinetics of cAMP hydrolysis by five human PDE4D
isoforms 154
VI
4.2.5 Inhibition of particulate and cytosolic forms of the five
human PDE4D enzymes by rolipram 156
4.3. Conclusion and Discussion 157
CHAPTER 5
ANALYSIS OF CH IM ERIC SPECIES FORM ED BETW EEN 
N- AND C-TERM INAL REG IO N  OF INACTIVE HUMAN 
PDE4A SPLIC E VARIANT 2EL 196-217
5.1 Introduction 197
5.1.2 Aim of the study 200
5.2. Results 200
5.2.1 Sequence alignments of 2EL, HYB1, HYB2, Delta-1,
PDE46 and h6.1 200
5.2.2. Expression and subcellular distribution of HYB 1, HYB2,
Delta-1 cDNAs in COS7 cells 201
5.2.3 Immunological detection of HYB 1 and Delta-1 202
5.2.4 Transcriptional analysis of HYB 1 and HYB2 chimeras 203
5.2.5 Kinetics of cAMP hydrolysis by HYB 1 203
5.2.6 Dose-dependent inhibition of HYB 1 by rolipram 204
5.3 Conclusion and Discussion 205
CHAPTER 6
FIN A L D ISCU SSIO N  218-227
R E FE R E N C E S 228-246
PU B L IC A T IO N S 247
vn
LIST OF TABLES
Table 1.1 Cyclic nucleotide phosphodiesterase families and their
properties 19
Table 1.2 Properties of PDE4 enzymes expressed in various
tissues 37
Table 3.1 Assessment of cAMP phosphodiesterase activities in
Jurkat T-cells 111
Table 3.2 The effect of actinomycin D on the increase in Jurkat
T-cell PDE3 and PDE4 activities induced upon activation 
of adenylate cyclase by forskolin and cholera toxin 112
T able 3.3 The enhancement of forskolin-stimulated cAMP
accumulation in Jurkat T-cells by PDE inhibitors 113
Table 3.4 Summary of forskolin mediated induction of PDE4
splice variants 114
Table 4.1 cDNA clones corresponding to transcripts from the
human PDE4D isoforms 161
Table 4,2 Subcellular distribution of human PDE4D activities,
as expressed in COS7 cells 162
Table 4.3 Properties of human PDE4D proteins expressed in
COS7 cells 163
Table 4.4 Solubilisation of membrane-associated human PDE4D
proteins by detergents or high salt concentrations 164
Table 4.5 Xm values for cAMP for human PDE4D isoforms
transfected in COS 7 cells 165
Table 4.6 Fmax values for cAMP for human PDE4D isoforms
transfected in COS7 cells 166
Table 4.7 Inhibition of human PDE4D isoforms from COS7
transfected cells by rolipram 167
Table 4.8 Hill coefficients for the inhibition of human PDE4D
isofoims by rolipram 168
Table 5.1 The human PDE4A splice variants 208
Table 5.2 Properties of the chimeric PDE4A species HYB 1 209
vni
LIST OF FIGURES
Figure 1.1
Figure 1.2
Figure 1.3 
Figure 1.4
Figure 2.1
Figure 2.2 
Figure 3.1
Figure 3.2
Figure 3.3
Figure 3.4
Figure 3.5
Figure 3.6
Figure 3.7
Figure 3.8
Figure 3.9 
Figure 3.10 
Figure 3.11 
Figure 3.12
Figure 3.13 
Figure 3.14 
Figure 3.15 
Figure 3.16 
Figure 3.17
Diagram illustrating the synthesis of cAMP by adenylate 
cyclase and its degradation by cAMP phosphodiesterase 3
Schematic representation of cyclic nucleotide 
phosphodiesterases (PDEs) 21
Schematic structure of fuU-lenght human PDE4 forms 33
Sequence alignment of four human PDE4 family 
enzymes 35
The principle of the cyclic AMP phosphodiesterase 
assay 67
Standard cui’ve for a Bradford protein assay 86
RT-PCR analysis of PDE 1 'generic' transcripts in 
Jurkat T-cells 115
Alignment of PDEl transcript RT-PCR products from 
human Jurkat T-cells 116
Identification of PDE3 activity in Jurkat T cells:
Inhibition by cGMP 117
Identification of PDE3 activity in Jurkat T cells:
Inhibition by cilostimide 118
Identification of PDE2 activity in Jurkat T cells:
Inhibition by EHNA 119
Identification of PDE4 activity in Jurkat T cells:
Inhibition by rolipram 120
The effect of forskolin on the accumulation of 
intracellular cAMP concentrations in Jurkat T-cells 121
Time course of total PDE activity in the presence 
of forskolin 122
Time course of cholera toxin activated total PDE activity 123 
Time course of forskolin activated PDEl activity 124
Time course of forskolin activated PDE2 activity 125
Time course of forskolin activated PDE3 activity 
over first two hours 126
Time course of forskolin activated PDE3 activity 127
Time course of forskolin activated PDE4 activity 128
Time course of cholera toxin activated PDE3 activity 129
Time course of cholera toxin activated PDE4 activity 130
Total PDE activity in the Jurkat T-cell line upon 
stimulation with anti-CD3 antibodies 131
IX
F igure 3.18 Time course of total PDE and PDE4 activities in the
presence of PHA 132
F igure  3.19 Time course of total PDE and PDEl activities in the
presence of PMA 133
F igure 3.20 Schematic representation of primers used to analyse
human PDE4 transcripts by RT-PCR 134
F igure  3.21 RT-PCR analysis of hormone effects on PDE4A
'generic' transcripts in Jurkat T-cells 135
F igure  3.22 RT-PCR analysis of hormone effects on PDE4D
'generic' transcripts in Jurkat T-cells 136
F igure  3.23 RT-PCR analysis of hormone effects on PDE4B
'generic' transcripts in Jurkat T-cells 137
F igure  3.24 RT-PCR analysis of hormone effects on PDE4C
'generic' transcripts in Jurkat T-cells 138
F igure  3.25 RT-PCR analysis of Jurkat T-cells using PDE4B1,
PDE4B2 and PDE4B3 specific primers 139
F igure  3.26 Immunoblot analysis of PDE4A immunoreactivity
in Jurkat T-cells 140
F igure  3.27 RT-PCR analysis of Jurkat T-cells using PDE46
specific primers 141
F igure  3.28 RT-PCR analysis of Jurkat T-cells using PDE4D3
specific primers 142
F igure  3.29 RT-PCR analysis of Jurkat T-cells using PDE4D4
specific primers 143
F igure 3.30 RT-PCR analysis of Jurkat T-cells using PDE4D5
specific primers 144
F igure 3.31 RT-PCR analysis of Jurkat T-cells using PDE4D1
specific primers 145
F igure  3.32 RT-PCR analysis of Jurkat T-cells using PDE4D1/2
specific primers 146
F igure  3.33 Immunoblot analysis of PDE4D immunoreactivity in
Jurkat T-ceUs 147
F igure  4.1 Alignment of the amino acid sequences of the human
PDE4D isoforms 169
F igure  4.2 Linearity of detection of various cytosolic PDE4D
proteins 170
F igure  4.3 Linearity of detection of various membrane PDE4D
proteins 171
XI
Figure  4.4 Immunoblotting of COS7 cells transfected with the
cDNA for human PDE4D1 172
F igu re  4.5 Immunoblotting of COS7 cells transfected with the
cDNA for human PDE4D2 173
F igu re  4.6 Immunoblotting of COS7 cells transfected with the
cDNA for human PDE4D3 174
F igu re  4.7 Immunoblotting of COS7 cells transfected with the
cDNA for human PDE4D4 175
F igu re  4.8 Immunoblotting of COS7 cells transfected with the
cDNA for human PDE4D5 176
F igure  4.9 Solubilisation of human PDE4D5 protein from
membranes using high salt and non-ionic detergent 
treatments 177
F igu re  4.10 Solubilisation of human PDE4D3 protein from
membranes using high salt and non-ionic detergent 
reatments 178
F igu re  4.11 Solubilisation of human PDE4D4 protein from
membranes using high salt and non-ionic detergent 
treatments 179
F igure  4.12 Effect of cAMP concentration on the velocity of
soluble hPDE4D 1 activity 180
F igu re  4.13 Effect of cAMP concentration on the velocity of
soluble hPDE4D2 activity 181
F igu re  4.14 Effect of cAMP concentration on the velocity of
soluble hPDE4D3 activity 182
F igure  4.15 Effect of cAMP concentration on the velocity of
soluble hPDE4D4 activity 183
F igure  4.16 Effect of cAMP concentration on the velocity of
soluble hPDE4D5 activity 184
F igure  4.17 Effect of cAMP concentration on the velocity of
particulate hPDE4D3 activity 185
F igu re  4.18 Effect of cAMP concentration on the velocity of
particulate hPDE4D4 activity 186
F igu re  4.19 Effect of cAMP concentration on the velocity of
particulate hPDE4D5 activity 187
F igure  4.20 Dose-dependent inhibition of soluble hPDE4Dl
activity by rolipram 188
F igure  4.21 Dose-dependent inhibition of soluble hPDE4D2
activity by rolipram 189
ÿ.
■
Figure 4.22
Figure 4.23
Figure 4.24
Figure 4.25
Figure 4.26
Figure 4.27
Figure 5.1
Figure 5.2
Figure 5.3
Figure 5.4 
Figure 5.5 
Figure 5.6 
Figure 5.7
Figure
Dose-response curve for the inhibition of soluble 
hPDE4D3 activity by rolipram 190
Dose-response curve for the inhibition of soluble 
hPDE4D4 activity by rolipram 191
Dose-response curve for the inhibition of soluble 
hPDE4D5 activity by rolipram 192
Dose-response curve for the inhibition of particulate 
hPDE4D3 activity by rolipram 193
Dose-response curve for the inhibition of particulate 
hPDE4D4 activity by rolipram 194
Dose-response curve for the inhibition of particulate 
hPDE4D5 activity by rolipram 195
Alignment of the amino acid sequences of PDE46, 
h6.1 ,2EL, HYB 1, HYB2 and Delta-1 210
Schematic representation of human PDE4A forms,
HYB 1 and HYB2 chimeras and Delta-1 truncated forms 211 
Immunoblot of HYB 1 and Delta-1 expressed in 
COS7 cells 212
Transcriptional analysis of HYB 1 chimera by RT-PCR 213
Transcriptional analysis of HYB2 chimera by RT-PCR 214
Determination of for the cytosolic HYBl fraction 215
Linearty of detection of vaiious concentrations of 
cytosolic h6.1 and HYB 1 216
Dose-response curve for the inhibition of cytosolic 
HYBl activity by rolipram 217
xu
LIST OF ABBREVIATIONS
^60
AKAP
ATF
ATP
BSA
[Ca2+li
CaM
CaMPK
cAMP
CAT
cDNA
cGMP
CHO
Cilostimide
C-terminal
CRE
CREB
CREM
DMSG
DNA
DTP
EDTA
EGTA
EHNA
ERK
FBS
FSEl
GDP
g
gav
Gi
Gs
G-protein
GST
absorbance at 260 nm 
PKA anchor proteins 
activation transcription factor 
adenosine trisphosphate 
bovine serum albumin 
intaceUular calcium concentration 
degrees celcius 
calmodulin
calmodulin-dependent protein kinase 
adenosine-3*,5'-cyclic monophosphate 
chloramphenicol acetyl transferase 
complementary deoxyribonucleic acid 
guanosine-3',5'-cyclic monophosphate 
Chinese hamster ovary ceU line
[4,5-dihydro-6[4-( IH-imadazol-1-yl)phenyl]-5-methyl
3(2H)-pyrazone]
carboxy-terminal of a protein
cAMP response element
cAMP response element binding protein
cAMP response element modulator
dimethyl sulphoxide
deoxyribonucleic acid
dithiothreitol
ethylenediaminetetra-acetic acid
ethylene glycolbis((3-aminoethylether)-N,N,N',N'-
tetra-acetic acid
erythro-9-(2“hydroxy-3-nonyl)-adenine 
Extracellular signal regulated kinase 
foetal bovine serum 
follicle stimulating hormone 
guanosine diphosphate 
gram
average gravitational force 
inhibitory G-protein to adenylate cyclase activity 
stimulatory G-protein to adenylate cyclase activity 
GTP binding protein 
glutathione S-transferase
xm
I
I
ÎI
:
GTP guanine trisphosphate
h6 .1 human PDE4A
h hour
Hepes N"2-Hydroxyethylpiperazine~N'"2“ethane"Sulphonic acid
EBMX l-isobutylmethyl-3-xanthine
IC50 concentration at which 50 % inhibition ensues
IL interleukin
kDa kilodaltons
Kia Michaelis constant, equal to the substrate concentration at
which the reaction rate is half the maximum value 
LH l/2 Linker Region 1/2
MAPK mitogen-activated protein kinase
Milrinone [ 1,6-Dihydro-2-methyl-6-oxo- (3,4’-bipyridine)-5-carbonitrile]
mg milligram
min minute
ml millilitre
NF-AT nuclear factor of activated T cells
N-terminus amino terminus of protein 
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PCR polymerase chain reaction
PDE phosphodiesterase
pH -logioCHi
PHA phytohaemagglutinin
PI3K phosphatidylinositol-3'-kinase
PKA protein kinase A
PKC protein kinase C
PKG cGMP dependent protein kinase
PMA phorbol- 12-myristate, 13-acetate
PMSF phenylmethylsulphonylfluoride
PTK protein tyrosine kinase
RDI rat i/w/îce-like 1 (PDE4A)
RNA ribonucleic acid
Ro 20-1724 [4-(Butoxy-4-methoxybenzyl)-2“imidazolidinone]
Rolipram [4- {3-(cyclopentoxyl)-4-methoxyphenyl} -2-pyiTolidone]
RT-PCR reverse transcriptase-polymerase chain reaction
s second
SD standard deviation
SDS sodium dodecyl sulphate
XIV
SH2/3 Src homology domain 2/3
TBS Tris buffered saline
TCR T cell antigen receptor
TEA txiethanolamine
TEMED N,N,N’,N’-tetramethylethylene diamine
TPA 12-O-tetradecanoylphorbol 13-acetate
Tris Tris (hydroxymethy l)methylamine
T N Fa tumor necrosis factor-alpha
TSH thyroid stimulating hormone
V volts
Vmax maximum reaction rate
UCRl/2 Upstream Conserved Region 1/2
XV
ACKNOW LEDGEM ENTS
I would like to express my sincere thanks to my supervisors, Professor Miles 
Houslay and Dr. Margaret Harnett, for their generous support, understanding, 
patience and friendly supervision throughout the course of this study and for their 
constructive comments and criticism in the preparation of this thesis. I am giateful 
to Professors Gordon Lindsay and Charles Fewson for allowing me to work in the 
the Division of Biochemistry and Molecular Biology for the use of their facilities 
throughout my period of study. Many thanks also to The Mustafa Kemal 
University in Turkey for financial support, without their help this study would 
never have been possible.
I am indebted to all the members of the 'Gardiner Lab' who have helped me in any 
way during my PhD,
My appreciation is also extended to Drs. Sandra Spence and Moira Wilson for their 
friendship and giving up their valuable time to read this thesis.
I am grateful to the Medical Illustrations Unit for the preparation of a poster 
demonstration and slides used for presentations.
I am totally indebted to my wife Dr. Zeynep Erdogan for her support and tolerance 
and my two sons Emre (<1) and F. Mert (3V2) who both were born during this 
study.
My final thanks go to my parents, brother and sisters in Turkey for their moral 
support and understanding over the past three years.
XVI
ABSTRACT
The second messenger cyclic AMP plays a pivotal role in the control of cell 
function through the transduction of extracellular signals into inti'acellular 
activation. However, this cyclic nucleotide negatively modulates the synthesis and 
release of inflammatory mediators and the proliferation of lymphocytes. The sole 
mechanism for degradation of cAMP is achieved through the action of cyclic AMP 
phosphodiesterses (PDEs). This activity is provided by a multigene family which 
produces a variety of enzymes. The PDE4 isoforms appear to be the predominant 
cAMP-metabolising enzymes in essentially aU pro-inflammatory and immune cells 
implicated in the pathogenesis of asthma, arthritis and atopic dermatitis. With 
respect to the development of novel drugs to treat such diseases, an understanding 
of the regulation and the function of PDE4 enzymes has been identified as crucial.
In this thesis, thi'ee different, but related, studies were earned out. The first study 
was an investigation of the expression and the regulation of cAMP 
phosphodiesterases in human Jurkat T lymphocytes. In the second study, the 
properties of the proteins encoded by rive different mRNA transcripts from the 
human PDE4D gene were analysed after transient expression in COS7 cells. 
These included the PDE4D1 and PDE4D2 forms which I had shown to become 
induced in Jurkat T-cells with chronically elevated cAMP levels. Finally, the role 
of the N- and C-terminal regions of the inactive human PDE4A splice variant, 2EL 
originally cloned from a Jurkat T-cell library, was investigated.
The Jurkat T-cell PDE activity was determined using selective PDE activators and 
inhibitors. Although a small amount of PDEl, PDE2 and PDE7 enzymes were 
present, PDE3 and PDE4 enzymes were shown to provide the major Jurkat T-cell 
PDE activity. Chronic elevation of intracellular cAMP levels achieved either by 
direct stimulation of adenylate cyclase or via stimulation of Gg or using a cell-
xvu
permanent cAMP analogue increased PDE3 and PDE4 activities but did not affect 
PDEl, PDE2 and PDE7 activities. Despite the fact that the major PDE activity in 
quiescent Jurkat T-cells was contributed by PDE3 enzymes, PDE4 activity 
appeared to play a key role in the control of intracellular cAMP levels. Analyses 
done using RT-PCR and immunoblotting demonstrated that forskolin-elevated 
intracellular cAMP levels induced the 'short' form of PDE4D isoforms, PDE4D1 
and PDE4D2, but did not induce any other PDE4 isoforms. However, chronic 
elevation of cAMP levels also led to the down-regulation of the novel 118 kDa 
PDE4A species found in resting Jurkat T-cells.
The two human 'short' forms (PDE4D1 and PDE4D2) and the three 'long' forms 
(PDE4D3, PDE4D4 and PDE4D5) of human PDE4D isoforms were transiently 
expressed in COS7 cells. The 'short' PDE4D forms exhibited similai' properties 
and were exclusively expressed in cytosol. In contrast, the 'long' forms showed 
different enzyme kinetics and were found in both particulate and cytosol fractions. 
It was suggested that the unique N-terminal regions of the PDE4D3, PDE4D4 and 
PDE4D5 proteins, which are derived from alternatively spliced regions of their 
mRNAs, are important in determining their enzyme activity, inhibitor sensitivity 
and subcellular localisation.
The inactive human PDE4A species 2EL was cloned from resting Jurkat T-cells. 
However, it was not known that the inactivity is due to the premature tnincation of 
either N- or C-terminal putative catalytic domain. This was investigated using 
chimeras and truncated PDE forms. It was shown that the C-terminal premature 
truncation terminates the 2EL's catalytic activity.
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CHAPTER
INTRODUCTION
1 . Introduction
1 .1 . Adenosine-3',5'-cyclic monophosphate (cAMP) signalling
The second messenger cAMP is an important mediator which is found 
ubiquitously in mammalian cells. The interaction between various extracellular 
ligands such as hoimones, growth factors, cytokines and neurotransmitters with 
their cell surface receptors can lead to the activation of plasma membrane bound 
adenylate cyclase (Macphee et al., 1988, Manganiello, et al., 1995), This 
activation of adenylate cyclase is mediated by the action of the stimulatory GTP- 
binding protein (G-proteins) called Gg. Various other receptors can cause 
inhibition of adenylate cyclase through the inhibitory Gi G-proteins (Milligan & 
Green, 1991). Adenylate cyclase catalyses the conversion of intracellular ATP to 
cAMP (Sutherland et al., 1968), cAMP mediates many important physiological 
responses and metabolic processes such as exocytosis, platelet aggregation and 
neurotransmission (Bourne et al., 1974, Omburo et al., 1997), for example, as 
well as having long teim effects on key processes such as cell growth and 
differentiation (Kammer, 1988). These actions are all mediated by cAMP- 
dependent protein kinase A (PKA), which serves to phosphorylate key target 
proteins and thus alter their functioning (Scott, 1991, Houslay et ah, 1995). 
Intracellular cAMP homeostasis is maintained not only by regulating its synthesis 
by adenylate cyclase (Taussig & Gilman, 1995), but also by control of its 
degradation through the action of the cyclic nucleotide phosphodiesterases (PDEs) 
(Houslay & Kilgour, 1990, Beavo, 1995, Conti et al., 1995b) (Figure 1.1).
binding of an effector to a cell surface receptor leads to the formation of an active 
conformation of the effector-receptor complex.
1 .1 .2 .  Generation of cAMP
■The receptor-adenylate cyclase complex consist of three components: the receptor,
■G-protein and the catalytic subunit of the adenylate cyclase (Figure 1.1). The
Figure 1.1. Diagram  illustrating the synthesis of cAMP by 
adenylate cyclase and its degradation by cAMP phosphodiesterase
Rs Adenylatecyclase Extracellu lar
eitibrane
G s-protein Gi-protein C y to so l
ATP cAMP •''^...^^Phosphodiesterases 
I  S’-AM P
ActivatesPKA1
PhosphorylatesCREB
N ucleus
TüâttSCMbtWIi: : bf : ttJètint: : g^fteS :
This complex cataiytically activates the heteroti’imeric GTP-binding proteins (G- 
proteins) by accelerating the exchange of bound GDP with GTP. The GTP-bound 
G-protein a-subunit then interacts with adenylate cyclase, either leading to its 
activation, in the case of Gs, or inhibition, in the case of G[. Inactivation of the G- 
protein results from the hydrolysis of the bound GTP to GDP by the intiinsic 
GTPase activity of the a-subunit. The reactivation of the G-protein requires a 
further replacement of GDP by GTP. Thus, the level of adenylate cyclase activity 
depends on the distribution between active and inactive G-protein units, which is, 
in turn, regulated by the relative rates of activation and inactivation of receptor 
through association-dissociation of agonist. i
1.1.3. G-proteins
All of the G-protein-coupled receptors consist of a single polypeptide chain with 
seven putative transmembrane domains. Upon agonist binding to the receptor, it is 
thought that the conformation of receptor changes, allowing the association of the 
G-protein with cytoplasmic regions of the receptor. Heterotrimeric G-proteins are 
a group of membrane-associated proteins that bind GTP with high affinity (Neer, 
1995). Each G-protein consists of three subunits called a ,  P and y  and such G- 
proteins are generally defined on the molecular identity of the a-subunit within the 
heterotrimer (Gilman, 1987, Milligan, 1995). In the complex, the a-subunit binds 
and hydrolyses GTP and the py-dimer serves as a functional monomer, in part by 
anchoring the a-subunit to the membrane. To date, about twenty a-sub units, five 
P-subunits and twelve y-subunits have been demonstrated (Milligan, 1995).
In the resting state, the a , p and y-subunits are complexed together with GDP 
bound to the a-subunit. Receptor activation results in the activation of the G- 
protein complex and release of the GDP from the a-subunit, which is in turn 
replaced by GTP. Upon binding GTP, the a-subunit dissociates from the py- 
dimer and diffuses along the inner surface of the plasma membrane and couples
with an effector molecule such as adenylate cyclase (Gilman, 1984). This active 
state is 'switched off via the OTP hydrolysing activity of the a-subunit. Once 
inactivated the a-subunit reassociates with the py-dimer and the complex returns to 
its resting state (Casey & Gilman, 1988, Houslay, 1992).
Inhibition of adenylate cyclase by G-inhibitory (Gi) family of G-proteins is less 
well understood. Gi is a guanine-nucleotide binding protein(s) defined originally 
by its ability to mediate inhibition of adenylate cyclase by agonists and other agents 
(Katada et al., 1984). Three form of Gi-proteins have now been cloned, G pl, Gi- 
2 and Gi-3 (Milligan & Green, 1991), all of which are subjected to ADP- 
ribosylation by pertussis toxin which prevents coupling of a i to appropriate 
inhibitory receptors. Current theories suggest that Gi can inhibit adenylate cyclase 
in two ways. One involves the release of py from Gi attenuating Gg dissociation 
and activation by a Mass Activation process. Another suggests a direct inhibition 
of adenylate cyclase by GTP-bound Gia- However, modulation is likely to 
depend upon adenylate cyclase isofoim and Gi isoforms present in cells.
1.1 A . Adenylate cyclases
Adenylate cyclases (EC 4.6.1.1) are a group of enzymes that are responsible for 
the synthesis of cAMP from intracellular ATP (Figure 1.1). The reaction catalysed 
by this enzyme can be represented by :
Mg2+ATP-------------- > cyclic AMP + PPi + H+
Their activity is controlled dynam ically by a variety of hormones, 
neurotransmitters and other regulatory molecules. At least eight genetically distinct 
adenylate cyclase encoding cDNAs have been cloned: six of these (types I-VI) are 
from mammalian sources, one is fr om Drosophila and one is from Dictyostelium 
(Tang & Gilman, 1992). Their molecular mass ranges from 120 to 165 kDa with a 
complex topology within the membrane (Cali et al., 1996). Adenylate cyclase 
consist of a single polypeptide which has a short cytoplasmic N-terminus and is
followed by a six transmembrane spanning region (M l), a large (40 kDa) 
cytoplasmic domain (C l), and a second set of six transmembrane spans (M2) and 
finally a second cytoplasmic domain (C2) (Tang & Gilman, 1992). This structure 
is highly similar to that of certain ion channels and ATP-dependent transporters, 
particularly the P glycoprotein and cystic fibrosis transmembrane conductance 
regulator (Taussig & Gilman, 1995). Although, there is little evidence to suggest 
that various adenylate cyclases may also serve as ion channels or transporters, one 
interesting observation from studies in Paramecium  suggest that the adenylate 
cyclase form expressed there can also serve as a K+ channel. However, the 
stincture of this one-form is not yet known (Schultz et al., 1992).
Among the different isofoims of adenylate cyclase, the amino acid sequence 
homology is about 50 % (Tang & Gilman, 1992). However, the two large 
cytoplasmic loops, Cioc and C2oc, show significant homology (>90 % identity) 
between family members whereas the two groups of putative transmembrane 
helices (Mi and M2 ) are quite distinct (Houslay & Milligan, 1997). The 
cytoplasmic regions of adenylate cyclase provide the active site(s) and their 
expression allows for the reconstitution of enzyme activity (Sunahara et al., 1996).
All adenylate cyclase isoforms are stimulated by both forskolin and the a-subunit 
of Gs (Gsa) and aU are inhibited by certain adenosine (P-site inhibitors) analogues. 
However, it is unclear whether the same is true for a range inhibitory effects upon 
adenylate cyclase where each enzyme family displays different properties of 
regulation by Ca^+, PKC, Gi form and py-subunits of G-proteins (Houslay & 
Milligan, 1997, Milligan, 1995, Taussig & Gilman, 1995). Changes in 
intracellular Ca^+ have profound effects on type I, III and VIII adenylate cyclase 
activity, being stimulated by nanomolar concentrations of Ca^+ /  calmodulin, thus 
causing an increase in intracellular cAMP levels. Although type V and VI activities 
are inhibited by Ca^+ at low micromolar concentrations, these and type II and IV
are insensitive to micromolar concentrations of calmodulin (Pieroni et aL, 1993). 
Indeed inhibition of cAMP production resulting from elevations in Ca^+ has been 
correlated with the expression of type V or type VI adenylate cyclases in some 
intact cells (Ishikawa et al., 1992, Yoshimura & Cooper, 1992).
Adenylate cyclase isoforms are differently regulated by py-subunits of Gg-proteins 
in a type-specific fashion, py-subunits inhibit solely the type I isoform activity. In 
contrast, Py-subunits can synergistically activate type II (Tang & Gilman, 1991) 
and type IV (Gao & Gilman, 1991) adenylate cyclases; in the presence of Gsa» 
activity is enhanced by 5-10-fold (Pieroni et al., 1993). Stimulation of these 
cyclases requires substantially higher concentrations of py than of Gga and the 
source of these subunits in physiological states is thought to be derived from Gi or 
Go*
The uncoupling of receptors from Gg stimulation appears to be a process that is 
mediated via receptor phosphorylation rather than G-protein phosphorylation or 
internalisation. The kinases that are involved in the phosphorylation are PKA and 
PKC and a variety of receptor-specific kinases that view the agonist-bound forms 
of receptors as preferential substrates (Houslay, 1992). However, inhibition of 
adenylate cyclase by PKA-mediated phosphorylation may also provide a key route 
in specific cell types. Type VI adenylate cyclase is found in S49 lymphoma cells 
and contains two PKA phosphorylation sites. Phosphorylation of these sites in 
v itro  causes inhibition of this enzyme (Premont et al., 1992). PKA 
phosphorylation of type V also inhibits this enzyme activity as shown in heart 
(Iwami et aL, 1995). In contrast to PKA, PKC phosphoiylation stimulates certain 
types of adenylate cyclases. It has been shown that PKC phosphorylation of the 
type V enzyme in vitro demonstrated a marked increase in enzymatic activity 
(Kawabe et al., 1994). This effect is specific to the PKC isoforms a  and ^ 
(Jacobowitz et al., 1993). PKC also can stimulate type III
Two classes of PKA have been identified, type-I and type-II, that differ with 
respect to their regulatory (R) subunits, as indicated by their differnt molecular
presence of a high affinity binding site for Mg^+ATP in the regulatory subunit (RJ) 
(Taylor et aL, 1990). Type-II were distinguished by autophosphorylation of the
■
'1
■(Jacobowitz et aL, 1993). In addition, the inhibition of type II adenylate cyclase 
activity mediated by Gi, has been noted to be suppressed by phorbol ester 
treatment (Chen & Iyengar, 1993).
1 . 1 . 5 .  cAMF-dependent protein kinase
The intracellular receptor system for cAMP is provided by cAMP-dependent
protein kinase (PKA). This has been shown to be the only protein, apart from the
■PDEs, that binds cAMP with high affinity in eukaryotic cells. PKA exists as a 
tetrameric conformation and comprises a family of enzymes within which each 
member consists of two regulatory (R) and two catalytic (C) subunits (R2 C2 ) 
which form an inactive holoenzyme (Tang & Gilman, 1992). In the absence of 
cAMP PKA is tightly regulated and maintained in an inactive state. Activation of 
PKA is mediated by cAMP binding with a high affinity to the R-subunits, which 
results in the dissociation of the complex and the release of the free and active 
monomeric catalytic subunits (Taylor et al., 1990), Activation can be shown by :
R2 C2 + 4 cAMP ---- ----- — > R2 (cAMP)4 + 2C
Indeed the released and activated catalytic subunits can even migrate from the 
cytoplasm to the nucleus. These subunits are able to phosphorylate tai’get proteins 
with target serine residues in the context X-Arg-Ai'g-X-Ser-X. Such functional 
motifs are found within a large number of cytoplasmic and nucleai' proteins (Lalli
■& Sassone-Corsi, 1994, Meinkoth et aL, 1990).
masses, amino acid sequences and affinity for cAMP analogues (Clegg et aL, 
1988, Oyen et aL, 1989). Type-I holoenzymes were originally classified by the
regulatory subunits (RII) (Taylor et al„ 1990). Isoforms of RI (a  and P) and RE 
(a  and p) subunits, as well as the catalytic (C) (a, p and y) subunit have also been 
isolated. These species all differ in their subcellular and tissue distribution. Thus 
R Ia  is expressed in most tissues, whereas the Rip is a tissue-specific isoform 
(Clegg et al., 1988). R lla  is found in a wide variety of cells, however, RIIp is 
expressed in only certain restricted cells (Luo et aL, 1990). Intracellular 
localisation also varies. The RI isoforms are found primarily in the cytosolic 
compartment of the cell, although a fraction has been found associated with the 
membranes of erythrocytes (Rubin et aL, 1972). In contrast to this, the RII 
isoforms are generally paiticulate, with up to 75 % of the cellular RII pool being 
associated with the plasma membrane and cytoskeletal components, secretory 
granules or the nuclear membrane (Nigg et al., 1985, Salavatori et aL, 1990).
1.1.6. Protein kinase A anchoring proteins
PKA is a multifunctional enzyme with a broad substrate specificity. It has been 
suggested that hormones and other agents able to increase intracellular cAMP 
levels may permit a preferential phosphorylation of certain specific target 
substrates. For such a scenario to occur, different Gg-coupled receptors are 
presumed to be located at spatially distinct sites on cells together with appropriate 
adenylate cyclase isoforms, again located at specific regions of the cell surface. 
The production of cAMP from such sites may produce distinct concentration 
gradients within the cell. These can be detected by PKA isoforms which must be 
localised in specific cell areas. Indeed, it has been demonstrated that association of 
the type-II PKA with the plasma and other membranes is determined by 
association with members of a large family of anchoring proteins (AKAPs) (Carr 
et aL, 1992, Faux & Scott, 1996). This localisation involves protein-protein 
interaction between regulatory RII subunits and specific RII-anchoring proteins 
(Carr et aL, 1991). The binding of cAMP to the inactive PKA holoenzyme, much 
of which is anchored in the perinuclear region of the cytoplasm through
membrane-associated anchoring proteins (Scott & Carr, 1992), releases the active 
C subunit, which is then competent to phosphorylate substrates.
A number of AKAPs have been demonstrated, each compartmentalising PKA to 
specific subcellular regions and often showing tissue specific expression (Carr et 
al., 1993, Carr et al., 1992). Intriguingly, it is now known that at least one 
anchoring protein binds more that one enzyme at a time. For example, AKAP79 
not only binds PKA but also the protein phosphatase, calcineurin (Coghlan et al.,
1995), as well as the a  and p isoforms of PKC (Klauck et al., 1996). It appears 
that AKAPs contain at least two functional domains (Faux & Scott, 1996): an 
enzyme binding site and a targeting site which is responsible for anchoring to 
subcellular structures such as DNA binding domains (Coghlan et aL, 1994) and 
cytoskeletal binding domains (Glantz et aL, 1993). The first 5 amino acids of each 
RII unit, particularly the isoleucines at positions 3 and 5, are critical for AKAP 
interaction (Hausken et al., 1994).
1.1.7. The nuclear response to cAMP
The released, active catalytic subunits of PKA can translocate to the nucleus. The 
nuclear targets for activated PKA are transcription factors which bind to the DNA 
sequences present in the promoter regions of cAMP-inducible genes (Figure 1.1). 
Most of these genes contain one or a few cAMP-responsive elements (CREs) 
(Comb et aL, 1986). The consensus CRE is a short palindromic core sequence 
(5'-TGACGTCA-3') (Montminy et aL, 1986) which mediates cAMP-dependent 
stimulation of transcription. The CRE-binding factors can be divided into 
activators and repressors. The ti'anscription activation factors are CRE-binding 
protein (CREB) and different members of the activation transcription (ATF-1) 
family and CRE-modulator (CREMr) (Meyer & Habener, 1993, Weng et al., 
1993, Yamamoto et al., 1988). The repressors include CREM a, -P and -y 
(Laoide et aL, 1993).
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1 . 2 .  The effects of cAMP in the immune system
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CREB is a dimeric protein (Gonzalez et aL, 1989, Hoeffler et aL, 1988) which 
contains three major structural elements: a DNA-binding domain rich in basic 
amino acids that recognise the CRE site, a leucine zipper responsible for 
dimérisation and a highly acidic transactivation region which contains a cluster of 
potential phosphorylation sites (for PKA, PKC, casein kinase I and II). The two 
other regions within the trans activation region are now known to be important for 
the stimulation of transcription by CREB. The first of these is the a  peptide which 
interacts co-operatively with the PKA phosphorylation site and is important for 
maximal cAMP-dependent induction (Yamamoto et aL, 1990). The second 
subdomain, which is required for full transcriptional activity, lies within the 
phosphorylation (P-box) region (Lee et al., 1990).
■Activated PKA leads to phosphorylation of serine residue 133 of CREB (de Groot
& Sassone-Corsi, 1992). This phosphorylation event is thought to activate CREB
■
by inducing a conformational change in the protein which, in turn, allows 
transcriptional activation from CRE-containing promoters (Gonzalez et aL, 1991).
Attenuation or inhibition of cAMP-stimulated gene transcription requires 
dephosphorylation of transcription factors to occur, representing a key mechanism 
in the negative regulation of CREB activity. It appears that protein phosphatase- 
2A (PP2A) and PPI can oppose the action of PKA (Hagawara et aL, 1992).
:
Early researches suggested that cAMP can exert positive modulatory effects on 
lymphocyte activation (Rochette-Egly & Kempf, 1981, Wang et aL, 1978). 
However, there is now general agreement that cAMP can serve as a negative 
regulator of mammalian immune system activation and cellular functions. The 
sustained elevation of cAMP can inhibit platelets responses to agonists including 
shape change, aggregation, adhesion and release of granule contents (Omburo et
al., 1997). An increased cAMP levels in leukocytes also results in the inhibition of 
specific differentiated cellular functions such as release of histamine (Bourne et aL, 
1974). Also in vitro studies on neutrophils have shown that elevated intracellular 
c AMP levels can inhibit superoxide production in response to stimulation with the 
chemotactic peptide fMLP (Nielson, 1987, Nielson et aL, 1990). A similar 
inhibition was also apparent in eosinophils with a reduction of respiratory burst, 
lipid mediator production, infiltration and adhesion functions as well as the release 
of pro-inflammatory mediators having been noted (Souness et aL, 1994, Teixeira 
et aL, 1996). Furthermore, enhanced cAMP can suppress synthesis of the pro- 
inflammatory mediator TNF-a via blocking of the cytokine pathway from human 
monocytes (Greten et aL, 1995) and can also inhibit release of inflammatory 
mediators histamine and leukotriene C4 from basophils (Peachell et aL, 1992).
cAMP is known to suppress lymphocyte proliferative responses and immune 
effector functions by acting at early points as well as at more distal steps of the 
response (Anastassiou et aL, 1992, Bourne et aL, 1974, Kammer, 1988, 
Vercammen & Ceuppens, 1987). Intracellular levels of cAMP in such cells have 
been manipulated using forskolin (a direct activator of adenylate cyclase), cyclic 
AMP PDE inhibitors and cell permeable cAMP analogues (Erdogan & Houslay, 
1997, Kelley et aL, 1990, Mai’coz et aL, 1993b, Novak & Rothenberg, 1990). 
Additionally, agonists to receptors which are coupled to Gg proteins, such as
prostaglandins E2 or isoproterenol as well as cholera toxin, (which by covalent 
modification (ADP-ribosylation) activates Gg) have also been used to increase 
cAMP levels (Alava et aL, 1992, Anastassiou et aL, 1992, Mary et aL, 1989,
Wacholtz et aL, 1991). The resultant increase in cAMP suppresses various 
functional indices of T-cell activation including exocytosis (Takayama et aL,
1988), proliferation (Krause & Deutsch, 1991, Lingk et aL, 1990), cytokine 
(IFNy, IL-2 and IL6 ) induction (Anastassiou et aL, 1992, Snijdewint et aL, 1993,
a
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Wacholtz et al., 1991) and expression of CD7 and ÏL2 receptors (Krause & 
Deutsch, 1991, Rincon et aL, 1988).
Increased cAMP levels also inhibits TCR-coupled early activation events such as 
P I P 2  breakdown (Alava et aL, 1992, Lerner et aL, 1988), tyrosine 
phosphorylation (Anastassiou et aL, 1992, Klausner et aL, 1987), [Ca^+]i 
elevations and PKC activation (Chouaib et aL, 1987, O'Shea et aL, 1987, 
Paliogianni et aL, 1993), raf-1 activation (Whitehurst et aL, 1995) and K+ 
conductance (Bastin et aL, 1990, Payet & Dupuis, 1992).
The molecular mechanism underlying the late cAMP inhibition of nuclear activation 
events in T cells is as yet poorly understood. However, in this system, the main 
target of T cell inhibition by cAMP appears to be at the level of IL-2 production 
(Anastassiou et al., 1992, Lemer et aL, 1988, Paliogianni et aL, 1993). It has 
recently been shown that cAMP inhibits the growth of fibroblasts, adipocytes and 
muscle cells by activation of PKA. The activation of PKA is believed to inhibit the 
activation o f mitogen-activated protein (MAP) kinase by eliciting the 
phosphorylation and activation of c-Raf (Cook & McCormick, 1993, Wu et aL, 
1993). However, other MAP kinase isoforms are resistant to cAMP inhibition 
because they do not have a PKA phosphorylation site (Hsueh & Lai, 1995). 
Indeed, cAMP elevations does not inhibit MAPK activation in T-cells, but rather 
elevated cAMP levels serve to inhibit c-Jun N-terminal kinase (INK) (Hsueh & 
Lai, 1995). As T-cell activation, including interleukin-2 gene activation, requires 
the integration of the Raf-1 and INK pathways, then a block in either will lead to 
an inhibitory effect. Indeed, transfection of constructs encoding competitive 
inhibitors of c-Jun phosphorylation by INK serves to inhibit IL-2 promoter 
activation (Su et aL, 1994).
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1 . 3 .  The effects of cAMP in various systems
1.3.1. cAMP in the central nervous system (CNS)
cAMP has major role in the biochemistry o f learning, memory and 
neurotransmission regulation in the central nervous system (CNS) (Byers et ah, 
1981, Nighorn et al., 1991). Investigations with two invertebrates, sea snail 
{Aplysia californica) and fruit fly {Drosophila melanogaster) have demonstrated 
that cAMP is important in this system. Indeed, numerous genetic mutations have 
been associated with alterations of the cAMP signalling pathway including dunce, 
which encodes a cAMP-specific PDE and rutabaga {rut ) which encodes a Ca^+ / 
CaM stimulated adenylate cyclase (Dudai, 1988, Levin et ah, 1988, Qui et al.,
1991). These studies have shown alterations in olfactory learning (Byers et ah, 
1981) caused by loss of the dunce PDE activity (Nighorn et ah, 1991). The 
functional role of cAMP in the mammalian CNS is not well understood yet. 
However, inhibitors selective for certain cAMP PDEs (PDEs), such as rolipram
have clinical activity as antidepressants (Wachtel, 1983). This suggests that cAMP 
PDEs may play a direct and active role in the biochemistry of learning and 
memory, by controlling cAMP levels.
1.3.2. cAMP in platelets
Platelets play a central role in thrombosis and homeostasis. The stimulated
response of platelets involves adhesion to the vessel wall, secretion of secretory
granule components and aggregation. This sequence of events leads to the final
platelet plug found in normal homeostatic events and the inappropriate increase in
platelet mass in thrombosis. These stimulatory events are dependent on both intra
.and extra cellular calcium. cAMP itself, and agents which elevate intracellular
.cAMP levels, inhibit these responses by regulation of the free calcium level in the 
platelet, or by the control of calcium-dependent reactions which are essential for 
these responses. It may be considered that platelet responsiveness depends on a
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critical balance between agents that alter cytosolic free calcium and cAMP (Beltman 
et ah, 1993, Feinstein et ah, 1981). Therefore, an increase in cAMP 
phosphodiesterase activity may play an important role in the desensitisation of 
platelets to further exposure to adenylate cyclase agonists.
1 3 3 ,  cAMP in the heart
cAMP has been shown to be crucial in the control of cardiac contraction and 
diastolic relaxation. The force of contraction in heart muscle is generated by the 
interaction between two proteins, actin and myosin, which can form cross-bridges. 
This interaction is regulated by the binding of Ca^+ to the protein complex troponin 
C (Wetzel & Hauel, 1988). Thus, the developed force ultimately depends on 
either the increase in intracellular free Ca^+ ions or the increase in the calcium 
sensitivity of the contractile elements or both. The other important positive 
inotropic agents in the heart is cAMP. cAMP activation of PKA leads to the 
phosphorylation of cardiac voltage dependent Ca^+ channels, resulting in an 
increase of Ca^"  ^release from the sarcoplasmic reticulum (Schmitz et ah, 1987). 
Indeed it has been shown that both PDE inhibitors and P-adrenergic agents, which 
elevate intracellular levels of cAMP, are therapeutically useful as positive inotropic 
agents (Beavo et al., 1994, Schmitz et al., 1987).
1 3 .4 . cAMP in smooth muscle
The intracellular second messenger cAMP is an important regulator of airway 
smooth muscle tone and vascular smooth muscle relaxation. Elevation of cAMP 
levels is associated with agonist-induced relaxation of bovine, canine and guinea 
pig tracheal smooth muscle (Torphy & Cieslinski, 1989). These actions are 
mediated by PKA that phosphorylates and consequently alters the activity of 
physiologically relevant substrates. Several mechanisms have been demonstrated 
for the inhibitory action of cAMP on smooth muscle contraction. Relaxation of 
smooth muscle occurs when there is a significant reduction in sarcoplasmic Ca^+
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concentrations (Gunts & Stropp, 1988, Scheid et a l, 1979) or when there is a
suppression of actin-myosin interaction due to phosphorylation of myosin light 
chain kinase (Adestein et a l, 1978). Selective inhibitors of either PDE3 or PDE4 
enzymes inhibit the proliferation of rat vascular smooth muscle cells following 
injury (Poison & Strada, 1996). Inhibition of PDE4 activity in vascular smooth 
muscle has also implicated in the treatment of pulmonary arterial hypertension 
(Poison & Strada, 1996). However, the exact role of PDEs in this disorder has 
not been determined.
1.3.5. cAMP as a hormonal second messenger
cAMP is the important second messenger that mediates the hormonal regulation of 
blood glucose and fatty acid levels. Lipolysis and glycogenolysis in adipocytes 
and hepatocytes, respectively are promoted by agents that increase intracellular 
cAMP levels and are antagonised by agents that decrease intracellular cAMP 
(Beebe et al., 1985). Stimulation of cAMP PDE activities by insulin (Heyworth et 
a l, 1983, Pyne et a l ,  1989) contributes to the mechanism by which this hormone
can lower cAMP in adipocytes and hepatocytes.
Lipolysis in adipocytes is promoted by hormones such as catecholamines, 
corticotrophin and glucagon which increase intracellular cAMP levels (Sti'alfors et 
a l, 1984). Conversely, lipolysis is completely or partially prevented by a number 
of antilipolytic agents, including insulin which activate PDEs and may also inhibit 
adenylate cyclase. The precise mechanism(s) of the antiglycogenolytic action of 
insulin is not well known (see section 1.5.6). Recent studies have demonsü'ated 
insulin inhibition of cellular responses and not only suggested a central role for 
activation of cAMP PDE in the antiglycogenolytic action of insulin but also 
showed that these actions did not require inhibition of adenylate cyclase (Beebe et 
al., 1985).
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1 . 4 .  Degradation of cAMP
The termination of second messenger cAMP is mediated by the heterologous 
family of enzymes known as the cyclic nucleotide PDEs (Beavo, 1995, Conti et 
al., 1995b). The degradation of cAMP through the action of PDEs (Figure 1.1) 
presents a physiological function the modulation of which may usefully be 
manipulated in the control of disease states. However, it has been established that 
cAMP is also excreted in substantial quantities in urine in human and animals 
(Ashman et al., 1963). Renal clearance of cAMP represents about 20 % of total 
body clearance depending on the species studied (Jard et al., 1975, Murad, 1973) 
suggesting an active extrusion of cAMP from kidney cells. Indeed, kidney MDCK 
cells appear to pump out both cAMP and cGMP (Woods & Houslay, 1991). 
cAMP is also actively extruded from pigeon erythrocytes (Muir & Murray, 1987) 
and Dictyostelium (Pitt et al., 1992).
.
1 . 5 .  Cyclic nucleotide phosphodiesterases (PDEs)
Cyclic nucleotide phosphodiesterases (PDEs) (EC 3.1.4.17) catalyze the 
hydrolysis of the 3 ’~phosphodiester bond of cAMP (Figure 2.1) and cGMP to 
form 5’-nucleoside monophosphate products (5'-AMP, -GMP respectively) which 
are unable to activate PKA. Therefore, breakdown of cAMP plays a pivotal role in
ftenninating cAMP signal transduction.
-S
'Cyclic nucleotide PDE family isoforms represents a family of enzymes with a wide 
range of properties that are exemplified by their different sensitivities to specific 
inhibitors, cofactor requirements, tissue and subcellular distributions, hormonal 
regulation, phosphorylation by kinases and interaction with other proteins. PDEs 
can be divided into at least seven identified classes that ai’e categorised on the basis 
of their primary sequence (Table 1.1). PDEl enzymes hydi'olyse both cAMP and
17
cGMP and have activities which are stimulated by Ca '^*' /  calmodulin at 
physiological concentrations (Beltman et al., 1993, Conti et al., 1995b, Wang et 
al., 1990) (Figure 1.2). PDE2 isofomis similarly hydrolyse both cAMP and 
cGMP but their activity is stimulated by micromolar concentrations of cGMP 
(Table 1.1, Figure 1.2). This is because cGMP binds to a distinct regulatory site 
on the PDE2 enzymes which is found towards the amino-teiminus (Beavo, 1995, 
Pyne et al., 1986, S troop et al., 1989). PDE3 enzymes specifically hydrolyse 
cAMP however, in this instance, cGMP can inhibit cAMP hydrolysing activity at 
lower, micromolar concentrations (Manganiello et al., 1995b) (Table 1.1). PDE4 
isoforms are cAMP specific and are insensitive to cGMP and Ca^+ /  calmodulin 
(Table 1.1). They are specifically inhibited by the antidepressant drug, rolipram 
(Beavo, 1995, Bolger, 1994). PDE5 and PDE6  both specifically hydrolyse cGMP 
but differ in structure and tissue distribution (Table 1.1). Indeed, PDE6  is found 
only in photoreceptor cells where it plays a pivotal role in visual signal 
transduction (Beavo, 1995, Pyne et al., 1996). PDE7 isoforms specifically 
hydrolyse cAMP and are insensitive to inhibition by all known PDE inhibitors 
including the non-selective PDE inhibitor isobutylmethylxanthine (IBMX) 
(Manganiello et al., 1995a, Michael! et al., 1993) (Table 1.1).
I
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1 . 5 . 1 .  Nom enclature
It has become clear that the PDE superfamily is a large and complex gene family. 
Initially, PDEs were classified into cGMP and cAMP PDEs simply on the basis of 
their substrate hydrolysing activities. However, with the realisation that multiple 
forms of each class existed it was necessary to develop a more sophisticated 
system. The new classification system is based on both the primary sequence and 
the way in which the enzymes are regulated (Beavo et al., 1994). The standard 
nomenclature for describing products of the PDE4 genes is as follows (i) the first 
two letters represent species (e.g. HS for homo sapiens', RN for ra ttus  
norvégiens), (ii) the designator 'PDE* for cyclic nucleotide phosphodiesterase, (iii) 
an arable numeral for the gene family, (iv) a single letter represents individual gene 
product (A/B/C/D for each of the four PDE4 gene families), (v) an arable numeral 
represents splice variant and (vi) a single letter for the report, for example 
HSPDE4A4B belongs to a homo sapiens PDE, from the PDE4 gene.
1 . 5 . 2 .  Primary structure of PDEs
All mammalian PDEs contain a core of about 300 amino acids that are highly 
conserved (with ~30 - 40 % amino acid identity) and aie likely to make up the 
catalytic domain of the enzyme (Charbonneau, 1990, Manganiello et aL, 1995a). 
Most of the individual types of PDE have closely related subfamilies. They are 
products of distinct but highly homologous genes, which give rise to alternatively 
spliced mRNAs. The amino acid identity of the core catalytic region rises up to 70 
- 90 % within a PDE family. Outside the catalytic domain, there is no region of 
sequence common to all PDEs. However, the members of each class often share 
additional motifs (Figure 1.3). For example, two highly conserved regions are 
located in the N-terminal region of the PDE4 proteins which are called UCRl and 
UCR2 (Upstream Conserved Region 1 and 2) (Bolger, 1994).
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1 . 5 . 3 .  PDEl: Ca^+/ calmodulin-stimulated PDEs (CaM-PDE)
This PDE was first described in bovine and rat brain (Cheung, 1967, Kakiuchi & 
Yamazaki, 1970). It was shown that PDEl activity was stimulated by Ca^+ in a 
manner that required a small protein-activator factor (Cheung, 1967, Cheung, 
1971, Kakiuchi & Yamazaki, 1970, Kakiuchi et al., 1970). Later, it was 
demonstrated that the PDE activity which was prepared from bovine heart, was 
dependent on the presence of both Ca '^*' and a binding protein (Teo et al., 1973). 
This activator protein was later named calmodulin (Cheung, 1978). PDEl appears 
to be widely distributed in mammalian tissues with the exception of human 
monocytes (Wang et al., 1990) and rat splenic lymphocytes (Hait & Weiss, 1977).
PD El subfamily possesses a great diversity in apparent molecular weight, 
substrate specificity, tissue distribution, kinetic properties and affinity for 
calmodulin (Beavo, 1988, Rybalkin & Beavo, 1996, Sharma & Kalra, 1994). 
Different isoforms were distinguished by direct protein sequencing and cDNA 
cloning studies (Bentley et al., 1992, Charbonneau et al., 1991). To date, three 
different genes have been identified in the Ca '^^ /  CaM-stimulated PDE family: 
PDEl A, PDE IB and PDE 1C. Alternative splicing of these genes is believed to 
lead to production of more than one protein from each locus (Beavo, 1995).
Two splice variants of the P D E l A gene, PD E lA l and PDE1A2, have been 
isolated from bovine heart and brain, respectively (Sonnenburg et al., 1993, 
Sonnenburg et al., 1995). Bovine heart PDEl A l (59 kDa) and bovine brain 
PDE1A2 (61 kDa) are identical in amino acid sequences apart from their extreme 
N-termini which contain unique sequences (Beltman et aL, 1993, Yan et aL, 
1996). This suggests that these two isoforms are generated from alternatively 
spliced genes (Novack et aL, 1991, Sonnenburg et aL, 1993).
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The 63 kDa PDEIBI was first described in bovine brain and only one mRNA 
product has been isolated so far (Sharma et ah, 1984). The amino acid sequences 
of PDE IB 1 and the 59/61 kDa PDEl A isoforms whilst similar, are not identical 
(Beavo, 1995, Beltman et al., 1993) thus PDEIBI is a product of a different but 
homologous gene (Bentley et al., 1992). PDEIBI has been cloned from bovine 
(Bentley et al., 1992), rat (Repaske et al., 1992) and mouse (Polli & Kincaid,
1992) brain cDNA libraries. In the present study is described the derivation of a 
partial sequence of the human form of PDE IB (see chapter 3) obtained by RT- 
PCR analyses done on RNA from a human Jurkat T-cell line (Spence et al., 1997). 
However, recently, the cDNA encoding the complete open reading frame of human 
PDE IB was cloned from a human leukemic B-cell line (Jiang et al., 1996).
The PD El C gene family is the largest and most diverse of the CaM-stimulated 
enzymes within the PDEl family. Five PDE 1C isoforms have been identified 
from human brain and heart, called PD EICI and PDE1C3 (Loughney et aL,
1996); rat olfactory epithelia, PDE1C2 (Yan et aL, 1995); mouse brain and testis, 
PDE1C4 and PDE1C5 (Yan et aL, 1996). The predicted molecular weights of the 
PDEIC  gene products are about 75 kDa (Beavo, 1995) which is higher than other 
PD El gene products shown so far. The PDE 1C 1, PDE1C3, PDE1C4 and 
PDE1C5 proteins have the same N-termini but different C-termini. However, they 
differ from the PDE1C2 protein sequence at both the N- and C-terminal regions
(Yan et aL, 1996). These five distinct types of cDNAs appear to be alternative 
splice variants of the PDEIC  gene.
The P D E l gene products require both Ca^+ and CaM for activity (Table 1.1). 
Ca^+/CaM increases the activity of all of the PDE Is by at least 6  - 20-fold (Wang 
et aL, 1990). However, they show different responses to Ca^ -*- stimulation. 
Although the PDE1A2 and PDE IB enzymes are encoded by different genes, they 
have similar affinities for Ca^+/CaM, whereas the PD ElA l, which differs from the
23
PDE1A2 only in the N-terminal region, has a higher affinity for Ca^+ 
(Charbonneau et ah, 1991). PDE1C2 also shows more sensitivity to Ca^+ 
stimulation than PD EICI, PDE1C4 and PDE1C5 isoforms (Yan et ah, 1996). 
This suggests that the different N-terminal region or perhaps the distinct region 
found  in the C -term inus in PD E1C2 are re sp o n sib le  for 
altering/determining/influencing the Ca^+ stimulation. All of the PD EIC  gene 
products have similar Km values and approximately the same maximum velocity 
(Umax) for cAMP and cGMP hydrolysis (Table 1.1) (Yan et ah, 1996). PDEIC 
variants have similar kinetic properties, however, they have higher affinity for both 
substrates whereas PD E l A and PDE IB hydrolyse cGMP preferentially 
(Manganiello et ah, 1995a, Rybalkin & Beavo, 1996).
It has been shown that at least three of the PDEl enzymes are regulated in vitro by 
phosphorylation/dephosphorylation (Table 1.1). Both bovine brain PD E lA l and 
PDE1A2 are phosphorylated by PKA (Hashimoto et al., 1989, Sharma & Wang,
1985). The 63 kDa PDE IB isoform found in brain can be phosphorylated by 
Ca^+ /  CaM dependent kinase II (Hashimoto et ah, 1989, Sharma & Wang, 1986, 
Zhang et al., 1993). Phosphorylation of these enzymes does not alter the catalytic 
properties, but it does cause a decrease in the affinity of the PDE for calmodulin 
and requires increased levels of calcium for optimal stimulation of activity (Sharma 
& Wang, 1985, Sharma & Wang, 1986). Phosphorylation of both enzymes can 
be blocked by Ca^+ /  CaM (Sharma & Wang, 1985). Calcineurin, a Ca^+ / CaM- 
sensitive phosphatase, can dephosphorylate these enzymes (Sharma & Wang, 
1985, Sharma & Wang, 1986) and this restores the initial CaM affinity and Ca^+ 
sensitivity.
It has been shown that PKC induces PDEl activity both rapidly and transiently in
'CHO cells following treatment with PMA (Spence et ah, 1995). This is due to the
■specific production of transcripts from the PDEIB  gene (Spence et ah, 1997).
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Such an action appears to be mediated specifically by PKC~a and PKC-e isoforms 
and identifies a novel PKC isoform-specific effect on cAMP signalling processes.
1 . 5 . 4 .  PDE2: cyclic GMP-stimuIated PDEs (cGSPDE)
PDE2 activity was initially described in rat liver supernatant fraction (Beavo et al.,
1970) and in the crude particulate fraction of several other rat tissues such as brain 
(Beavo et al., 1971). This enzyme was purified initially from bovine heart tissues 
and adrenal glands (Martins et al., 1982) and also from liver (Yamamoto et ah,
1983a) as well as having been identified in a number of other tissues and cell types 
(Erdogan & Houslay, 1997, Michie et ah, 1996, Pyne et ah, 1986). PDE2 
efficiently hydrolyses both cAMP and cGMP with positively co-operative kinetics 
for cGMP as an effector. cGMP, however, is the prefeiTed substrate and also 
serves at low concentrations (p-M) as an activator of cAMP hydrolysis (Table 1.1)
(Manganiello et ah, 1990b, Moss et ah, 1977) where it can stimulate the 
hydrolysis of cAMP by -50-fold (Beavo et al., 1971).
The native cGMP-stimulated PDE2 is a homodimer with apparent molecular mass
of -240 kDa (Martins et ah, 1982, Yamamoto et ah, 1983a). The purified bovine
V .adrenal and heart tissue PDE2 appears to be composed of a single 105 kDa species 
(Martins et ah, 1982). The first PDE2 to be cloned was from bovine adrenal 
cortex (Sonnenburg et ah, 1991) and then, subsequently, from rat brain (Yang et 
ah, 1994) and liver (Repaske et ah, 1993). Two distinct PDE2 splice variants
have been described, the PDE2A1 cytosolic isoform identified in bovine 
heart/adrenal (Martins et ah, 1982) and membrane-associated PDE2A2 form
identified in liver (Yamamoto et ah, 1983a). RNAase protection assays 
(Sonnenburg et ah, 1991) and sequence analysis done on rat brain PDE2 (Epstein
25
et ah, 1994) are consistent with generation of soluble, cytosolic and membrane-
■associated PDE2 isoforms by alternative mRNA splicing. The sequence of these
isoforms show homology to segments of other PDEs. A comparison of this 
region of homology shows it to be comprised of -260 residues and is thought to 
contain the catalytic site (Charbonneau et aL, 1986, Sonnenburg et al., 1991).
PDE2 takes the form of a chimeric molecule having two distinct regions forming 
an allosteric regulatory site and a catalytic domain (Chai bonne au et al., 1986). 
This allosteric domain, which is near to the N-terminal region, consists of about 
360 residues that shows similarity to a region found in the retinal rod PDE5 and 
photoreceptor PDE6  (Charbonneau et aL, 1989, Sonnenburg et al., 1991) and 
represents a putative cGMP binding domain. The degree of homology in this 
region is reasonably good (30 %) between PDE2 and PDE6  (Stroop & Beavo, 
1991, Stroop & Beavo, 1992). cGMP binds to PDE2 with high affinity via this 
allosteric regulatory domain so as to cause stimulation of activity when cAMP is 
the substrate (Charbonneau et aL, 1986, Erneux et aL, 1985, Yamamoto et aL, 
1983b). The resultant cGMP activity increase is transient unless cGMP synthesis 
is constantly elevated, since the PDE2 hydrolyses both cAMP and cGMP.
Soluble and particulate forms of PDE2A1 and PDE2A2 have similar kinetic 
properties (Murashima et aL, 1990). However, specificity of PDE2s for 
hydrolysis of cGMP are about 3-fold higher than hydrolysis of cAMP (Moss et 
aL, 1977, Wada et aL, 1987). One of the PDE2 isoforms has been shown to be 
phosphorylated both in vitro and in vivo by PKA. This is the particulate 105 kDa 
brain enzyme. However, this modification appears not to alter the kinetic 
properties of the enzyme (Whalin et aL, 1988).
Only one PDE2 specific inhibitor has recently been found, namely EHNA 
(erythro-9-(2-hydroxyl-3-nonyl)-adenine) which was originally called MEP-1 
(Mery et aL, 1995, Michie et aL, 1996, Podzuweit et aL, 1995). EHNA exerts 
selective inhibition of PDE2 activity with an IC50 of 1-3 |iM  compared to an IC50
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of more than 100 jiM for other PDE forms (Mery et ah, 1995, Michie et aL, 1996, 
Podzuweit et aL, 1995) (Table 1.1).
1 . 5 . 6 .  PDE3: cyclic GMP-inhibited PDEs (cGIPDE)
PDE3 isoforms are found in a large array of tissues, including bovine and rat 
adipose tissues, human platelets and T-cells, rat liver and epididymal tissues, 
human and bovine heart (Degerman et aL, 1987, Erdogan & Houslay, 1997, 
Giembycz et aL, 1996, Grant & Coleman, 1984, Kasuya et aL, 1995, Taira et aL,
1993). The subcellular distribution of PDE3 species varies, with the enzyme 
present in the cytosol (Grant & Coleman, 1984) as well as membrane-associated 
(Anderson et aL, 1989, Giembycz et aL, 1996, Pyne et aL, 1987). The
iidistribution between membrane and cytosol fraction appears to vary in different 
cell types. The basis of the differences in distribution is not understood, however, 
such PDE3 activity is encoded by two genes, PDE3A and PDE3B (Meacci et aL,
1992, Taira et aL, 1993). Recombinant PDE3A and PDE3B proteins exhibit high |
affinities for both cAMP and cGMP, with Km values in the range of 0.1 - 0.8 jiM 
(Table 1.1) and the Umax values for cAMP greater (4-10-fold) than those for 
cGMP (Degerman et aL, 1987, Degerman et aL, 1994, Manganiello et aL, 1990a). i
Low (pM) concentrations of cGMP serve as a competitive inhibitor of cAMP 
hydrolysis by PDE3s (Table 1.1). Another characteristic of PDE3s is their 
sensitivity to inhibition by certain drugs that augment myocardial conti’actility, 
inhibit platelet aggregation and relax smooth muscle. These include cilostimide 
(IC50  = 0.005 pM), milrinone (IC50  = 0.3 |iM) and enoximone (IC50  = 1 fiM)
(Beavo & Reifsnyder, 1990, Manganiello et aL, 1990a, Manganiello et aL, 1995b)
(Table 1.1). Such compounds have IC5 0  values at least 10-100-fold lower for
PDE3s than for other PDE enzymes, indicating a profound selectivity.
-I
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In situ hybridisation studies have showed that PDE3A transcripts are most 
abundant in white and brown adipose tissue and in hepatocytes, whereas PDE3B 
transcripts occur at high levels in the gastrointestinal and cardiovascular systems in 
rats (Reinhardt et al., 1995). This suggests that PDE3 forms exhibit cell-specific 
differences in properties. Primary sequence analysis indicates that the PDE3 forms 
contain the conserved catalytic domain found among all PDEs. PDE3A and 
PDE3B catalytic regions are highly conserved and are followed by a hydrophilic 
C-terminal region. The N-terminal region is distinct and contains putative 
hydrophobic membrane-association domains and several consensus PKA 
phosphorylation sites (Figure 1.2), Within the conserved domain of the PDE3s is 
a unique insertion of 44 amino acids which is not present in the conseiwed domains 
of other PDE families (Manganiello et ah, 1995b, Taira et al., 1993).
Some variation has been found in the analysis of the moleculai* masses of PDE3 
isoforms. It has been shown that PDE3A and PDE3B cDNAs encode proteins of 
-125 kDa. However, PDE3s are particularly sensitive to endogenous proteolysis 
producing fragments of around -110 kDa from human platelets and bovine cardiac 
tissues (Rascon et ah, 1992, Smith et ah, 1993). Indeed, a 62 kDa 'dense-vesicle' 
rat liver PDE has also been purified (Marchmont et ah, 1981, Pyne et ah, 1987) 
although it is unclear as to whether this is a proteolysed species or splice variant.
Platelets have a central role in thrombosis and homeostasis where cAMP plays an 
inhibitory role in platelet action and aggi’egation. PDE3A is a major PDE in these 
cells and probably serves as a principal homeostatic regulator of basal cAMP in 
platelets. Treatment of intact rat or human platelets with prostaglandin Ei or cAMP 
elevating agents, such as forskolin, stimulates PDE3 activity (Alvarez et ah, 
1981). This was shown to be due to PDE3A becoming phosphorylated by PKA. 
This can be expected to occur in response to anti-aggregatory signalling molecules 
(such as the prostaglandins) in human platelets (Macphee et ah, 1988). The
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increase in PDE activity may play an important role in the desensitisation of 
platelets to further exposure to adenylate cyclase agonists.
The purified heart PDE3 can also serve as a substrate for PKA in vitro (Harrison et 
al., 1986). This phosphorylation may mediate a negative feed back mechanism 
which co-operates with in the restoration of resting cAMP levels within the system 
(Manganiello et al., 1990a). The inhibition of PDE3s causes a substantial increase 
in cardiac contractility. There are several inhibitors of this family of PDEs, 
including the cardiotonic agents cilostimide, milrinone and amrinone as well as 
cGMP (Reeves & England, 1990).
Incubation of intact adipocytes and hepatocytes with agents that increase cAMP 
leads to activation of PDE3 (Beltman et al., 1993). This activation is thought to be 
important in 'feedback* regulation of intracellular cAMP levels and the activation 
state of PKA phosphorylation.
There is considerable evidence that PDESs are important regulators of the effects of 
insulin on lipid and carbohydrate metabolism (Houslay & Kilgour, 1990, 
Manganiello et al., 1990a). Incubation of intact rat adipocytes and hepatocytes 
with insulin results in rapid phosphorylation and activation of the membrane- 
bound (or dense-vesicle) PDE3B (Gettys et al., 1987, Heyworth et al., 1983, 
Smith et al., 1991). Activation of PDE3B by insulin results in reduction in cAMP 
levels, PKA activation, net dephosphorylation and decreased activity of hormone- 
sensitive lipase and reduced hydrolysis of triglyceride (Degerman et a l, 1996). A 
possible route for the insulin-stimulated PDE3B phosphorylation of Ser^O^ niay 
involve an insulin-stimulated protein serine kinase (PDE3IK) (Rahn et a l, 1994). 
Insulin-induced activation of PDE3IK leading to the phosphorylation and 
activation of PDE3B can be blocked by the phosphatidylinositol 3-kinase (PI3-K) 
inhibitor wortmannin (Rahn et a l, 1994). This suggests that the antilipolytic 
signal cascade is mediated via receptor activation of PI3-K.
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Further studies have been carried out with cAMP-mediated activation of PDE3s by 
lipolytic hormones and agents. In adipocytes, lipolysis can be promoted by 
hormones such as adrenaline via beta adrenoceptor stimulation (Anderson et al.,
1989) resulting in the elevation of intracellular cAMP levels. Isoproterenol rapidly
activates adenylate cyclase and increases the concentration of cAMP, resulting in 
the phosphorylation by PKA, of Ser302 and activation of PDE3B in rat adipocytes 
(Degerman et ah, 1990, Smith & Manganiello, 1989). This PKA-mediated 
phosphorylation o f PDE3B causes the activation of the enzyme, resulting in a 
short-term negative feedback (Manganiello et al., 1990a). Conversely, stimulation
of adipocytes by insulin, prostaglandin E i and adenosine causes an antilipolytic
effect by reduction of cAMP levels within the cell (Manganiello et al., 1990a).
'These antilipolytic agents also mediate an effect by inhibiting adenylate cyclase via 
Gi. Thus, there is a fine balance between cAMP production by adenylate cyclase 
and cAMP degradation by PDE3s.
1 .5 .7 .  PDE4: cyclic AM P-specific PDEs (cAMP PDE) '
1.5.7.1. Background
The PDE4 enzymes are a large multi-gene family consisting over 13 different 
isoforms seen in both humans and rodents (Bolger, 1994, Conti et ah, 1995b).
Four different genes encode mRNAs for PDE4 isoforms in mammals with a great 
similarity between species. These are called PDE4A, PDE4B, PDE4C and PDE4D 
(Table 1.2). The first gene was cloned in rats (Bolger, 1994, Davis et ah, 1989,
Swinnen et ah, 1989a) and later in humans (Bolger et ah, 1993, Engels et ah,
1995, Horton et ah, 1995, Livi et ah, 1990, McLaughlin et ah, 1993, Sullivan et 
al., 1994) and in mice (Milatovich et ah, 1994). The four genes are distiibuted on 
tltree chromosomes. The gene for PDE4A is localised on the short arm of human 
chromosome 19 as is that for PDE4C (Horton et ah, 1995, Milatovich et ah,
1994). However, PDE4B is found on chromosome 1 (Milatovich et ah, 1994, I
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Szpirer et al., 1995) and PDE4D on chromosomeS (Milatovich et al., 1994, 
Szpirer et al., 1995). Each of these four genes appear to produce multiple mRNA 
transcripts involving 5'-domain swopping, yielding isoforms with distinct N- 
terminal domains (Bolger, 1994) (Figure 1.3). In contrast the C-terrainal domain 
of each particular PDE4 gene family is unique and is thus common to all active 
isoforms produced from a particular PDE4 gene. The four rat and four human 
genes show a one to one homology, in that each of the four human PDE4 genes is 
more closely related to one specific rat gene than to any other human gene (Bolger,
1994, Bolger et al., 1994).
The enzymes of the PDE4 multigene family are characterised by their high and 
specific affinity for cAMP, selective and specific inhibition by the anti-depressant 
drug rolipram (Table 1.1), and insensitivity to the cGMP and Ca^+/ CaM (Beavo,
1995, Beavo & Reifsnyder, 1990, Conti et al., 1991, Conti et al., 1995b, 
Thompson, 1991), This group of PDEs are the closest mammalian homologues to 
the dunce gene of Drosophila melanogaster (Figure 1.4), which was first isolated 
as a mutation effecting a phenotypic learning defect (Qiu & Davis, 1993, Qui et al., 
1991). It was shown that mutation within this locus also led to a variety of 
behavioural defects, disturbed cAMP metabolism and caused sterility in adult 
females (Tulley & Quinn, 1986). The abnormal cAMP metabolism was due to a 
mutation in a PDE gene, leading to an absence or greatly reduced PDE activity and 
an enhanced cAMP level within the cell (Byers et al., 1981, Davis & Kiger, 1981). 
Analyses subsequently showed that dunce was the structural gene for a cAMP- 
specific PDE (Davis & Kauvar, 1984). Indeed, defects in memory and learning in 
dunce flies can be rescued by the expression of a mammalian PDE4 cDNA 
Drosophila (Dauwalder & Davis, 1995). Such experiments demonstrate the close 
functional homology between the Drosophila and mammalian PDE4 enzymes.
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1.5.7.2. Molecular cloning ofPDE4 isoforms
■
Three approaches have been used to clone members of the PDE4 enzymes. The 
Drosophila dunce gene was isolated by a chromosome walking technique before 
cDNAs were isolated for any of the mammalian PDE4 genes (Davis & Davidson,
1986). Subsequently the dunce cDNA was used to probe mammalian cDNA 
libraries (Davis et al., 1989). A second strategy was to isolate cDNA clones 
whose expression would suppress the heat-shock sensitive phenotype of 
Saccharomyces cerivisiae having mutations in the RAS-cAMP pathway (Colicelli 
et al., 1989). RAS proteins are regulators of adenylate cyclase and consequently 
involved in cAMP production in yeast. Activating mutations of this pathway 
produce their phenotype by elevating cAMP levels as a consequence of acute 
sensitivity to heat-shock. Selection was performed on the basis of rescue of heat- 
shock sensitivity, by a lowering of cAMP levels. PCR is another approach which 
has also been employed, using oligonucleotide primers designed to amplify DNA 
sequences with homology to both the dunce gene and previously isolated 
mammalian PDE4 clones (Bolger et al., 1994).
1.5.7.3. The structural features o f the PDE4 isoforms
The human and Drosophila dunce PDE4 amino acid sequences demonstrate 
regions of strong conservation within their coding sequences. Alignment of the 
full length sequences of both human (Figure 1.4) and rat PDE4s shows that there 
are three distinct conserved regions. The core region is, o f course, that which 
shows similarity with all other PDE enzyme classes and which forms the putative 
catalytic region (Jin et al., 1992). The catalytic core region of PDE4s shows -30- 
40 % similarity with various PDE proteins (Houslay et al., 1997). The other two 
regions which are found upstream of the catalytic region, that is towards the N~ 
terminal region of these proteins, are called UCRl and UCR2 (Upstream 
Conserved Region 1 and 2) (Figure 1.3, 1.4).
."W
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Figure 1.3. Schematic structure of full-lenght human PDE4 forms
Shown is the schematic representation of the four human PDE4 mRNAs. Black 
areas denote regions of lower or absent sequence homology. Regions of the 
strongest sequence conservation (UCRl, UCR2 and catalytic; shown by arrows) 
are shown in the light areas. Regions of sequence unique to an individual 
alternatively spliced mRNA is shown by thin branched lines. The tiiangle in the 
PDE4D2 cDNA indicates lacking 8 6  bp sequence, as compared to the PDE4D1 
clone.
Î
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Figure 1.3. Schematic structure of full-length human PDE4 forms
PDE4A
PDE461
PDE4B
PDE4C
C4
PDE4D
D4
D5
D3
D1
N-terminus
UCRl UCR2
C-terminus
CATALYTIC REGION
UCRl and UCR2 appear to be distinct features of the PDE4 family, as these 
regions, although strongly conserved between organisms as evolutionary divergent 
as Drosophila melanogaster and humans (Figure 1.4), have no close homologues 
in any other sequences in the GenBank or EMBL database (Bolger, 1994, Bolger 
et al., 1993). The comparison between the three conserved regions of the 
mammalian PDE4s shows >80 % sequence identity and greater than 95 % 
homology to both each other and to the coiTesponding regions in the Drosophila 
melanogaster dunce PDE. However, UCRl and UCR2 are distinct in that they 
lack homology to each other and are separated by relatively low homology regions 
that have been called LRl and LR2 (Linker Region 1 and 2) (Houslay et a l, 1997) 
(Figure 1.4). LRl region, is formed from -33 residues, and shows no homology 
between isoforms, whereas LR2 region, a -76  residues, exhibits loose similarity 
between the various PDE4 classes. The functions of UCR1/UCR2 and LR1/LR2 
regions are unknown. However, U CRl, but not UCR2, is affected by alternative 
mRNA splicing in that 'short' PDE4 forms lack UCRL Whilst the short forms of 
PDE4B/C/D all possess an intact UCR2 region together with a unique N-terminal 
region, the splice junction is different for the PDE4A gene, resulting in a 
disruption of UCR2. It would seem that these conserved regions are likely to be 
important in the functioning or regulation of members of the PDE4 isoforms. 
Whilst, however, this is poorly understood, the phosphorylation of PDE4D3 
(Sette & Conti, 1996) within UCRl leads to a marked increase in catalytic activity. 
Furthermore a yeast-two hybrid system study has been used to show that UCRl 
may interact directly with UCR2 region (Bolger, unpublished work).
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Figure 1.4, Sequence alignment of four human PDE4 family
enzym es
The peptide sequences of human PDE4 isoforms and the PDE4B splice product of 
the Drosophila melanogaster dunce gene (exons 3 to 13, excluding exon 4) have 
been aligned. The specific cDNA clones are: PDE4A species: PDE46, PDE4B 
species; PDE4B1, PDE4C species: PDE4C1B, PDE4D species: PDE4D4. 
Horizontal lines indicate the positions of UCRl, UCR2 and the catalytic region of 
the proteins. ♦ denoted an identical amino acid residue in both sequences.
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Figure 1.4. Sequence alignment of four human PDE4 family
enzym es
HSPDE4AHSPDE4BHSPDE4CHSPDE4Ddunce
HSPDE4AHSPDE4BHSPDE4CHSPDE4Ddunce
HSPDE4AHSPDE4BHSPDE4CHSPDE4Ddunce
HSPDE4AHSPDE4BHSPDE4CHSPDE4Ddunce
HSPDE4AHSPDE4BHSPDE4CHSPDE4Ddunce
HSPDE4AHSPDE4BHSPDE4CHSPDE4Ddunce
HSPDE4AHSPDE4BHSPDE4CHSPDE4Ddunce
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1 .5 .7 A. PDE4A
The human PDE4A gene is localised between the genes for TYK2 and the LDL 
receptor in the pl3.2 region on the short arm of human chromosome 19 (Olsen, I
$A., Sullivan, M. and Houslay, M.D. unpublished data). It has been demonstrated 
that this gene family consists of at least three catalytically active and two 
catalytically inactive isoforms which are produced by alternate splicing (Table 5.1).
Active products of the PDE4A  gene, like other active PDE4s, have identical 
catalytic sites and C-terminal regions but exhibit highly distinct N-terminal regions.
Catalytically active PDE4A isoforms are; PDE46 (HSPDE4A4B) (Bolger et al.,
1993), hPDE-IVA-li6.1 (h6.1, HSPDE4A4C) (Sullivan et al., 1994) and hPDE- 
IVa -l IvI (hPDE-1, HSPDE4A4A) (Livi et al., 1990). However, resequencing of 
the hPDE-1 clone showed that errors were made in the original sequence and that 
h6.1 provided the correct one (Jacobitz et al., 1996) (h6.1 and hPDE-1 properties 
are discussed in chapter 5). Catalytically inactive products are; 2EL (HSPDE4A8)
(Horton et al., 1995) and TM73 (HSPDE4A5?) (Bolger et al., 1993) (Table 1.2).
It is possible that more PDE4A isofonns will be isolated in the future. Indeed, this 
study shows that a novel, active human PDE4A species to exist in human Jurkat T- 
cells (see chapter 3).
PDE46 reflects a full-length 'long' isoform of human PDE4A  gene which is 
analogous to the rat PDE4A splice variant RPDE6 (Bolger, 1994, Bolger et al.,
1996, McPhee et al., 1995). PDE46 consists of 886 amino acids as deduced from 
the cDNA sequence. Expression of the cDNA for PDE46 in COS7 cells produced 
a —125 kDa species which reflects a similar form seen in human monocytes and 
U937 cells (Huston et al., 1996, Manning et al., 1996, Torphy et al., 1995). The 
hô.l isoform was cloned from a cDNA library of human T-cells using a PDE 
specific probe (Sullivan et ah, 1994) which was generated by PCR using primers 
based on the reported h-PDE-1 (Livi et ah, 1990).
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approximately half of that of the cytosolic form, suggesting that particulate 
association altered enzyme conformation. However, truncated form h6.1
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The amino acid alignment shows that h6.1 is an N-terminally truncated form of 
PDE46 and the identical region is from the amino acid residue at position 210 of 
PDE46 to the extreme C-teiminus of PDE46. However, the first 9 amino acids of 
h6.1 are non-native and were engineered to reflect the sequence of h-PDEl, which 
is now known to be artefactual.
2EL was cloned from resting a human Jurkat T-cell library. It exhibits no apparent 
PDE activity (Horton et a l, 1995). This inactive PDE4A is a 323 residue protein 
which differs markedly from PDE46 or h6.1 in two aspects (Figure 5.2), In 2EL, 
the catalytic 'core' region is truncated at both its N- and C-terminal ends, leaving a 
portion of the 'core' region which reflects residues 365 and 643 in PDE46 (Bolger 
et al., 1993). It also has a novel sequence of 33 amino acids at its N-terminus 
(Figure 5.1) and due to a 34 bp insert within the catalytic region, is prematurely 
terminated as a result of the frameshift of the 2EL open reading frame (ORF) 
leading to a unique sequence of 14 amino acids which foims its novel C-terminus 
(Horton et al., 1995). It is possible that loss of either or both the N- and C- 
terminal regions found in active PDE46 and h6.1 might account for 2EL being 
catalytically inactive. Neither the functional significance of producing such a 
protein, nor the molecular basis for lack of catalytic function is known.
On a subcellular level, PDE46 is found both in the cytosol and also associated with 
membranes, where it is preferentially located in cortical areas of the cell (Huston et 
a l, 1996, Houslay et a ll, 1997). In contrast, h6.1 does not show any association 
with the cell plasma membrane (Huston et a l ,  1996). The particulate PDE46 
activity and immunoreactivity were not solubilised by either high salt
concentrations nor by the non-ionic detergent, Triton X-100. From kinetic 
studies, the particulate form of PDE46 exhibited a relative Umax value which was
demonstrated a -11-fold higher catalytic activity than PDE46 (Huston et al., 1996) 
suggesting again that the N-terminal region of PDE46 can modulate the 
conformation and activity of the catalytic unit. Particulate PDE46 also showed a 
-60-fold higher affinity for rolipram than cytosolic PDE46 (Huston et al., 1996) 
Interestingly, both PDE46 and h6.1 were inhibited by rolipram in a simple 
competitive fashion with h6.1 showing a -2-fold higher affinity for rolipram than 
cytosolic PDE46 (Huston et al., 1996, Wilson et al., 1994) (Table 1.2).
In rats, PD E4A  gene encodes three splice variants, which are called RDI 
(RNPDE4A1A), RJPDE6 (RPDE4A5) (McPhee et al., 1995) and RPDE39 
(RPDE4A8) (Bolger et ah, 1996). RDI was the first mammalian PDE4A  
transcript to be described. The cDNA clone encodes an enzyme of 610 amino 
acids that is expressed primaiily in the brain, particularly the cerebellum (Bolger et 
al., 1994, Shakur et al., 1993, Shakur et al., 1995). Native RDI which lacks the 
UCRl region and the N-terminal portion of UCR2 (Davis et al., 1989) is found 
associated predominantly with membranes (93 %) in cerebellum (Shakur et a l, 
1995), RPDE6 is expressed in a number of different tissues, although it is highly 
expressed in the brain and encodes a protein of 844 amino acids which is present 
in both particulate (25 %) and soluble (75 %) forms (Bolger et al., 1994, McPhee 
et al., 1995). Another alternatively spliced form RPDE39 (763 amino acids) is 
found distributed between the membrane (15 %) and cytosol (85 %) in transfected 
COS7 cells (Bolger et al., 1996) and appear to be exclusively expressed in the 
testis (Bolger et al., 1996) and hepatocytes (Zeng, L. and Houslay, M.D., 
unpublished data).
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Products of each of the PDE4 loci appear to have distinct tissue distributions, 
suggesting that these alternatively spliced transcripts have specific and subtle 
differences in function, regulation and subcellular targeting. For example, the 
unique amino terminal region of RDI encodes a membrane association motif.
__
Thus, whilst RDI is exclusively membrane-associated an N-terminally truncated 
RDI species, which lacks the first 25 amino acids (met^^RDl) forming the 
alternatively spliced region, was found as a cytosol species when expressed in 
COS7 cells (Shakur et ah, 1993). It was shown that the unique N-terminal splice 
region of RDI encodes a structure able to target an essentially soluble core PDE to 
the membrane fraction (Scotland & Houslay, 1995). This was confirmed by 
forming a chimera o f the N-terminal first 23 amino acids of RDI fused to the N- 
terminus o f the normally soluble bacterial enzyme, chloramphenicol 
acetyltransferase (CAT). Whilst CAT alone is normally expressed in the soluble 
fraction, chimeric protein was associated with membranes (Scotland & Houslay, 
1995). Further deletion studies demonstrated that the membrane-association of 
RDI was determined by the distinct tryptophan-rich region (Smith et al., 1996). 
RDI protein can be released from the membrane by non-ionic detergent Triton X- 
100 but not high salt treatments (Shakur et al., 1993). This suggests that 
membrane-association occurs by virtue of hydrophobic interactions (McPhee et al.,
1995). A relative F^iax study showed that the N-teiminal domain also profoundly 
reduces catalytic activity. Indeed, experimentally truncated form met^^RDi jg 
catalytically 2-fold more active than RD1 and RD1 exhibits ~3-fold higher activity 
than long forms (Bolger et ah, 1996). This indicates that N-terminal portions of 
RPDE4A not only regulate membrane-association but also regulate catalytic 
activity,
7.5.7.5. PDE4B
Three catalytically active human PDE4B splice variants have been cloned (Table 
1.2 and Figure 1.3). These reflect alternate mRNA splicing of products of the 
PDE4B gene. These various PDE4B isoforms have distinct N-terminal regions 
where PDE4B1 (Bolger et ah, 1993) and PDE4B3 (Huston et ah, 1997), contain 
both UCRl and UCR2, whereas PDE4B2 (McLaughlin et ah, 1993) contains 
only the UCR2 region. The 721 residue PDE4B3 is the largest protein migrating
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as a -104 kDa species on SDS-PAGE when expressed in transfected COS7 cells 
(Huston et ah, 1997) (Table 1.2). All the three PDE4B splice variants 
compartmentalised between cytosol and particulate fractions of transfected C0S7 
cells. Treatment either with the detergent Triton X-100 or high salt concentrations 
released both the PDE4B1 and PDE4B2 membrane PDE proteins. This may 
reflect the association of PDE4B1 and PDE4B2 to a particulate component via 
either integral membrane interactions or binding through hydrophobic interactions. 
However, particulate PDE4B3 was not solubilised by using any of the previous
procedures. This may suggest binding of this isoform with cytoskeletal 
components associated with the P2 pellet fraction.
The Xrti values for cAMP of all the isoforms were similar (Table 1.2) with the 
relative Umax value of PDE4B2 being -4-fold higher than that of the long forms 
(Table 1.2) (Huston et al., 1997).
Immunoblotting and mRNA transcription studies have shown that PDE4B 
isoforms are present in most circulating human and rat blood cells except T-cells 
(Engels et al,, 1994, Erdogan & Houslay, 1997, Manning et al., 1996),
As for the human PDE4B  gene, three rat PDE4B splice variants have been
described. These are DPD (RNPDE4B1A) (Colicelli et al., 1989), ratPDE4 
(RNPDE4B2A) (Swinnen et ah, 1989a) and the novel pRPDE74 (RNPDE4B3) 
(Bolger, G.B. unpublished work). However, it is unclear whether the DPD 
cDNA represents a distinct isoform or an N-terminally truncated form. Indeed, the 
human homologue of this species TM72 appears to encode a rather larger protein 
suggesting that DPD is N-terminally truncated.
.The distribution of rat PDE4 and DPD has been characterised in rat brain (Lobban 
et ah, 1994) and showed distinct localisation patterns in various brain areas. The
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cerebellum, mid brain and brain stem did not contain DPD but expressed ratPDE4, 
whereas the hypothalamus, the striatum, hippocampus and cortex expressed both 
species. Transcription analysis showed that rat PDE4B isoforms are also found in 
liver, lung, kidney, heart (Engels et ah, 1994) and Sertoli cells (Monaco et ah, 
1994).
1.5.7.6. PDE4C
Products of the PDE4C gene are the least well characterised compared with those 
of other PDE4 genes. Two rat and four human partial PDE4C clones have been 
reported which are now believed to be the result of cloning artefacts or incomplete 
clones (Table 1.2). The rat clones are RNPDE4C1A (Swinnen et ah, 1989b) and 
RNPDE4C1B (Bolger et ah, 1994). The human partial PDE4C clones are 
HSPDE4C1A (Bolger et ah, 1993), HSPDE4C1B (Engels et ah, 1995), 
HSPDE4C2A and HSPDE4C3A (Owens et ah, 1997). However, one human full 
length PDE4C (HSPDE4C4A) splice variant from foetal lung library has recently 
been cloned (Obernolte et al., 1997) (Table 1.2),
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The amino acid sequence of HSPDE4C1B and HSPDE4C2A showed the same 
identity in the catalytic domain with other PDE4 isoforms. These PDE4C enzymes 
also show low for cAMP (Table 1.2) (Engels et ah, 1995, Owens et al., 
1997). However, in general, PDE4 inhibitors have little selectivity for PDE4 Li
subtypes although most appear to be less potent against PDE4C compared with
other subtypes (Engels et ah, 1995). In contrast to the other PDE4A/B and D 
isoforms, the human PDE4C is absent in cells of the immune system and present at 
very low levels in brain (Engels et ah, 1994, Erdogan & Houslay, 1997). RT- 
PCR analysis however, suggests that transcripts for this enzyme occur in rat liver, 
lung, kidney, brain and heart, and in human liver, kidney and heart (Engels et ah,
1994).
Î
i . 5.7.7. PDE4D
PDE4D  gene encodes a number of alternatively spliced isoforms in rats and 
humans (Bolger, 1994, Sette et al., 1994b). In humans, five variants are found. 
These are called PDE4D1, PDE4D2 (Nemoz et al., 1996), PDE4D3, PDE4D4 
(Bolger et al., 1993) and PDE4D5 (Bolger et al., 1997). Each of these isoforms 
possesses identical C-terminal catalytic 'core' regions and have uniquely spliced 
N-terminal regions (Bolger et ah, 1997, Jin et ah, 1992, Nemoz et ah, 1996) 
(Figure 1.3). Three of the PDE4 proteins contain both UCRl and UCR2 regions; 
PDE4D3, PDE4D4 and PDE4D5, which are so-called 'long' forms. PDE4D1 and 
PDE4D2 are so-called 'short' forms that lack UCRl (Figure 1.3) (Bolger, 1994). 
PDE4D2 differs from PDE4D1 by virtue of a small deletion (86 bp) in its N- 
terminal region (Figures 1.3 and 4.1).
Four different transcripts of the PDE4D  gene have been demonstrated in rats 
(Table 1.2). These are called rat PDE4D1, rat PDE4D2, rat PDE4D3 (formerly 
known as ratPDE3.1, ratPDE3.2 and ratPDE3.3, respectively) (Swinnen et ah, 
1989b, Jin et ah, 1992, Sette et ah, 1994) and PDE4D4 (Vicini and Conti, 
unpublished data). The rat counterpart of human PDE4D5 has also been shown in 
rat brain by immunoblotting using an antibody generated to the common C- 
terminal region (Bolger et ah, 1997). An alignment of the rat and human 
PDE4D1, PDE4D2 and PDE4D3 amino acid sequences shows highly conserved 
features. Each of the human proteins is nearly identical in length to its rat 
counterpart and has greater than 90 % amino acid identity. However, recent data 
suggests that each of the various isoforms may have a distinct function. For 
example, they differ in their ability to be induced by increased cAMP levels 
(Erdogan & Houslay, 1997, Sette et ah, 1994a, Verghese et ah, 1995) and in 
protein-protein interaction with SH3 domains (O'Connell & Houslay, unpublished 
data). The rat PDE4D1, PDE4D2 and PDE4D3 proteins also vary in their 
enzymologic properties and in their regulation by phosphorylation (Sette & Conti,
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1996, Sette et al., 1994a). However, no comparative analyses have been done on 
all five PDE4D forms expressed in a single cell type.
1 .5 .7 .8 .  R egulation of PDE4 enzymes
Differential regulation of PDE4 enzymes can be achieved by regulation of the level 
of cAMP. This may form part of a long-term adaptation process for PDE4 
isoforms which is mediated via a cAMP-dependent mechanism. Such a process i
may result from hormonal or direct activation of adenylate cyclase and can also be 
achieved with cAMP analogues. Short-term regulation of specific PDE isofoims
may also be achieved by cAMP-dependent phosphorylation.
1
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1.5,7.9. Phosphorylation ofPDE4 isoforms
Protein phosphorylation has been described as a physiological regulator of PDEs 
(Beltman et al., 1993). Thyroid-stimulating hormone (TSH) stimulation of rat 
FRTL-5 thyroid cells caused elevation of intracellular cAMP levels and results in a 
PKA mediated phosphorylation of PDE4D3 (Sette et al., 1994a). PDE4D3 has 
also been shown to be phosphorylated when the recombinant enzyme was 
transfected into both MA-10 cells (Sette & Conti, 1996) and Sf9 cells (Alvarez et
i
al., 1995).
There are two potential sites for PKA mediated phosphorylation of PDE4D3 which 
are formed by serine/threonine residues within a RRxS/T motif (Sette & Conti,
1996). Serl3 and Sei’54 residues foim potential phosphorylation sites and these are 
found in the N-terminal region of the protein. However, whilst both can be 
phosphorylated it has been shown that only the phosphorylation of Ser^4 leads to 
activation of PDE4D3 (Sette & Conti, 1996). Ser54 jg located in the UCRl region 
which is found in all 'long' foim PDE4 enzymes. However, to date, no other
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PDE has been shown to be phosphorylated by PKA. This may reflect however, 
simply the lack of studies done or specificity effects.
Within the PDE4 family, the human PDE4B2 isoform has also shown to be 
phosphorylated by MAP kinase on Ser487 (Lenhard et al., 1996). This serine 
residue is found in the catalytic region of the enzyme. PDE4B2 when expressed in 
v itro  by Sf9 cells and in yeast, but not in E. coli, was shown to be 
phosphorylated. However, the functional and physiological significance of this 
phosphorylation is as yet unclear.
1.5.7.10. Regulation ofPDE4 expression
Long-term incubation of various cells with cAMP elevating agents have been 
shown to lead to an increase in PDE4 activity in certain cell types (Conti et al., 
1991, Erdogan & Houslay, 1997, Manning et al., 1996, Verghese et al., 1995). 
In some cells, this up-regulation of PDE activity forms part of the general 
phenomenon of desensitisation, a homeostatic mechanism whereby cells reduce 
their responsiveness in the face of repeated or continuous stimulation with 
hormones or other agents that increase cAMP (Collins et al., 1992, Sette et al., 
1994a). The PDE4 family plays an important role in this phenomenon. Exposure 
of rat FRTL-5 thyroid cells to TSH showed that PDE4D1 and PDE4D2 were up- 
regulated whilst, at the same time, PDE4D3 became phosphorylated (see above) 
(Sette et al., 1994b). This investigation demonstrated that splice variants from the 
same locus could be differentially regulated on stimulation of a cell by a particular 
hormone. Similarly, challenge of rat Sertoli cells with either follicle stimulating 
hormone (FSH) or dibutyryl cAMP led to the induction of the 'short' forms of the 
PDE4D  gene; PDE4D1 and PDE4D2 (Swinnen et al., 1991b). Furthermore, 
prolonged exposure of human monocytes and Mono Mac 6 cells with cAMP 
elevating agents caused the up-regulation of PDE4D1 and PDE4D2 (Verghese et 
al., 1995). This is consistent with the suggestion that regulation of the
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transcription of a specific subset of PDE4D transcripts, namely PDE4D1 and 
PDE4D2, is determined by cAMP. Thus, the 'short' forms of PDE4D appear to 
be under the control of a cAMP-sensitive promoter. Because no induction of the 
three 'long' form transcripts was apparent in such studies, it is likely that the long 
isoforms are under the control of one or more cAMP-insensitive promoter(s).
Prolonged exposure to the p-adrenoreceptor agonist salbutamol in both human 
monocytes (Manning et ah, 1996) and U937 monocytic cell line (Torphy et ah,
1995) caused an increase in PDE4A as detected by both transcript analysis and by 
immunoblotting. This PDE4A elevation appeared to be due to increases in the 
-125 kDa PDE46 isoform.
Studies in human monocytes (Manning et al., 1996), monocytic cells (Verghese et 
ah, 1995) and U937 cells (Torphy et ah, 1995) have also shown that the -7 4  kDa 
PDE4B2 isoform was increased upon chronic elevation of cAMP levels. This has 
also been noted to occur in rat Sertoli cells upon chronic cAMP elevation (Swinnen 
et ah, 1991a).
1.5.7.11. Regulation ofPDE4 byphosphatidic acid
It has been demonstrated that there is an interaction between lipid signalling and 
PDE4 regulation. Stimulation of lipid signalling pathways can produce 
phosphatidic acid (PA) and increased PDE4 activity has been seen in rat 
thymocytes in response to PA (Marcoz et ah, 1993a). One of the PDE4 forms 
which could be separated biochemically from rat thymocyte homogenates was 
shown to be activated specifically by PA (Savany et ah, 1996). Consistent with i
this, a partially purified PDE4 activity from human monocytic U937 cells was also 
shown to be activated - 2 -fold by phosphatidic acid in a dose dependent fashion 
with an IC50  of -4 0  pg/ml (DiSanto & Heaslip, 1995). This suggests that PA may
I
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regions of the rat PDE4A splice variant RPDE6 and its human counterpart PDE46
Such interactions may be important in targeting the expression of specific PDE4 
isoforms to specific locations within the cell.
be able to activate specific PDE4 species. The identity of such isoforms and the 
mechanism of activation remains to be determined, although recent work suggests 
that the long but not short PDE4D forms may be specifically activated by PA 
(Grance et al., 1997).
1.5.7.12. Interaction ofPDE4 with SH3 domains
Src Homology 3 (SH3) domains are structurally distinct globular structures found 
in a variety of signalling and cytoskeletal proteins which can direct the formation of 
functionally important complexes (Mayer & Baltimore, 1993). These include 
tyrosyl protein kinases involved in cellular regulation, adapter proteins such as 
Grb2 which is involved in MAP kinase activation, phox proteins involved in 
macrophage activation, as well as various cytoskeletal proteins (Musacchio et al., 
1992, Pawson & Gish, 1992). SH3 domains thus play a pivotal role in the 
assembly of important signalling complexes at functionally relevant intracellular
locations. They interact with target proteins through proline-rich domains where 
the basic motif requirement for SH3 interaction is PxxP (Mayer & Baltimore,
-1993, Pawson & Gish, 1992). Such a motif is found in the N-terminal splice
;!!■ '■-te.
as well as PDE4D4. RPDE6 was the first specific PDE to be shown to interact 
with an SH3 domain, namely that of v-Src. This interaction occured by virtue of 
its N-terminal splice region (O'Connell et al., 1996). The binding of RPDE6 to 
the SH3 domain of v-Src did not cause a change in PDE activity.
i
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1 ,5 .7 .1 3 . Therapeutic role of PDE4 inhibitors
A large number of compounds which can serve as selective PDE4 inhibitors have 
been described (rolipram, Ro 20-1724, CDP840, RP73401) and these compounds 
inhibit PDE4 enzymes with IC50  values in the nM - qM range (Alvarez et al., 
1995, Muller et al., 1996, Souness & Scott, 1993). To date, however, there is no 
compound which can potently and selectively discriminate between the various 
PDE4 isoforms.
Rolipram is a highly specific and selective inhibitor of PDE4s and has been 
reported to inhibit all known members of the PDE4 family to a relatively equal 
extent (Bolger et al., 1993, Muller et al., 1996). Rolipram is known to interact 
with PDE4s in at least two distinct fashions: either by binding to 'high-affinity' 
binding sites at very low concentrations (AT^  = 0.4 - 6  nM) or by a ’lower-affinity' 
interaction {K\ -  0.06 - 1 pM) which is presumed to occur at the enzyme catalytic 
domain (Schneider et al., 1986, Torphy et al., 1992).
PDE4s are the predominant cAMP hydrolysing enzymes family found in most, if 
not all, immune and inflammatory cells (Erdogan & Houslay, 1997, Manning et 
al., 1996, Thompson et al., 1976, Torphy & Undem, 1991, Torphy et al., 1995, 
Verghese et al., 1995). Investigations have revealed that many functions of the 
immune system and inflammatory responses are inhibited by agents that increase 
intracellular cAMP concentrations. Elevation of cAMP levels by rolipram can 
markedly inhibit the production of the pro-inflammatory mediator TNF-a but not 
other cytokines such as IL-1 and arachidonic acid metabolism in monocytes (Kelly 
et al., 1996, Souness et al., 1996). PDE4 inhibitors rolipram and RP 73401 
suppress the functioning of eosinophils by reducing their superoxide generation, 
infiltration and adhesion functions (Kaneko et al., 1995, Souness et al., 1995, 
Underwood et al., 1993). Inhibition of PDE4s in T-lymphocytes causes a
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profound decrease in exocytosis, proliferation, cytokine production (IFN-a, IL2, 
IL6) and expression of CD7 and IL2 receptors (Anastassiou et al., 1992, Averill et 
al., 1988, Giembycz et al., 1996, Krause & Deutsch, 1991, Takayama et al., 
1988). Enhanced cAMP levels in neutrophils can inhibit both PLA2 and PLD 
activities but not PLC responses (Nakashima et al., 1995). Due to the effect of 
selective PDE4 inhibitors on the reduction of pro-inflammatory cell functions, 
inhibitor development has focused on the central nervous system (CNS), with 
emphasis on depression (Krause et al., 1990, Scott et al., 1991), in disorders of 
the immune and inflammatory systems, vascular intimai proliferation and 
relaxation o f airway smooth muscles (Francis et al., 1988, Pan et al., 1994). 
Experimental and clinical trials have been done to examine the role of such 
inhibitors in the treatment of atopic and inflammatory diseases including atopic 
dermatitis (Chan et al., 1993) and particularly asthma (Giembycz, 1996, Torphy & 
Undem, 1991) as well as in autoimmune diseases such as arthritis and multiple 
sclerosis (Tracey & Cerami, 1993), viral diseases such as AIDS (Fauci et al., 
1991) and bacterial or parasitic infections like septic shock (Sekut et al., 1995). 
However, although PDE4 inhibitors promise to be useful in the treatment of certain 
diseases, it appears that they also have some unwanted side-effects. A particular 
contra-indication of PDE4 inhibitors is gastro-intestinal discomfort, mainly 
indicated by nausea and vomiting (Palfreyman & Souness, 1996).
1 .5 .8 .  PDE5: cyclic GM P-specific PDEs (cGMP PDE)
PDE5 enzymes have been purified from rat lung (Francis & Corbin, 1988) and are 
present in a variety of tissues including platelets (Hamet & Coquil, 1978), vascular 
smooth muscle, rat spleen (Coquil, 1983) and guinea pig lung (Burns et al., 1992, 
Davis & Kuo, 1977). To date, only one gene isoform has been cloned for this 
family, BTPDE5A (McAllister et al., 1993). Although, PDE5 and the other 
cGMP-specific PDE, PDE6 have similar kinetic properties, sequence alignment of
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catalytic region indicates only around 60 % identity (Beavo, 1995). Therefore, 
this demonstrates that they represent different gene families.
PDE5 has a high affinity for cGMP and practically no hydrolysing activity for 
cAMP (Table 1.1). It forms a homodimer of native mass -177 kDa from two, -93 
kDa subunits (Francis et al., 1990). PDE5 also has two Zn^+ binding sites which 
are found in the catalytic domain (Francis et al., 1994) and whose role has yet to 
be determined.
Intriguingly, as in PDE2, PDE5 contains two distinct binding sites for cGMP. 
One of these is the catalytic site where cGMP is enzymatically converted to 5'- 
GMP and the other is a non-catalytic binding site. The non-catalytic cGMP- 
binding site is found towards the N-terminal regulatory portion of the protein, thus 
resembling PDE2 and PDE6 (McAllister et al., 1993). Binding of cGMP to the 
non-catalytic site o f PDE5 induces a conformational change in an N-terminal 
domain of 142 amino acids, the result of which is that Ser^2 becomes a target for 
phosphorylation by PKG (Francis et al., 1990, Thomas et al., 1990). It has also 
been shown that PKA catalyses the phosphorylation of the same site, although 
PKG phosphorylated this site at a 10-fold faster rate (Thomas et al., 1990). 
Phosphorylation at this site did not appear to modulate activity in the purified 
enzyme analysed in this study. However, in contrast to this other studies have 
shown that PKA can catalyse a 10-fold increase in the catalytic activity of the 
guinea pig lung PDE5 and also decrease the sensitivity of PDE5 to inhibition by 
zaprinast (Burns & Pyne, 1992, Burns et a l, 1992).
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1 .5 .9 . PDE6: photoreceptor PDEs (cGMP-specific PDE)
PDE6 enzymes play key roles in photoreceptor signal transduction. In retinal rod 
photoreceptor cells, visual signalling is triggered upon the absorption of photons 
by rhodopsin. Photoexcited rhodopsin leads to an activation of the retinal GTP- 
binding protein (transducin). Rapid hydrolysis of cGMP by activated PDE6 
results in closure of the cGMP-dependent Na**" channel in the plasma membrane 
which is normally kept open by cGMP (Stryer, 1986).
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Three distinct genes encode this PDE family (Table 1.1); one cone and two rod 
PDE genes. Rod PDE6 protein consists of a  (88 kDa) and P (84 kDa) and two 
inhibitory y (11 kDa) subunits (Lipkin et al., 1990, Miki et al., 1975, Pittler et al.,
1990) as indicated by sequence comparison and DNA hybridisation. PDE6a and 
PDE6p contain two catalytic sites that are inhibited by the binding of PDE6y, The 
cone PDE6 consists of a  homodimers (94 kDa) and 11- and 13 kDa inhibitory 
subunits (Gillespie, 1990). Both rod and cone PDE6s contain two internal repeats 
that make up the noncatalytic cGMP-binding domain conserved in PDE2, PDE5 
and PDE6 families (Gillespie, 1990, McAllister et al., 1993, Sonnenburg et al.,
1991, S troop & Beavo, 1992).
.11
Phosphorylation of rod PDE6s has been shown to occur within the catalytic
(Udovichenko et al., 1993) and inhibitory subunits (Tsuboi et al., 1994) and this 
is achieved by different kinases. Phosphorylation of Thr^S in the bovine PDE6y 
subunit by PKC increases the inhibitory activity of PDE6y, perhaps by increasing 
its affinity for PDE6ap catalytic subunits (Udovichenko et al., 1994).
IBMX inhibits the bovine rod PDE6 with a Ki of 10 pM  in a similar way to all 
other PDE enzymes (except PDE7) (Baehr et al., 1979, Gillespie & Beavo, 1989).
1 .5 .1 0 . PDE7: cAMP-specific rolipram-insensitive PDE
Only one member of the PDE7 gene family has been cloned to date. This was 
from a human glioblastoma cDNA library (Michaeli et al., 1993) using a method 
similar to that used to isolate rat DPD (Colicelli et al., 1989). Northern blotting 
and transcript analyses have shown that PDE7 is highly abundant in human 
skeletal muscle with much lower levels noted in a number of other human tissues 
including kidney, brain, heart and some, but not all, T lymphocyte forms (Bloom 
& Beavo, 1994, Giembycz et al., 1996, Ichimura & Kase, 1993, Michaeli et al., 
1993).
In this thesis, I have investigated the catabolism of cAMP in human Jurkat cells, 
which serve as a model for human T lymphocytes. The research concentrated on 
the regulation of cAMP PDEs at the transcriptional and translational levels using 
cAMP-elevating agents. I then characterised the five human PDE4D isoforms
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The PDE7 clone (HCPl) shows high homology in the presumed catalytic domain 
of ~300 amino acids to other cAMP PDEs. This PDE enzyme is most closely 
related to the PDE4 family (<60 %) in the catalytic region which is consistent with 
its specificity for cAMP and insensitivity to cGMP both as a substrate and 
inhibitor. However, PDE7 activity is not inhibited by PDE4 specific inhibitors 
such as Ro 20-1724 and rolipram (Table 1.1). HCPl appears not to be a full- 
length cDNA and thus only this truncated form has been characterised to date.
Recombinant PDE7 exhibits high affinity for cAMP (/fni = 0.2 pM) and is most 
similar to the of PDE3 but it was not selectively inhibited by the PDE3 
inhibitors milrinone and cGMP and, unlike PDEl, its activity was not affected by 
Ca^+ /  CaM. Additionally, PDE7 family enzymes appear to be resistant to 
inhibition by the non-selective reversible PDE inhibitor, IBMX (Lavan et al.,
1989, Michaeli et al., 1993).
I
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expressed in C0S7 cells including the PDE4D1 and PDE4D2 forms which I had 
shown to become induced in Jurkat T-cells whose cAMP levels had been 
chronically elevated. I then studied the role of N- and C-teiminal regions of the 
inactive human PDE4A splice variant, 2EL which was originally cloned from a 
Jurkat T"CeU library.
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CHAPTER 2
MATERIALS and METHODS
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2.1 Materials
2.1.1, R adiochem icals;
A m ersham  PLC
Amersham, Bucks., U.K.
[8-^H] Adenosine 3’, 5’-cyclic 
monophosphate
[5, 8-3H] Adenosine 3’, 5’-cyclic 
monophosphate 
[I25j]„iabelled anti-mouse IgG 
[i^C]-labelled protein molecular weight 
markers
2.1.2. Tissue cu ltu re  plastic w are:
C ostar Co 
U.S.A .
Filters (0.22 pm) 
Multiple cell plates 
50 ml centrifuge tubes 
Tissue culture pipettes
2.1.3. Tissue cu ltu re  medium: 
Gibco BRL 
Paisley, U.K.
DMEM (Dulbecco’s Modified Eagle 
medium, 1 x)
Foetal bovine serum 
Nuserum
Glutamine (200 mM)
Penicillin (10 000 lU/ral) 
RPMI-1640 medium 
Sodium bicarbonate (7.5 %) 
Streptomycin (10 mg/ml) 
Trypsin/EDTA
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N unc
InterMed, U.K.
W hatm an Ltd,
Maidstone, U.K.
2.1.4, G eneral reagents
2.1.4.1. C hem ical com pounds: 
BDH, M ERCK  L td  
Glasgow, U.K.
Cryotubes
25 and 80 cm^ tissue culture flasks 
6 well plates
Whatman 3 mm Paper
Whatman 0.2 pM nitrocellulose paper
S igm a
Poole, Dorset, U.K.
p-Mercaptoethanol 
Charcoal (Norit Gsx)
EDTA (Ethylenediaminetetraacetic acid)
Glycine
Glucose
HEPES (N-2-Hydroxyethylpiperazine- 
N'“2-ethane-sulphonic acid)
Methanol
Peptone from casein (pancreatically 
digested)
SDS (Sodium dodecyl sulphate)
TEA (Triethanolamine hydrochloride) 
Universal indicator 
Yeast extrsact
EGTA [Ethylene glycol-bis (b-aminoethyl 
ether) N,N,N',N'-tetraacetic acid]
Tris
Triton X-100 
Tween-80
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Fisons Scientific Equipment
Loughborough, U.K.
Dimethyl sulphoxide 
Glycerol 
Sodium Acetate 
Sodium Citrate 
Sucrose
Boehringer
Lewes, E. Sussex, U.K.
Dithiothreitol
Nicotinamid adenine dinucleotide 
(reduced form)
2.1.4.2. Biochemical reagents: 
Sigm a
Poole, Dorset, U.K.
Actinomycin D 
AmpicilUn 
Antipain 
Aprotinin
Benzamidine hydrochloride
Bovine brain calmodulin
Bromophenol blue
BSA (Bovine serum albumin)
Chloroquine
Cholera toxin
Cyclic AMP
Cyclic GMP
Dextran T-500 (Mw 500 kDa) 
Digitonin
Dowex 1X8-400 (chloride form; 200- 
400 mesh)
8-bromo cAMP
PHA (Phytohaemagglutinin)
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IBMX (3-isobutyI-l-methylxanthine) 
Pepstatin A
PMSF (Phenylmethylsulphonyl fluoride) 
Snake venom (Hannah ophiophagus) 
Sodium pyruvate
TEMED (N,N,N’,N’-Tetramethylethylene 
diamine)
Trypan Blue (0.4 %) 
12-0-tetradecanoylphorbol 13-acetate 
CTPA/PMA)
Peptide R esearch Foundation  Leupeptin 
London, U.K.
C alb iochem
Cambridge, U.K.
B io-rad L aboratories L td  
Hertfordshire, U.K.
N ational D iagnostics
Buckinghamshire, U.K.
M  & B
Dagenham, U.K.
Gibco BRL
Paisley, Scotland
Forskolin
Pansorbin
30 % Acrylamide/bis acrylamide mix 
(29:1)
Bradford reagent 
Ecoscint scintillation fluid
Ammonium persulphate
Pre-stained molecular weight maikers
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:
A m ersham  In ternational 
Amersham, Buckinghamshire 
U.K.
Anti-mouse IgG conjugated to
horseradish peroxidase
ECU (enhanced chemiluminescence)
SAPU
Scotland, U.K.
HRP conjugated anti-rabbit IgG
Gift from A ktiengesellschaft Rolipram {4-[3-(cyclopentoxyl)-4-
Berlin 65, Germany methoxyphenyl] -2-pyrolidone}
Gift from Dr. T. Podzuweit EHNA [erythro-9-(2-hydroxy-3-nonyl)-Max
Planck Institute,
Bad Nauheim, Germany
adenine]
Pfizer C entral R esearch 
Sandwich, Kent, U.K.
Cilostimide {4,5-dihydro-6[4-( IH- 
imidazol-1 -yl)pheny 1] -5-methy 1-3 (2H) 
pyrazone}
2.1.5. M olecular Biology reagents:
Pharmacia Biotech First strand cDNA synthesis kit
Herts, U.K.
Stratagene
Cambridge, U.K.
Sigm a
Poole, Dorset, U.K.
pCRscript AMP cloning kit 
Pfu DNA polymerase
Agarose (low melting temperature) 
DEPC (Diethyl pyrocarbonate (1 % ) in 
water)
Ethidium bromide 
Tri-reagent
:;i
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Promega 
Southampton, U.K.
2.1.6. Equipment: 
Progene
Cambridge, U.K.
Deoxyribonucleoside trisphosphates 
MgCl2
Phixl74 DNA/Hae HI Markers 
Taq buffer 
Taq polymerase
Wizard™ Mini, Maxi, PCR and Clean-up 
preps (DNA purification system)
PCR amplification machines
2.1.7. Cell lines
2.1.7.1. C 0S 7  cells
These are SV-40 immortalised kidney fibroblasts isolated from an African Green 
monkey. They express SV-40 large antigen and therefore permit the replication 
and expression of plasmids which contain an SV-40 origin and promoter region. 
They were cultured in DMEM (x l) medium supplemented with 1 % (v/v) 
penicillm/sti'eptomycin, glutamine and 1 0  % (v/v) foetal bovine serum.
2.1.7.2. Human leukaemic T-cell line Jurkat (J6)
The Jurkat T-cell line was obtained from European Collection of Cell Cultures 
(ECACC), Centre for Applied Microbiology and Research, Salisbury, UK. This 
is a proliferating mature T-cell line which was isolated from a 14 year old boy 
suffering from acute lymphoblastic leukaemia and grown in suspension with a 
doubling time of 24 h. They were cultured in plastic flasks (80 cm^) in RPMI- 
1640 medium supplemented with 5 % (v/v) heat-inactivated foetal bovine serum, 
1% (v/v) penicillin/streptomycin and 1 % (v/v) glutamine solution at 37 °C in a
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humidified atmosphere of 95 % afr, 5 % CO2 . Culture medium was changed twice 
a week. Cells were seeded at 1 in 5 dilution into fresh, pre-warmed medium under 
sterile conditions.
On removing cells from liquid nitrogen the medium was further supplemented with 
5 % (v/v) FBS, 0.1 % (v/v) gentamycin and 0.1 % (v/v) ciproxin for the first 
week of culture. When freezing cells, they were first pelleted by centrifugation at 
440 gav for 5 min before being resuspended in the freezing medium at a density of 
10^ cells/ml. This medium consisted o f 90 % FBS (v/v) and 10 % (v/v) DMSO. 
After aliquoting into cryotubes the cells were frozen slowly overnight in a -80 °C 
freezer and then stored in liquid nitrogen until required.
2.2. Methods
2.2.1. Treatment of Jurkat T-cells with vehicles
The cells were split two days before treatment with any of the vehicles and on the 
day of incubation they were harvested. The cell pellets were then diluted with 
fresh medium at the densities of 1.0-1.5 x 10^ cells/ml. They were then incubated 
as indicated for the particular experimental procedure. At the end of the incubation 
the cells were washed twice with serum-free medium, counted and homogenised 
(section 2 .2 .1 .2 .).
2.2.1.1. Determination of cell number and viability
An aliquot of Jurkat T-cells in suspension was mixed with an equal volume of 
Trypan Blue solution (0.4 %) and the number and viability of the cells was 
determined. This was achieved by viewing the cells under a light microscope in a 
haemocytometer. The viability of cells was established as the percentage of cells 
that excluded the Trypan Blue dye, that is the proportion of total cells whose
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mmembranes remained intact and appeared white under the microscope (>95 %) 
were determined to be viable. The cell number was calculated by using the grid on 
the slide which ensured that the same area was counted for each determination. 
100 cells in 32 squares denoted 1x10^ cells per ml thus the viable cell number 
could be calculated.
2 .2 .I.2 . Cell lysis and homogenisation of Jurkat T-cells
minutes prior to use. The dismption method was described previously (Harnett et 
al., 1991). Using digitonin released all (>98 %) of the lactate dehydi’ogenase 
activity (section 2.2.13) associated with these cells and also rendered soluble all 
(>98 %) cAMP phosphodiesterase activity. This method of cell disruption was 
employed rather than either homogenisation or sonication procedures as they not 
only failed to dismpt all the cells as indicated by Trypan Blue exclusion but caused 
disruption in a highly variable fashion. Samples were then taken either for 
immediate assay of PDE activity or were snap frozen in liquid nitrogen and stored 
at -80 °C until use.
I
Following incubation, cells were harvested by centrifugation (5 min, 440 gav, at 
room temperature), and then washed twice with serum-free RPMI-1640 medium
under the same centrifugation conditions and resuspended in ice-cold
homogenisation buffer. This buffer comprised 10 mM tris/HCl pH 7.4 containing 
0.25 M sucrose, 25 mM MgCU, 1 mM EDTA, 0.5 mg/ml detergent digitonin, 0.1 
mM dithiothrietol and protease inhibitors at a final concentration of 40 jig/ml 
PMSF, 156 jag/ml benzamidine, l|ag/ml each of aprotinin, leupeptin, pepstatin A 
and antipain. The protease inhibitors were initially dissolved as a 1000 x stock in 
100 % DMSO before addition to the buffer. This extract was left on ice for 5-10
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2.2.2. Antibody preparation
Polyclonal anti-PDE4A sera was used for im m unoprécipitation and 
immunoblotting. It was developed against a C-terminal human PDEA fusion 
protein by using the a 300 bp DNA fragment which was cloned into the inducible 
bacterial expression vector pGEX-3X (Huston et al., 1996) and raised in New 
Zealand White rabbits. Immunoblotting was also carried out using monoclonal 
antibodies designed to be specific for particular PDE4 families. A glutathione-S- 
transferase (GST) fusion proteins formed from portions of the C-terminal ends 
found to be unique to each of the PDE4 families. They were generated using the 
vector pGEX2T. Mice were immunised, hybridomas were generated and the 
monoclonal antibodies were cloned using standaid methods. Antibody names and 
peptides aie listed below:
Antibodv code PDE epitope Antibody name
PDE4A-GST (polyclonal) 
66C12H (monoclonal) 
96G7A (monoclonal) 
61D10E (monoclonal)
788-886 in PDE46 
800-810 in PDE46 
529-558 inTM72 
634-650 inPDE4D3
PDE4A
PDE4A
PDE4B
PDE4D
2.2.3. SDS-FAGE electrophoresis
Separation of proteins by electrophoresis was carried out on 8  % polyacrylamide 
gels as previously described (Laemmli, 1970). Samples (5-100 pg protein) were 
solubilised in a volume of Laemmli buffer containing 0.1 M Tris/HCl pH 6 .8 , 20 
% (v/v) glycerol, 2 % (w/v) SDS, 0 .0 2  % Bromophenol blue and 5 % (v/v) P~ 
mecaptoethanol (which was added just prior to use) and immediately boiled for 3 
min. An 8 % resolving gel containing 30 % acrylamide/bisacrylamide (29:1), 1.5 
M Tris/HCl pH 8 .8 , 10 % (w/v) SDS, 10 % (w/v) ammonium persulphate and
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0.06 % (v/v) TEMED was made up before being allowed to set to a final volume 
of 30 ml in 1.5 mm glass electrophoresis apparatus. Then 5 % stacking gel 
containing 30 % acrylamide/bisacrylamide (29:1), 1 M Tris/HCl (pH 6 .8 ), 10 % 
(w/v) SDS, 10 % (w/v) ammonium persulphate and 0.1 % TEMED was made up 
to a final volume of 8  ml before being poured on the top of the resolving gel with a 
comb in place. Samples and prestained protein molecular weight standards (214.2 
kDa, 111.4 kDa, 74.25 kDa, 45.5 kDa and 29.5 kDa) were loaded in the wells and 
electrophoretically separated in running buffer (0.2 M Glycine, 25 mM Tris, 0.1 % 
(w/v) SDS) at 8 mA/gel overnight or 60 mA/gel for 3-4 h with cooling. When the 
dye front reached the edge of the gel electrophoresis was stopped and proteins 
transfeired to nitrocellulose paper by Western blotting.
2.2.4. Western blotting
Proteins were ti’ansferred from SDS gel to nitrocellulose paper using constant 
current and 90 volts for 90 min in a Bio-Rad transblot apparatus with blotting 
buffer (0.2 M Glycine, 25 mM Tris, 20 % Methanol). Non-specific binding to
■filters was blocked by incubation in 5 % non-fat dried milk powder/TBS buffer 
(500 mM NaCl, 20 mM Tris, pH 7.4) at room temperature for 90 min or 
overnight. The blot was washed briefly with distilled water before washing twice 
with TBS containing 0.2 % Tween-80 and twice with TBS, each for 5 min. The 
nitrocellulose was then immunoblotted with a 1:300 or 1:2000 dilution of the 
appropriate antisera with TBS containing 1 % dried milk powder for 2 h.
The blot was then washed as above and then incubated for 90 min at room 
temperature with a 1:1000-2000 (in TBS buffer containing 1 % non-fat dried milk 
powder) dilution of anti-rabbit peroxidase linked IgG, anti-mouse IgG or ^^^I- 
labelled anti-mouse IgG. With anti-rabbit peroxidase linked IgG and anti-mouse 
IgG, the Amersham enhanced chemiluminescence (ECL) Western blotting
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visualisation protocol was used to detect the bands, whilst ^^^I-labelled bands 
were visualised by phosphoimaging. Quantification of the relative amounts of 
antigen present in each of the fractions was done in a vaiiety of ways, in order to 
identify situations where a linear relationship held between the amount of antigen 
present and the magnitude of the signal detected. The densitometric scanning of 
the ECL experiments was done using both photosensitive Amersham film and 
Kodak X-ray film with various exposure times and a range of applied protein 
concentrations so as to identify a linear detection range. Confirmation was also
obtained in selected instances using ^^I-labelled anti-mouse IgG with excision of 
the labelled bands identified by auto-radiography for counting.
2.2.5. Cyclic AMP phosphodiesterase assay
Cyclic nucleotide phosphodiesterase activity was determined by a modification of 
the two-step assay (Rutten et al., 1973, Thompson & Appleman, 1971) as 
previously described by (Marchmont & Houslay, 1980b) using pH]-cAMP and 
sufficient unlabelled cAMP to produce the desired substrate concentration.
Briefly, [% ]-cyclic nucleotide (8 -%-adenosine 3',5'-cyclic mono-phosphate) is 
hydrolysed to labelled nucleotide 5'-mono-phosphate by PDEs (Figure 2.1). The 
nucleotide mono-phosphate ring is then converted to the corresponding labelled 
nucleoside by incubation with snake venom which has 5’-nucleotidase activity.
The conditions are such that complete conversion takes place within the incubation 
time. Unhydrolysed cyclic nucleotide is separated from the nucleoside by batch 
binding of the mixture to Dowex 1-chloride. This binds the charged nucleotides,
,but not the unchai’ged nucleosides.
Figure 2.1. The principle of the cyclic AMP phosphodiesterase assay
NH2
O ------  CH2
O OHO =  P
NH2
Cyclic AMP 
Phosphodiesterase
' Site of hydrolysis
3',5'-cAMP
(Adenosine-3',5'-cyclic 
monophosphate, cAMP)
OH
P “  0 ~  CH2
OH OH
S'-AMP
(Adenosine
monophosphate, AMP)
Snake Venom
NH2
HOCH2
OH OH
ADENOSINE
Dowex
Precipitation of 
unhydrolysed cAMP
ISOplof 
supemetant
Liquid Scin. Counter 
(Reacted Adenosine)
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2.2.5.1. Preparation of reagents
(i) 3',5'-cyclic AMP: 1 mM stock solution was prepared and diluted in 20 mM 
Tris/HCl, 10 mM MgCla pH of 7.4 (Tris/MgCl2 buffer) and aliquots were frozen 
as stock. The concentration required for the assay was obtained by diluting the 
stock on the day of each assay, Mg^+ ions which were in dilution buffer are 
required as a cofactor for c AMP PDE activity.
(ii) Effectors: Rolipram, cilostimide and IBMX were dissolved in DMSO at 
concentrations such that the final DMSO concentration was 0.1 %. This was 
demonstrated to have no effect on PDE activities (Michie, 1995). All the ligands 
were stored at -20 °C. Cyclic GMP and EHNA were dissolved in distilled water. 
On the day of the assay, they were subsequently diluted in 20 mM Tris/HCL, pH 
7.4 to the desired concentration.
(ill) Snake venom {Hannah ophiophagus): A 10 mg/ml stock solution was 
dissolved in distilled water and stored frozen in aliquots. This was diluted to 1 
mg/ml in distilled water for use in the assay.
(iv) Dowex lx8-400-chloride: This was prepared as described previously 
(Thompson et al., 1979). Briefly, at 4 °C, 400 g Dowex 1-chloride was washed 
with 1 M NaOH for 15 min. Resin was then washed extensively with distilled 
water, until the pH of the eluate fell to 7.0. After this time the resin was washed 
with 1 M HCl for 15 min, followed by more washing in distilled water until the 
eluate pH rose to 3.0. The dowex was stored at 4 ^C with distilled water (1:1). 
For use in the assay, the Dowex was further diluted with ethanol, to a final ratio of 
Dowex:watenethanol (1:1:1, by volume). Ethanol is used in order to prevent non­
specific binding of adenosine to Dowex and to prevent adenosine deaminase 
converting adenosine to inosine, which can also bind to Dowex.
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2.2.5.2. Assay procedure
Appropriate amounts of homogenate enzyme extracts were used to give linear time 
courses. These were incubated in a final volume of 100 pi containing 25 pi of 
phosphodiesterase effector maintained at 4 in 1.5 ml Eppendorf tubes. Blanks 
were included with every experiment by replacing the enzyme sample with 25 pi of 
the homogenisation buffer and the effector buffer. The reaction was initiated with 
the addition of 1 pM cAMP, unless stated otherwise. This substrate contained 50 
pi of 0.15 pCi cAMP. The tubes were mixed by vortexing and incubated for 10 
min at 30 ”C. The reaction was terminated by placing the tubes in a boiling water 
bath for 2 min. The samples were then allowed to cool to 4 °C. 25 pg snake 
venom was added to the tubes and they were incubated for 10 min at 30 °C. The 
tubes were then placed on ice and 400 pi of a freshly prepared slurry of 
Dowex:ethanol:water (1:1:1) was added. During this addition the Dowex was 
stirred gently in order to ensure a homogeneous suspension was being added. The 
tubes were left at 4 °C for 30 min, remixed and then centrifuged at 16 000 gav for 3 
min to sediment out the Dowex resin. A 150 pi aliquot of supernatant was 
removed and mixed with 2 ml Ecoscint and the amount of ^H-adenosine was 
counted in a LICB scintillation counter for 60 s per sample.
2.2.5.3. Calculation of specific activities
The corrected cpm per sample was obtained by subtracting the blank value in each 
case. Determining the protein content (section 2.2.10.) of each sample allowed the 
results to be expressed in terms of specific activity. The results were then
II
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calculated as pmols cAMP hydrolysed/min/per mg of protein ± SD.
2.2.6. Determination of kinetic constants
Value of Km was determined by varying the amount of unlabelled cAMP ranging 
from 0.25 pM to 25 pM (unless stated otherwise) in the reaction cocktail in the 
presence of a fixed concentration of radiolabelled cyclic nucleotide tracer. In order 
to calculate values the data from PDE assays were computer fitted to the 
hyperbolic form of the Michaelis-Menten equation where Vobserved -  (Pmax [S] / 
(Xm + [S]) using the Ultrafit (Levenberg-Marquardt algorithm with the 
KaleidaGraph package for the Apple Macintosh, experimental enors supplied; 
Biosoft, U.K.) graphical package. In each case, the 'robust weighting' facility 
was used and the 'goodness of fit' index was not less than 0.99 with each 
estimation.
2.2.7. Determination of IC50  values
Dose-effect studies were perfoimed with 1 pM cAMP (unless stated otherwise) as 
substrate over a range of inhibitor concentrations as shown in the appropriate 
figures. Inhibitors were added at a volume of 25 pi, which was included in the 
assay volume of 100 pi. As such, a 4 times final inhibitor concentration was 
prepared, of which 25 pi was added to each reaction mixture. For each inhibitor 
study, a DMSO control was included in the assay which contained the highest 
DMSO concentration used. In each case, the DMSO concentration was shown to 
have no effect. The data analysed by curve-fitting to the appropriate equation 
using the Levenberg-Marquardt algorithm with the KaleidaGraph package for the 
Apple Macintosh in order to derive IC50 values with associated errors. The 
effector concentration used is described in the appropriate figure legends.
70
1
- II
2.2.8. Relative V m a x  determinations
Relative activity was done using a modification of the methodology described 
previously by others (Shakur et al., 1993, McPhee et al. 1995). Increasing 
concentrations of protein (5 to 50 pg) from C0S7 cells, transfected with different 
PDE expressing-plasmids, were analysed by Western blotting either using 
labelled second (anti-mouse) antibody as a detection system or an ECL procedure. 
For i25i_iabelling, quantitative data was obtained from phosphoimager analysis. 
For ECL, the blots were scanned. The appropriate signal absorbance (A) versus 
amount of protein (pg) was plotted in order to gauge the relative concentrations of 
PDE protein in each of the preparations. For the Vmax determinations, amounts of 
protein from transfected cells which would provide equal amounts of PDE protein 
were taken for PDE assay. Relative Umax values could be calculated using the 
Michaelis equation and the experimentally derived Km (see section 2.2.6.) values.
2.2.9, Cyclic AMP determination
2.2.9.1. Assay principle
Determination of cAMP content was based on the saturation assay of (Brown et 
al., 1972) as described (Kishihara et al., 1993). The binding protein utilised in the 
assay is cyclic AMP-dependent protein kinase (PKA) which has binding sites for 
cAMP. Following stimulation of the cells in the presence of the desired effectors 
for a fixed time the ceUs were lysed, thus releasing the cytosolic cyclic nucleotides. 
After neutralising, the cells were incubated with pH]-labelled cAMP (5- and 8 - 
position of the adenine ring) and cAMP binding protein, allowing competition of 
labelled and unlabelled cAMP for a limited number of binding sites on the binding 
protein. A standaid curve was obtained by incubating known concentrations of 
unlabelled cyclic AMP with fixed amounts of binding protein and radioactive cyclic 
AMP. Thus the unknown cAMP concentrations can be determined in samples by
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comparison with the standard curve. After the incubation, activated charcoal was 
added to the sample to absorb unbound cyclic nucleotide from the solution. The 
charcoal with the bound cyclic nucleotide was removed by a brief centrifugation 
step. 300 \xl of the supernatant was mixed with Ecoscint and the cAMP content 
was determined (see 2.2.9.5.).
2.2.9.2. Preparation of cyclic AMP binding protein
A crude preparation of cAMP binding protein was made according to the procedure 
of (Brown et al., 1972) using bovine adrenal glands which are a rich source of this 
enzyme. Adrenal glands (20-30), obtained from the abattoir were transported to 
the laboratory on ice and all procedures were carried out at 4 °C. The fat was 
removed from the outside of glands, and they were then hemisected revealing the 
pale coloured inner medulla and the darker outer cortex. The medulla was 
removed and discarded while the cortex was retained. One volume of tissue was 
homogenised in one and a half volumes of buffer (250 mM sucrose, 25 mM KCl, 
5 mM MgS0 4 , 50 mM Tris/HCl, pH7.4) in a Waring blender. The homogenate 
was filtered through muslin and then centrifuged at 15 000 rpm using an MSE 18 
centrifuge for 15 min at 4 °C. The supernatant was decanted through filter paper 
and the eluate was aliquoted into 1 ml fractions and stored at -20 °C for up to 3 
months. Separate samples were thawed and diluted for each assay.
2.2.9.3. Assessing intracellular cAMP concentrations
Jurkat T-cells were prepared as described previously (section 2.2.1.2.) and 
resuspended at a density of 1 x 10  ^cells/ml in RPMI-1640 medium. The agonist 
was added to the culture and incubated at 37 °C. After the appropriate incubation 
period, 1 0 0  fil (1  X 1 0  ^cells/assay) of ligand treated sample was placed into a 
microfuge tube containing 100 pi of 4 % perchloric acid to terminate the reaction
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(samples were assayed in triplicate for each condition). The cells were incubated at 
4 °C for 3 min to allow the lysing of the membrane and the extraction of the cychc 
nucleotides. After this time the cell debris was removed by centrifuging at 16 000 
gav for 2 min. Universal indicator was added to the supernatant which made the 
solution turn pink. The solution was then neutralised by addition of 2 M KOH/0.5 
M triethanolamine (TEA) dropwise until the solution turned green. Any precipitate 
that formed was pelleted in a microfuge for 3 min and 50 pi of the supernatant was 
removed for determination of intracellular cAMP concentration using a cAMP 
binding protein prepared as described previously (section 2.2.9.2.).
2.2.9.4. Preparation of reagents for assay
(i) [5, 8~3H]-cyclic AMP: 65 pi (-50 000 cpm) radioactive cAMP was added to 
100 ml of cAMP assay binding buffer (50 mM Tris/HCl pH 7.4, 4 mM EDTA) 
and stored at 4 °C until required for use.
(ii) Binding protein: the binding protein was prepared (section 2.2.9.2) and then 
the aliquoted sample diluted in cAMP assay binding buffer to the desired 
concentration.
(iii) Charcoal solution: The charcoal solution was made up of 2 % (w/v) 
activated charcoal and 1 % (w/v) bovine serum albumin in cAMP binding buffer. 
This was stirred on ice for at least 45 min before it was required.
2.2.9.5. Assay procedure
As mentioned previously, a standard curve was carried out with each assay, for 
cAMP concentrations between 0.0625 and 16 pmols. This part of the assay was
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carried out in duplicate, whilst the unknown samples were assayed in tiiplicate and 
was set up as follows:
Tube Samples Buffer (pi) pH]-cAMP (pi) Binding Protein (pi) 
1-2 -  200 100
3-4 - 100 100 100
5-22 Standards 50 100 100
(0.0625-16)
23-25 Unknowns 50 100 100
Tube 1 and 2 were blanks, calculating the amount of cAMP not bound by charcoal, 
tubes 3 and 4 represented the total binding of cAMP and tubes 5-22 represent the 
standard curve, giving counts for fixed concentrations of cAMP, allowing 
unknown cAMP values to be calculated. The tubes were set up at 4 °C, with 
binding protein added last which allows a fair competition for binding sites 
between the labelled and unlabelled cAMP. They were vortexed and incubated at 4 
for 2-3 h. After this 250 p i charcoal solution was added and the tubes were 
immediately vortexed and spun in a microfuge for 5 min. This step was crucial 
because if the charcoal solution was not centrifuged promptly, cyclic nucleotides 
would be stripped from the binding protein. An aliquot of 300 pi was removed 
from the resulting supernatant and added to 4ml Ecoscint and counted using 
scintillation counter fitted with a curve fitting programme. The results are 
determined as an average of the triplicates assayed and expressed as pmols cAMP 
produced/1 0  ^cells.
2.2.10. Protein determination
Protein was routinely measured by the method of (Bradford, 1976) with BSA as a 
standard. A standard curve was constiucted using 0-20 pg range of bovine serum 
albumin. The standard and unknown protein solutions were made up to a volume 
of 800 pi with distilled water before the addition of 2(X) pi of Bradford reagent and
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the tubes were vortexed. Absorbance was determined at 595 nm using a Shimadzu 
UV-1201 spectrophotometer. Unknown concentrations were determined by 
plotting the standard curve (x axis = mg/ml of protein concentration, y axis = 
A595) (Figure 2.2).
2.2.11. Immunoprécipitation
Homogenates (0.5-1 mg of protein) were resuspended in immunoprécipitation 
buffer (1 % Triton X-100, 10 mM EDTA, 100 mM NaH2 P0 4 .2 H2 0 , 50 mM 
HEPES, pH 7.2) containing protease inhibitors. For the solubilisation o f the 
proteins this mixture was left at 4 °C for 10 min and centrifuged at 16 000 gav for 4 
min in a microfuge. Antiseium (1:50 final dilution) was added and the sample was 
mixed for 2 h at 4 °C. An aliquot (100 pi) of 10 % Pansorbin was washed twice 
in ice-cold PBS (140 mM NaCl, 2.7 mM KCl, 8 mM NaH2P04, 1.5 mM 
K H 2 PO 4 , pH 7.4) then added to the homogenate. This mixture was than 
incubated as before. Following this, the sample was centrifuged in a microfuge 
for 2 min, the pellet was washed twice in PBS buffer and resuspended in 
Tris/MgCl2  buffer (2.2.5.1.) for determination of PDE activity.
2.2.12. Expression of the PDE cDNAs in C 0S7 cells
2.2.12.1. DEAE dextran method of transient transfection
For the characterisation of various phosphodiesterases the SV-40 transformed 
monkey kidney cell line (COS7) was used. The cells were split at approximately 
1/3 confluence by plating in 80 cm^ flask or 10 cm diameter plates, 18 h before the 
transfection. For transfection, the culture medium was replaced with 5 ml of 
DMEM [10 % (v/v) Nuserum together with 0.1 mM chloroquine]. DNA for 
transfection (5-10 pg) was diluted in 250 pi of TE buffer (10 mM Tris/HCl, 0.1 
mM EDTA, pH 7.6) and 200 pi of a 10 mg/ml DEAE-dextran solution. This
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DNA/dexti'an mixture was incubated at room temperature for 15 min before being 
added dropwise to the cell culture. The cells were incubated at 37 °C for 4 h. The 
transfection medium was aspirated and the cells 'shocked' for 2 min with a 5 ml of 
10 % DMSO in PBS at room temperature. The culture was then rinsed with PBS 
before DMEM, containing 10 % (v/v) foetal bovine serum, was added and the 
plates were incubated at 37 for 72 h. Mock-transfected cells were treated as 
above without addition of DNA.
2.2.12.2. Disruption of transfected C 0S 7 cells
After cells were transfected as described above, they were prepared for 
homogenisation as follows: the growth medium was aspirated and the cells 
incubated in 5 ml (for 80 cm^ flask) complete KHEM (50 mM KCl, 50 mM 
Hepes/pH 7.4, 10 mM EGTA, 1.92 mM MgCh, 1 mM DTT and a mixture of 
protease inhibitor cocktail (see section 2.2.1.2.) for 45 min at 4°C. The cells 
were then washed with 5 ml of TEA/KCl (10 mM Triethanolamine/pH 7.2, 150 
mM KCl) at 4 °C for 10 min, the buffer was aspirated and ceUs washed with 5 ml 
of KHEM incomplete buffer (as KHEM complete buffer but without protease 
inhibitors). Finally cells were washed with 1 ml of complete KHEM for 2 min and 
then the buffer drained. The cells were scraped into a final volume of about 100 pi 
per 80 cm2  plate and this cell suspension was distrupted by 2 0  strokes of the pestle 
in a Dounce homogeniser.
2.2.12.3. Subcellular fractionation
A post-nuclear (PI) fraction was generated by centrifuging the cell homogenate for 
10 min at 1 000 gav in a refrigerated centrifuge at 4 °C. High-speed centrifugation 
for 1 h at 100 000 gav at 4 °C of remaining supernatant yielded a membrane 
fraction (P2) pellet and a high speed supernatant (S) termed the cytosolic fraction.
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The P2 pellet was then washed in KHEM and recentrifuged as before. Finally, the 
P2 pellet was resuspended in KHEM buffer to the same volume as the S fi-action.
2.2.12.4. Treatment of membrane with high salt concentration
Membranes (200 p.g of protein) from COS7 cells previously transfected with 
various plasmid DNAs were treated with KHEM (100 jil) buffer containing the 
indicated NaCl concentrations (final pH 7.2). The extracts were left on ice for 30 
min before centrifugation at 100 000 gav for 1 h at 4 °C. The resulting pellet was 
resuspended in KHEM buffer containing the appropriate NaCl concentration and 
the pellet and supernatant fi'actions analysed by Western blotting.
2.2.12.5. Solubilisation of membranes with Triton X-100
Detergent solubilisation involved the membranes (200 fig of protein) from COS7 
cells previously transfected with various plasmid DNAs. The extracts were treated 
with KHEM (100 fil) buffer containing the indicated Triton X-100 concentrations. 
The membranes were left on ice for 30 min before centrifugation at 100 000 gav for 
1 h at 4 °C. The resulting pellet was resuspended in KHEM buffer containing the 
appropriate Triton X-100 concentration and the pellet and supernatant fractions 
analysed by Western blotting.
2.2.13. Lactate dehydrogenase assay
Lactate dehydrogenase activity was measured by the rate of oxidation of NADH 
which absorbs at a wavelength 340 nm therefore, the rate of decrease of optical 
density at 340 nm is a measure of enzyme activity. Briefly, 1.35 ml of 0.15 M 
Tris/HCl pH 7.4 and 50 fil each of 10 mM sodium pyruvate and tissue sample 
were added to a 1.5 ml cuvette and used to zero a spectrophotometer set at 340 nm
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and linked to a pen recorder. Free lactate dehydrogenase activity was measured by 
the addition of 50 p.1 of 2 mM p-NADH and the trace followed for several minutes. 
Finally 10 % Triton/Tris was then added to the cuvette to release entrapped activity 
and the total activity was calculated from this trace. Lactate dehydrogenase activity 
was then calculated using the following:
% cells broken = (£fgoXiDH),.x,1 0 0  
(Total LDH)
2.2.14. P rec ip ita tion  of oligonucleotides
Synthesised oligonucleotides were supplied as NH4 OH solutions and had to be 
purified before use, 300 |il of oligonucleotide solution, 30 jil of 3 M sodium 
acetate (pH 4.6) and 1 ml of absolute ethanol were mixed together and incubated at 
-70 °C for at least 30 min or overnight at -20 °C. Oligonucleotides were then spun 
in a microcentrifuge at 16 000 gav for 15 min. The supernatant was removed and 
discarded, leaving the pellet visible in the bottom of the tube. The pellet was then 
washed with 1 ml of 75 % ethanol and spun as above, after which it was either 
vacuum dried for 15 min or dried on air for about 30 min and then re suspended in
i
40 jal of sterile (IH2O.
2.2.14.1. Q u an tita tio n  of oligonucleotides
ÎIAThe principles of oligonucleotide concentration measurements are the same as for RNA (section 2.2.15.1.) except that here a solution of oligonucleotides with an 
OD26O "  1 contains approximately 33 fig of RNA per ml, therefore the reading 
was multiplied by the dilution factor and then by 33 to give the concentration per 
ml.
Î
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2.2.15. RNA extraction by Tri-Reagent
Total RNA was extracted from the cultured cells using a modification of the 
protocol originally described by (Chomczynski & Sacchi, 1987). Cells were lysed 
by the addition with 1ml of Tri-Reagent™ to either pre-washed 10 x IQb cells or 
confluent 80 cm^ flask. Then the cell suspension was transferred into an 
Eppendorf tube and homogenised by 5-10 passages through a Gilson pipette tip. 
The homogenate was stored at room temperature for 5 min. Cell membranes/high 
molecular weight DNA and polysaccharides were pelletted by centrifugation (11 
000 gav for 10 min at 4 °C) and the supernatant transferred to a fresh microfuge 
tube. RNA was then separated from DNA and protein by the following phase 
separation: to each tube 0.2 ml RNase-free chloroform/ml of Tri-Reagent™ 
originally used was added and vortexed for 15 s and then stored at room 
temperature for 3 min. Following centrifugation at 11 000 gav for 15 min at 4 °C 
most of the upper aqueous phase was transferred to new tube.
The RNA was then precipitated from this phase by adding 0.5 ml of propan-2-ol 
per 1 ml of Tri-Reagent used initially. Samples were left at room temperature for 
5-10 min and centrifuged at 11 000 gav for 10 min at 4 °C. RNA pelleted on the 
side and bottom of tubes.
The supernatant was discarded and 1 ml of 75 % ethanol was added to wash the 
RNA. Ethanol was removed by spinning at 7 000 gav for 5 min at 4 °C and the 
RNA pellet either air-dried or dried under vacuum for 5-10 min. The RNA was 
resolubilised in (1 %) DEPC treated water by pipetting a few times and incubated 
for 10-15 min at 55-60 ”C if necessary to help dissolve it.
2.2.15.1. Determination of RNA concentration
The concentration of the RNA was determined by measuring the absorbance, or 
optical density (OD), of a 10 (il of sample at wavelengths of 260 nm and 280 nm 
in quartz cuvettes using a Shimadzu UV-1201 spectrophotometer. A 1/100 
dilution of the resuspended RNA was used to read the absorbance against a dH20 
blank. The OD260 /A2 8O ratio was determined, ideally yielding, a result of 1.8 to 
2.0. The concentiation of RNA as jig/ml was calculated by the multiplication of 
the OD2 6O by the dilution factor (100) and by a constant (40) where 40 = 1 OD 
gives 40 p.g RNA at 260 nm. Isolated total RNA (5 pg/lane) was then checked by 
electrophoresis on 1.5 % agarose gel. Extracted RNA was either used fresh or 
stored at -80 until use.
2.2.16. First-strand cDNA synthesis
Preparation of first-strand cDNA was achieved using the 'First-strand cDNA 
synthesis kit' with a total reaction volume of 33 pi. 5 pg of total RNA was diluted 
with DEPC treated water to a total volume of 20 pi. This was then denatured by 
heating to 65 °C for 10 min. Denatured RNA was then incubated with murine 
reverse transcriptase, 6 mM dithiothreitol, 0.6 mM of each dNTPs and 0.2 pg of 
the supplied poly(dT) primer [NorI-d(T)ig] for 1 h at 37 °C. The resultant first 
strand cDNA synthesised using the RNA as a template was then stored at -20^C.
2.2.17. The Polymerase Chain Reaction (PCR)
The polymerase chain reaction is a technique for the in vitro amplification of 
specific DNA sequences by the simultaneous primer extention of complementary 
strands of DNA, Standard PCR amplification reactions were performed in 1 x 
PCR buffer (50 niM KCl, 20 mM Tris/HCl) with a total reaction volume of 50 pi.
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This contained final concentrations of 0.2 mM of each dNTP (adenine, guanine, 
thymidine and cytosine bases), 1.5 mM MgCl2  together with 25 pmoles of 5'-end 
and 3'-end primers, 5 units of Taq DNA polymerase and 3 pi of template DNA. 
The PCR machine was programmed for denaturation/annealing and extension of 
the selected region by the primers. These were performed using various times, 
temperatures and repeated cycles. See individual experiments for relevant cycling 
conditions.
2.2.18. A garose gel e lectrophoresis
The required amount of high melting temperature agarose (1.5 to 2 %) was 
dissolved in 18 ml of 0.5 x TBE buffer (45 mM Tris/HCl, 45 mM boric acid, 1 
mM EDTA, pH 8.0) and melted in a microwave for 1 min. After cooling, the 
agarose was poured into an electrophoresis tank and allowed to settle. 5 to 10 pi 
of RT-PCR reaction mixture was loaded. In order to determine the size of the 
RNA/DNA fragments, Phixl74 DNA/Hae III Markers were loaded also. Samples 
were analysed by electrophoresis in TBE buffer containing ethidium bromide (50 
pg/150 ml buffer) at 75 mA for 90 min. After electrophoresis, the gel was 
visualised under UV light and photographed.
2.2.19. Purification of DNA from  PCR products
RT-PCR products were separated by electrophoresis through 1.5 % low melting 
agarose gel. DNA bands ( -  300 mg) were excised using a sterile scalpel and 
transferred to Eppendorf tubes. DNA purification was performed according to 
'Promega DNA purification systems'. The DNA slice was incubated in a 
waterbath until the agarose completely melted (~3 min). Then 1 ml of the 
purification resin was added and the solution mixed through for 20 s. The
.resin/DNA mix was then tiansferred into syringe barrels and a vacuum applied to
i-..
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draw the solution through the syringe. Columns were washed by running 2 ml of 
80 % isopropyl alcohol through the syringe and the vacuum re-applied. The resin 
was dried by continuing to draw a vacuum for an additional 1-2 min. After 
discarding the syringe, the minicolumn was transfemed to a 1.5 ml microfuge tube 
and spun for 20 s in a microfuge to elute the bound DNA fragment. The 
minicolumn was placed in a fresh microcentrifuge tube and 30-50 pi of dH2 0  
(preheated to 70 ^C) was added to the minicolumn. After incubation at room 
temperature for 1 min the DNA was collected by centrifuging the tube in a 
microfuge at 16 000 gav for 5 s. 50 pi of purified DNA fragment was then blunt- 
ended by incubating with 1 pi of Pfu DNA polymerase (Stragene) in the presences 
of 5 pi of 10 X polymerase buffer and 5 pi of 10 mM dNTPs. The tubes were 
covered with 20 pi of mineral oil and incubated for 30 min at 72 “C. Blunt-ended 
fi-agments were subsequently cloned into pCRscript using the pCRscript AMP SK 
cloning kit. E. coU strain JM109 was used for routine plasmid transformation and 
propagation (Nishimura et al., 1990). Plasmid DNA was purified using the 
Wizard™ Miniprep kit and inserts sequenced using the PRISM Ready Reaction 
DyeDeoxy Terminator Cycle Sequencing kit (Perkin-Elmer). Sequence analyses 
was performed on model 373 automated sequencer (Applied Biosystems).
2.2.20. C om petent cell p rep ara tio n
JM109 E. Coli cells was first grown in 10 ml of Luria-Bertani (LB) medium (5 g 
NaCl, 2.5 g yeast extract, 5 g tryptone in 500 ml water, sterilised by autoclaving at 
121 "C for 15 min) overnight at 37 °C with shaking. 2 ml of the culture was 
transferred into 100 ml of fresh prewarmed medium and was grown at 37 °C until 
ODgoo -  0.6-1. The culture was then harvested by centrifugation at 950 gav for 5 
min at room temperature and the pellet was resuspended in 20 ml of O.IM MgCl2 . 
This suspension was recentrifuged as before and the final pellet was resuspended
in 2 ml of ice cold 0.1 M CaCl2  and left on ice for 30 min then immediately used or 
stored at -80 °C.
2.2.21. Transformation of plasmid vector into competent cells
1 pg of the plasmid DNA was added to 50 pi of competent E. coli cells and 
incubated on ice for 15 min. Bacteria were then heat shocked for 90 s at 42 and 
again incubated on ice for Imin. All of these transformed bugs were then 
transferred to 1 ml of LB medium and incubated for 45 min at 37 with shaking. 
100 pi of the culture was smeared onto LB bacto-agar (as LB medium plus the 
addition of 1.5 % of agar and 50 pg/ml Amplicillin) with negative control. The 
plates were incubated at 37 °C overnight. A single colony was used to inoculate 
10 ml of LB medium containing Ampicillin and grown overnight at 37 with 
shaking. 4 ml of this starter culture was then transferred to 500 ml of LB medium 
and grown as above.
2.2.22. Storage of E. coli cells
E. coU cells were maintained on LB bacto agar at 4 °C for short term storage. For 
long term storage, 1 ml of culture was taken from 1 0  ml of overnight culture and 
then mixed with glycerol to a final concentration of 15 % (v/v) and stored at -70°C.
2.2.23. Plasmid DNA purification
500 ml of plasmid DNA containing culture was harvested at 53(X) gav for 10 min at 
room temperature and the DNA purified using the Promega Maxiprep kit. Here the 
pellet was resuspended in 15 ml of cell lysis solution and mixed gently. Lysis was 
determined to be complete when the solution became clear and viscous. The 
mixture was neutralised with neutralisation solution and immediately mixed by
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gently inverting the centrifuge bottle several times. This suspension was 
centrifuged at 14 000 gav for 15 min at room temperature. The cleared supernatant 
was transferred by filtering it through muslin. 0.5 volume of isopropanol was 
added to the filtered supernatant and mixed by inversion and recentrifuged as 
above. The supernatant was discaided and the DNA pellet resuspended in 2 ml of 
TE buffer. 10 ml of resin was added to the DNA solution and mixed.
The Maxicolumn tip was inserted into the vacuum source and the resin/DNA mix 
transferred into the column. Vacuum was applied to pull the mixture through the 
column. 13 ml of Column wash solution was added to rinse the centrifuge bottle 
and then poured into the column. The vacuum was applied and 12 ml of same 
solution was added to wash the column. 5 ml of 80 % of ethanol was added to the 
column to rinse the resin. The vacuum was allowed to draw the ethanol through 
and then continued for a further 1 min. The column was centrifuged in a 50 ml 
tube at 500 gav for 5 min and the resin was dried by applying an additional 5 min 
of vacuum. Finally 1.5 ml of 65 °C preheated distilled water was applied to the 
column and left for 1 min to elute the DNA, again the column was centrifuged as 
above and plasmid DNA was taken.
2.2.24. Estimation of DNA concentration
The concentration of probe DNA was estimated by measuring the optical density 
(OD) at 260 nm in Shimadzu UV-1201 spectrophotometer. The optical density of 
1 ml distilled water was measured at 260 nm and then the spectrophotometer 
settled to zero. 10 p-1 of aliquot probe DNA was added to 990 p,l distilled water, 
vortexed and then estimated at 260 nm and 280 nm in quartz cuvettes. The purity 
of the DNA was determined by division of the OD2 6O by the OD2 8O, yielding, 
ideally, a result of 1.8-2.0. The concentration of DNA in the suspension as pg/ml
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was calculated by the multiplication of the OD26O by the dilution factor (1 0 0 ) and 
by a constant (50), where 50 = 1 OD gives 50 pg DNA at 260 nm.
2.2.25. Storage of plasmid DNA
DNA was routinely stored in TE buffer at -20 ^C. DNA stored in this way remains 
stable for several years. Long-term storage of DNA was under 100 % ethanol at 
-70 °C.
2.2.26. Analysis of data and statistics
The data given in this study represent the mean ± SD of n independent 
determinations. The significance of differences was calculated with the Student's 
t-test.
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Figure 2.2. S tandard  curve for a B radford  pro tein  assay 
The samples for the standard curve were prepared as described in section 2.2.10. 
Bovine serum albumin concentrations of 0-20 |i.g were used as indicated and the 
absorbance was read at 595 nm. The blank without protein was used to zero the 
spectrophotometer. The assays were carried out in duplicate. This is a 
representative experiment which has been canied out at least twenty times.
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CHAPTER 3
INVESTIGATION OF THE EFFECT OF cAMP 
ELEVATING AGENTS ON PHOSPHODIESTERASE 
ACTIVITIES IN HUMAN JURKAT T-CELLS
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3 .1 .  Introduction i
Cyclic adenosine monophosphate (cAMP) is an important second messenger that 
mediates biological responses generated by a variety of extracellular signals,
including hormones, neurotransmitters and pathogenic bacterial toxins (Alava et
.ah, 1992, Kammer, 1988, Manganiello et ah, 1995a). Control of intracellular 
cAMP concentration is critical to the regulation of inany cellular responses to
phosphorylation of specific target proteins, leading to altered cell function 
(Houslay et ah, 1995, Kammer, 1988).
extracellular stimuli. Generation of cAMP is initiated via cell surface 
transmembrane receptors which, through a G-protein-ti’ansduced process, leads to 
changes in the activity o f the enzyme adenylate cyclase (Figure 1.1). Adenylate
cyclase produces cAMP within the cell which serves to activate cAMP dependent 
protein kinase A (PKA) activity. PKA then exerts its action through the
I
Many hormones exert their actions on target cells by elevating the intracellular 
concentration of cAMP, through coupling of their specific cell surface receptor to 
the stimulatory G-protein, Gg, However, enhanced cAMP concentration return 
towards basal levels in spite of the continuous presence of hormone. This 
phenomenon involves the expression of active intracellular mechanisms 
terminating the hormonal stimulation, since extracellular dissociation of the
hormone from the receptor might not be the primary cause of cessation of a 
stimulus (Collins et ah, 1992, Dohlman et ah, 1991). It is also thought to be the 
result o f mechanisms that protect the cell from excessive stimulation 
(desensitisation) or adjust the cell sensitivity to circulating hormone levels (cell 
adaptation). The regulation of cAMP hydrolysis has been shown to play an 
important role in terminating the hormonal stimulus and inducing desensitisation in 
the target cell. The only known mechanism for the degradation of cAMP is by the
1
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action of PDEs; these enzymes therefore provide important sites for hormonal 
regulation (Gierabycz, 1996).
Degradation of intracellular cAMP levels can be regulated by a complex family of 
cyclic nucleotide phosphodiesterases (PDEs). PDEs catalyse the hydrolysis of the 
3'-phosphoester bond on adenosine cyclic 3',5’-monophosphate (cAMP) and 
guanosine cyclic 3',5'-monophosphate (cGMP) to form the 5'-monophosphate 
products AMP and GMP, respectively (Figure 2.1). In turn, 5'-AMP and 5'- 
GMP cannot activate cyclic nucleotide dependent PKA and PKG, respectively. 
Seven distinct mammalian PDE families (Beavo, 1995, Beavo et al., 1994, 
Rybalkin & Beavo, 1996) have been identified on the basis of molecular cloning 
and enzymatic characterisation (Table 1.1). These are encoded by distinct genes. 
The PDE classes are: PD E l, Ca^+Zcalmodulin-stimulated; PDE2, cGMP- 
stimulated; PDE3, cGMP-inhibited; PDE4, cAMP-specific and rolipram-inhibited; 
PDB5, cGMP-specific; PDE6 , cGMP-specific photoreceptor and PDE7, cAMP- 
specific but insensitive to inhibition by the non-selective PDE inhibitor IB MX 
(Beavo et al., 1994, Manganiello et al., 1995a). In the seven gene families at least 
14 different PDE genes generate more than 34 different PDE isoforms (Beavo et 
al., 1994). PDEs are encoded by different genes but with additional multiplicity 
representing splice variants and possibly different transcriptional start products of 
the same gene (Beavo & Reifsnyder, 1990). Mammalian PDEs posses a central 
conserved region of approximately ~ 300 amino acids which is thought to contain 
the catalytic domain. However, they vary widely in their extreme N- and C- 
terminal amino acid sequences, kinetic characteristics, substrate affinities, 
biochemical and pharmacologic properties, cellular distribution and subcellular 
localisation (Beavo, 1988, Manganiello et al., 1990a, McLaughlin et al., 1993, 
Swinnen et al., 1989b).
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Two regulatory processes may provide a highly coordinate mechanism for short- 
and long-term control of cAMP levels through PDE action. One of these is the 
short term regulation by phosphorylation of PDEs by cAMP-dependent protein 
kinase (Beltman et al., 1993, Gettys et al., 1987). This can play an important role 
in terminating the hormonal stimulus and in inducing desensitisation in the target 
cells. Rapid regulatory changes can be elicited by the phosphorylation of PDE3 
enzymes (Houslay & Kilgour, 1990, Manganiello et al., 1995b) and isoforms of 
PDE4 enzymes (Marchmont & Houslay, 1980a, Sette et al., 1994a). Long-term 
regulation requires hours to develop, may be mediated again via a cAMP- 
dependent protein kinase mechanism, but which involves inducing PDE isoform 
expression (Conti et al., 1991). This has been defined as an adaptive response to 
chronic increases in intracellular cAMP levels (Conti et al., 1995b, Thompson, 
1991) and described in particular detail for splice variants arising from the PDE4D 
gene (Conti et al., 1995a, Conti et al., 1995b, Sette et al., 1994b).
Current studies have been focussed on the cAMP-specific PDE4 isoenzymes 
where compounds able to exert selective inhibition of such enzymes can exert anti­
depressant and anti-inflammatory actions (DiSanto & Heaslip, 1995). Presently, 
such PDE4 selective inhibitors are being considered for the treatment of asthma, 
multiple sclerosis, septic and iox ic  shock and atopy (Barnes, 1991). PDE4 
isoforms can be selectively inhibited by certain drugs such as rolipram and Ro 20- 
1724 (Beavo et al., 1994, Bolger, 1994, Manganiello et al., 1995a). Both 
inhibitors exhibit considerably higher affinity for the binding site rather than the 
catalytic domain of the enzyme (Kelly et al., 1996).
Molecular cloning approaches have recently demonstrated that PDE4 is a family of 
enzymes comprising four distinct genes, designated PDE4A, 4B, 4C and 4D 
which produce a variety of splice variants in both humans (Baecker et al., 1994, 
Bolger, 1994, Livi et al., 1990) and rats (Davis et ah, 1989) (Figure 1.3 and
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3.20). These subtypes share much greater catalytic domain sequence homology 
with each other (> 90 %) than with other PDEs and they also share two highly 
conserved regions (UCRl and UCR2) in the putative regulatory domain upstream 
of the catalytic region (Bolger, 1994). Mapping studies have been shown that 
human PDE4 forms are localised to three chromosomes with PDE4A (Horton et 
al., 1995) and PDE4C being located on chromosome 19 (Milatovich et al., 1994), 
PDE4B on chromosome 1 and PDE4D on chromosome 5 (Szpirer et al., 1995). 
Over 16 isoforms of the PDE4 family (Bolger, 1994) are produced by these genes 
as a result of alternative splicing. This predominantly takes the form of 5'-domain 
swops, leading to the production of enzymes with distinct N-terminal regions. 
The amino termini of these proteins has been postulated to have regulatory 
functions which include stabilisation of the enzymes (Shakur et al., 1993), 
intracellular targeting (Scotland & Houslay, 1995) and protein-protein interactions 
(O'Connell et al., 1996).
The cyclic AMP-specific PDE (PDE4) is the predominant cAMP hydrolysing 
isoenzyme class found in most, if not all, immune and inflammatory cells (Alvarez 
et al., 1995, Manning et al., 1996, Torphy & Undem, 1991). The precise role(s) 
of cAMP in the immune response remains unclear. However, it is well defined 
that cAMP has a role as a second messenger mediating a generalised suppression 
of immune and inflammatory cell activity (Kammer, 1988), Recent investigations 
have led to the recognition that PDE4 plays a critical role in regulating the function 
of these cells (Torphy et al., 1995, Verghese et al., 1995). Most interest to date 
has focused on the development of inhibitors of PDE4 isoenzymes for the 
treatment of inflammatory diseases including arthritis, atopic dermatitis and, in 
particular, asthma (Asthon et al., 1994, Kelly et al., 1996). Although, the 
therapeutic potential of PDE4 inhibitors in chronic inflammatory disorders seems 
considerable, the utility of isoenzyme non-selective PDE4 compounds induces
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side-effects. Development of isozyme-selective therapeutic agents may avoid 
unwanted effects.
T lymphocytes play key role in regulating immune responses. There is general 
agreement that cAMP is a negative modulator on mitogenesis and activation of 
mature T lymphocytes (Alexander & Cantrell, 1989, Goodwin & Ceuppens, 1983, 
Kammer, 1988). The rise in cAMP also inhibits interleukin-2 (IL-2) production 
(Anastassiou et al., 1992, Wacholtz et al., 1991) and stimulation of thymic 
apoptosis (Kaye & Ellenberger, 1992), although the precise molecular mechanisms 
that underlie such effects are not understood in detail. However, consistent with 
such a notion, leukemic lymphocytes appear to have lowered cAMP levels by 3 - 
25 fold than normal T cells in murine and in human systems (Epstein & Hachisu, 
1984). This may be attributable to the elevated PDE activity that has been 
observed in such instances (Thompson, 1991). One possible route through which 
cAMP might exerts an inhibitory effect on cell growth is that, in many cells, 
protein kinase A can seemingly inhibit the activation of MAP kinase by eliciting the 
phosphorylation and inactivation of B-raf (Cook & McCormick, 1993). However, 
there is evidence which suggests that this does not occur in T-cells, but that 
elevated cAMP levels serve to inhibit c-Jun N-terminal kinase (INK) (Hsueh & 
Lai, 1995). As T-cell activation, including IL-2 gene activation, requires the 
integration of Raf-1 and INK pathways, then a block in either will lead to an 
inhibitory effect (Hsueh & Lai, 1995).
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3 .1 .1 .  Aim of the study
The purpose of this study was to investigate whether chronic elevation of 
intracellular cAMP concentrations can adaptively alter the expression of specific 
PDE isoforms in T lymphocytes and, in particular, the control of expression of 
PDE4 splice variants. Here the human leukemic T-cell line, Jurkat J6 , has been 
studied as a model of T lymphocytes activation with either the adenylate cyclase 
activator forskolin or G-protein activator cholera toxin used to elevate cAMP 
levels.
3 .2 .  R esults
3 .2 .1 .  Characterisation of the phosphodiesterase isoforms of Jurkat 
T -cells
To determine which forms of PDE activity are present in human Jurkat leukemic T- 
cells, a pharmacological approach was employed using selective inhibitors and 
activators. Compounds selective for effects on specific PDE isoforms (Beavo et 
al., 1994, Beavo & Reifsnyder, 1990, Houslay & Kilgour, 1990, Spence et al.,
1995) were used to identify and gauge the magnitude of various PDE isoforms in 
this cell line.
Homogenates of Jurkat T-cells exhibited cAMP phosphodiesterase activity of 
18.0-20.5 pmol of cAMP hydrolysed/min per mg of protein when assayed with 1 
pM  cAMP as substrate (mean ± SD; n = 8 ). Jurkat cells appeared to express 
PD E l, PDE2, PDE3, PDE4 and PDE7 activities (Table 3.1). Ca^+ZCaM- 
stimulated PDEl activity was assayed by performing PDE assays in the presence 
o f EGTA, to chelate any endogenous Ca^+ and then adding excess 
Ca^+Zcalmodulin (50 pM and 20 ngZml respectively) in order to determine the 
degree of stimulation o f this isoform (Manganiello et al., 1995a). There is a 
possibility that sufficient endogenous Ca^+ might elicit the full activation of any
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PDEl activity without added exogenous Ca '^"' (Spence et ah, 1995). PDE assays 
were also carried out in the presence of EGTA (2 mM) to determine whether the 
subsequent addition of Ca^+ (5 mM) then caused stimulation. However, in no 
instance was any difference observed between analyses done in this fashion and 
those where Ca^+ was added without EGTA. Here, Ca^+ /  CaM (50 pM; 20 
ng/ml) elicited an increase in PDEl activity of some 3.5±1.0 pmol/min/mg protein, 
indicating that low levels of PDEl were present (Table 3.1).
PDEl family is one of the key enzymes involved in the complex interactions which 
occur between the cyclic-nucleotide and Ca^+ second-messenger systems (Yan et 
al., 1996). PDEl isoenzymes are expressed in distinct cell types in various tissues 
and have different substrate affinities and molecular and/or catalytic properties and 
tissue-specificities (Rybalkin & Beavo, 1996, Wang et al., 1990). Stimulation of 
this group of enzymes require the simultaneous presence of both Ca^+ and 
calmodulin (Wang et al., 1990). At least three different genes {PDEIA, PDEIB 
and PD FiC) have been identified in the CaM-PDE family (Loughney et ah, 1996). 
Here RT-PCR analyses are used to detect PDEl forms employing degenerate 
primers based upon on all known PDEl sequences from rat, mouse, human and 
bovine sources. One set could be designed to detect both PDEIA and PDEIB but 
not PDE 1C isoforms (Spence et al., 1995). A second set of degenerate primers 
were used to detect PDE 1C. The PDE 1C specific primers did not amplify any 
fragment using RNA from either this Jurkat cell line or from Chinese hamster 
ovary cells (CHO), although they did from the human thyroid carcinoma FTC 133 
cell line. Thus the PDE 1C isoform was not expressed in Jurkat cells. Using the 
PDEIA/B degenerate primer pair a 601 bp fragment of the predicted size was 
successfully amplified (Figure 3.1) from RNA preparations from human Jurkat T- 
cells. In addition, using the same primers with RNA extracts from PMA- and 
ATP-treated CHO cells a similar sized fragment was amplified (Spence et ah, 
1997). Sequencing of both the CHO and Jurkat T-cell PCR products yielded 602
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bp and 554 bp of novel sequence, respectively, which have been deposited in the 
GenBank data base (accession numbers, U40585 and U40584, respectively)
(Spence et al., 1997) (Figure 3.2), These both show strong identity with sequence 
reported for bovine (M94867) and mouse (M94538) PDEIB forms. Indeed, pair­
wise alignments found that the two existing PDEIB sequences shared 91-95 % 
and 90-92 % nucleotide identity with the Chinese hamster sequence and the human 
Jurkat T-cell sequence, respectively, whereas the PDEIA (U40371) and PDE 1C 
(U40370) sequences show 68-69 % identity to Chinese hamster and 67-71 % 
identity to human sequence (Figure 3.2). Moreover, alignment of the amino acid 
sequences found that the conservation between the CHO sequence was 99 % and 
Jurkat T-cell sequence 96-97 % identity when compared pairwise with the other 
PDEIB  sequences. In contrast the CHO sequence has 65-69 % and Jurkat T-cell 
sequence 66-70 % amino acid identity when compared pairwise with the non- 
homologus P D EIA  and PDE7C sequences. Analysis of Jurkat T-cell PDEl 
sequence and recently published (Jiang et al., 1996) full length human PDEIB  
sequence (GenBank; U56976), from human RPMI-8392 B-cells, showed that the 
two share 99 % nucleotide identity. This suggests that the cDNA fragment 
amplified from human Jurkat T-cells by RT-PCR clearly belongs to the PDEIB  
gene family.
Low concentrations of cGMP serve as a competitive inhibitor of PDE3 activity 
(Beavo et al., 1994, Manganiello et al., 1995a) and stimulator of PDE2 activity 
(Manganiello et al., 1990a, Manganiello et al., 1995b, Michie et al., 1996, Tenor 
et al., 1995). The PDE3 isoform can also be selectively inhibited, with high 
specificity, by the compound cilostimide (Beavo & Reifsnyder, 1990, Manganiello 
et al., 1995b). In order to gauge PDE3 activity, PDE assays were performed with 
1 p-M cAMP as substrate and in the presence and absence of 10 |iM  cilostimide, 
which can be expected to inhibit all of the PDE3 activity. Using this it appears that 
PDE3 forms ~ 55 % of total Jurkat T-cell cAMP homogenate PDE activity (Table
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3.1). Low concentrations of cGMP caused a profound, dose-dependent, 
inhibition of Jurkat cell PDE activity (Figure 3.3), with an IC50  of 0.9±0.2 p.M. A 
similar degree of profound, dose-dependent, inhibition was also elicited (Figure 
3.4) using the PDE3 selective inhibitor cilostimide with an IC50  of 178±38 nM.
cGMP can also affect cAMP PDE activity by causing the stimulation of any PDE2 
activity. However, the similarity in the magnitude of inhibition caused by both 
cGMP and by cilostimide would appear to suggest that any PDE2 activity in Jui’kat 
T-cells was relatively small in comparison to that of PDE3 activity, PDE2 activity 
can be gauged by the selective inhibitor EHNA (previously known as MEP-1) 
(Beavo et al., 1994, Mery et al., 1995, Michie et al,, 1996) which appears to exert 
its most profound effect on the cGMP-stimulated state of PDE2 (Michie et al., 
1996). EHNA achieved but a very small inhibitory (~ 5 %) effect on the cGMP- 
stimulated PDE activity of Jurkat T-cells (Table 3.1), consistent with this PDE 
form providing a minor component of the total cellular PDE activity. The IC50 of 
3.210.5 pM  (Figure 3.5) noted was of a similar magnitude for that reported for the 
inhibition of PDE2 activity in both hepatocytes and thymocytes (Michie et al.,
1996).
Rolipram is a highly selective inhibitor for cAMP-specific PDE4 family enzymes 
(Beavo & Reifsnyder, 1990, Bolger, 1994, Manganiello et al., 1995a, Marcoz et 
al., 1993b, Nicholson et al., 1991, Shakur et al., 1993). These enzymes typically 
exhibit IC50  values of 0.1 pM to 1 pM range for rolipram when assayed at 1 pM 
cAMP (Lobban et al., 1994, Michie et al., 1996, Nicholson et al., 1991), whereas 
other PDE species are either insensitive to rolipram or show IC50  values at least 
100-1000 fold higher (Nicholson et al., 1991, Torphy & Cieslinski, 1989). Thus 
the inhibition of PDE4 monitored in the presence of 10 pM rolipram, with IpM  
cAMP as substrate, can be expected to lead to maximal inhibition of this isoform 
group with either little or no effects on other species. Rolipram caused a marked.
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dose-dependent, inhibition of Jurkat T-cell cAMP PDE activity with an IC5 0  of 
13±7 nm (Figure 3.6). At concentrations between 1 and 20 pM, where it can be 
expected to have selectively inhibited all of the PDE4 activity, the magnitude of the 
inhibition seen suggested that PDE4 activity provided ~ 22 % of the total PDE.
PDE7 family enzymes specifically hydrolyse cAMP and are resistant to inhibition 
by the non-selective reversible PDE inhibitor, IB MX (Lavan et al., 1989, Michaeli 
et al., 1993). There is no satisfactory way to measure PDE7 activity, but one can 
reasonably calculate, on the basis of (cAMP) and Ki (IBMX) values for 
various PDE species (Houslay & Kilgour, 1990, Jin et al., 1992) that 100 pM 
concentration of IB MX could be expected to achieve ~ 82 % inhibition of PDE 
activity. Here I found that IBMX caused -  85 % inhibition of PDE activity with 1 
pM cAMP as substrate. This suggest tliat there might be a small amounth of PDE7 
activity in Jurkat T-cells (Table 3.1). Indeed, transcripts for PDE7 have resently 
been identified in human T-cells (Giembycz et al., 1996).
These data suggest that PDE3 and PDE4 isoforms provide the major PDE activities 
in Jurkat T-cells, accounting for -  77 % of the total under the assay conditions 
used here.
3.2.2, Effect of cyclic AMP-elevating agents on phosphodiesterases 
of Jurkat T-cells
f
Forskolin binds to and directly activates the catalytic subunit of adenylate cyclase 
both in the absence and presence of the stimulatory G-protein (Gg) (Seamon et ah, 
1981). Prolonged treatment of Jurkat T-cells with this diterpine produced a 
dramatic but transient increase in intracellular cAMP content (Figure 3.7). In order 
to appreciate if changes in PDE activity contributed to the mechanism responsible 
for the transience of this accumulation of cAMP, the effect of forskolin on PDE
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activity in human Jurkat T-cells was investigated. Jurkat T-cells were treated for 
different times up to 24 h with 100 pM forskolin and the total PDE activity was 
measured. This time course study showed that forskolin produced a profound 
elevation of total homogenate PDE activity (Figure 3.7). Treatment with 1 pg/ml 
cholera toxin, which elicits the NAD'^-dependent ADP-ribosylation of Gg causing 
adenylate cyclase to become constitutively activated (Nel & Daniels, 1988, 
Sommermeyer et al., 1990), produced an even larger stimulation of the PDE 
activity (Table 3.2; Figure 3.9). Using isoenzyme-selective activators and 
inhibitors to make an estimation of the relative contribution of different PDE 
classes to the total homogenate PDE activity of Jurkat T-cells, it was assessed 
whether chronic elevation of intracellular cAMP levels could alter cellular PDE 
activities.
%
Elevation of cAMP levels by chronic exposure to forskolin did not cause any 
significant change in either PDEl (Figure 3.10), PDE2 (Figure 3.11) or IBMX- 
insensitive PDE activity over a period of up to 24 h. In contrast, PDE3 activity 
was increased profoundly (Figures 3.12-13). An initial transient increase in PDE3 
activity occurred over the first 45 min (Figure 3.12) and was followed by a 
sustained increase, which began after about 3-4 h of exposure and continued 
through to 24 h (Figure 3.13). While no immediate increase in PDE4 activity 
occurred upon challenge of cells with forskolin, after an initial lag period of 3-4 h a 
profound increase in PDE4 activity occurred which remained elevated over the 24 
h period (Figure 3.14). The long term activation of PDE3 and PDE4 activities, 
which began after about 3 h forskolin challenge, were completely prevented by 
inhibiting transcription using actinomycin D (Table 3.2). This indicates that the 
up-regulation of PDE3 and PDE4 activity depended upon the synthesis of protein. 
Actinomycin D treatment, however, did not block the rapid, transient increase in 
PDE3 activity (<5 % change; n = 3; 45 min exposure to 100 p,M forskolin in the
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presence compared with the absence of actinomycin D), suggesting that this 
Increase not involving enzyme induction.
In a similar way using cholera toxin instead of forskolin to stimulate adenylate 
cyclase activity, a profound increase in the homogenate PDE activity also occurred 
(Figure 3.9). For treatment of the cells with cholera toxin PDE3 activity was 
maximal in the first 45 min and then gradually decreased (Figure 3.15). PDE3 
activity was also measured after 6  h challenge and shown to be increased by about 
1-fold (Table 3.2). At this time of exposure PDE4 activity was also increased by 
~2.5-fold (Table 3.2; Figure 3.16). As found with forskolin activation of PDE 
activity the long-term up-regulation of PDE3 and PDE4 activities by cholera toxin 
was also inhibited by actinomycin D (Table 3.2).
Incubation of Jurkat cells with the cell-permeable cAMP analogue 8 -bromo-cAMP, 
also induced both PDE3 and PDE4 activities (Table 3.2). However, this occurred 
to a lesser extent than seen with the other agents, which may reflect the metabolism 
of this compound.
Intracellular cAMP content was measured at various times over a 24 h period. In 
forskolin treated cells, basal cAMP content was rapidly increased by -  18-fold 
within ~ 3 min. This reached a maximum value after about 6  h and was followed 
by a gradual decline to a new steady-state which was still elevated above that seen 
in cells which had not been treated with forskolin (Table 3.3; Figure 3.7). When 
the forskolin-elevated intracellular cAMP levels began to decline then total PDE 
activity began to be elevated (Figure 3.8). At the point where the increase in PDE 
activity reached maximum levels,^ **9 h after forskolin challenge, selective PDE 
inhibitors were used to determine the effect of blockade of this PDE activity on the 
regulation of intracellular cAMP levels. The non-selective PDE inhibitor IBMX is 
known to inhibit PDE activity and to increase cAMP levels synergistic ally when
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adenylate cyclase is stimulated. Therefore, the presence of IBMX led to forskolin- 
stimulated cAMP levels being increased by -  5-fold (Table 3.3). Interestingly, the 
PDE4-selective inhibitor rolipram was able to elicit a similar amplification to that 
seen with IBMX, whereas the PDE3-selective inhibitor cilostimide appear to be far 
less potent in increasing intracellular cAMP levels in these cases by only -  50 % 
(Table 3.3). Such effects appear to be a little surprising in that homogenate PDE 
assays showed PDE3 activity to be considerably greater than PDE4 activity (Table
3.1). One possibility is that cilostimide did not achieve equilibrium concentrations 
inside the T-cells over the 9 h period. However, this seems somewhat unlikely, 
especially as cilostimide did cause an increase in cAMP levels and achieves 
inhibition of PDE3 at very low concentrations (Manganiello et al., 1995a) (Figures 
3.3-4). It has also been shown that effect of the PDE4 activity on cAMP 
regulation is more important than PDE3 activity in human monocytes (Verghese et 
al., 1995), The data indicate that Jurkat T-cell PDE4 species may play a major role 
in controlling the bulk or major pool of cAMP produced by the forskolin- 
stimulated activation of adenylate cyclase and that the action of PDE3 may be more 
limited. This might explain why PDE4 inhibitors are potent anti-inflammatory 
agents (Barnes, 1991), inhibiting T-cell functions, whilst PDE3 inhibitors have 
little effect (Marcoz et al., 1993b).
The effect of the transcriptional inhibitor actinomycin D on cAMP content was also 
examined in cells which had been challenged with forskolin. Incubation of cells 
with actinomycin D considerably enhanced, by ~ 2.4-fold, the ability of forskolin 
to increase intracellular cAMP concentrations in Jurkat T-cells (Table 3.3), Such a 
treatment will have stopped PDE4 induction by forskolin. The forskolin-mediated 
induction of PDE enzyme was clearly able to exert a considerable influence on 
intracellular cAMP levels. That addition of actinomycin D did not affect the 
forskolin-stimulated rise in cAMP, assessed in the presence of the PDE inhibitor
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rolipram (Table 3.3), showing that inhibition of transcription did not affect the 
forskolin-stimulated adenylate cyclase activity itself.
Multiple biochemical and biological events are triggered by the interaction of the T- 
cell antigen receptor/CD3 complex (TCR) with processed antigens in tlie context of 
the major histocompatibility complex (MHC) molecules found on the surface of 
antigen-presenting cells (Weiss et al., 1986). Ligand-mediated perturbation of the 
TCR complex provokes an increase in protein-tyrosine kinase, phospholipase C 
and protein kinase C activities as well as changes in phosphatidylinositol 
breakdown, lymphokine secretion, calcium accumulation and a transient increase 
in cAMP concentrations (Cooke et al., 1991, Kvanta et al., 1990). It has also 
been shown that lectins [phytohemagglutinine (PHA)] bind specific glycoproteins 
on the cell surface of the cells which leads to the polyclonal stimulation of 
lymphoid cells. Initial events in lectin-induced activation include tyrosine 
phosphorylation (Hirata et al., 1984), calcium influx (Coffey et al., 1981) and 
inositol phosphate production (Taylor et al., 1984). Observations concerning 
fluctuations in the intracellular concentrations of cyclic nucleotide levels are, 
however, confused (Derubertis et a l ,  1974, Hurwitz et a l ,  1990). This may be 
due to complex changes in both adenylate cyclase and PDE activities and to various 
ligands having been used. In order to see whether ligation of the T-cell receptor 
can alter Jurkat T cell PDE activity I used the monoclonal antibody 0KT3 which is 
directed against the CD3 complex (Phillips et al., 1991) and also the mitogenic 
lectin PHA. However, incubation of the cells for various times with either OKT3 
or the PHA antibody (Figures 3.18-19) did not lead to any clear change in total 
PDE activity. These results suggest that the signalling pathways emanating from 
the TCR/CD3 complex are not coupled to the regulation of PDE activities in Jurkat 
T-cells.
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TCR ligation can however be bypassed as a requirement for T-cell activation 
through the synergistic action of the PKC activator phorbol 12-myristate 13-acetate 
(PMA), implying that the activation of PKC is one of the on' signals for T-cell 
activation (Albert et al., 1985). Recently, Spence et al. (1995) have demonstrated 
that PMA can rapidly induce PD El activity and this activity was related to 
activation of specific protein kinase C isoforms. This suggests that there might be 
'cross-talk' between the cAMP- and lipid-signalling pathways in CHO cells.
Here, however, incubation of Jurkat T-cell with 1 pM PMA for vaiious times 
showed that neither total PDE nor PDEl activity were changed (Figure 3.19).
This suggest that the 'cross-talk' between the cAMP- and lipid-signalling pathways 
occurs in a cell-specific manner.
' 'p'
3 .2 .3 .  Determ ination of PDE4 subtype gene expressions and the 
effect of elevated cyclic AMP
PDE4 activity is encoded for by four genes which produce a variety of protein 
products due to multiple splicing (Bolger, 1994). Such multiple splicing takes the 
form of 5' domain swops with resultant considerable heterogeneity among the 
mRNAs of PDE4 family members at their 5' regions. In contrast, the 3' region of 
each active member of particular PDE4 gene families is unique and is thus common 
to all active isoforms produced from a particular PDE4 gene. Thus, in order to 
identify PDE4 isoforms occurring in Jurkat T-cells, I first designed generic PCR 
primers which would be able to identify all active members of each of the four 
isoform families. This approach was taken in order to maximize the chances of 
detecting changes due to any unknown active PDE4 isoforms. The design of these 
generic, PDE4-class specific primers was based on the fact that, within each PDE4 
class, all active splice variants have identical sequences 3' to the splice junction. I 
also, however, employed primers able to detect specific, known, splice variants. 
This is shown schematically in figure 3.20 and the primers used are given in the
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individual legends. Finally, immunological methods were employed to identify 
protein products.
Using sets of generic primers, I was able to identify transcripts for both PDE4A 
and PDE4D (Table 3.4; Figures 3.21-22) in control Jurkat T-cells but none for 
PDE4B and PDE4C (Table 3.4; Figures 3,23-24). I also confirmed the absence of 
the two known forms of human PDE4B isoforms PDE4B1 (PDE72) and PDE4B2 
(PDE32) (Bolger, 1994, Bolger et al., 1993, McLaughlin et al., 1993) and 
PDE4B3 (Huston et al., 1997) in both control and forskolin-treated cells by using 
isoform-specific primers (Figure 3.25) and by Western blotting procedures. 
Forskolin treatment did not cause the induction of PDE4C isoforms on the basis of 
analyses done using generic primers (Figure 3.24).
The rat PDE4A gene produces multiple splice variants which all arise from 5' 
domain swops. There have been three rat PDE4A gene products cloned from 
various specialised cells which are called RDI (Davis et al., 1989), rPDE -6  
(Bolger et ah, 1994, McPhee et al., 1995) and rPDE-39 (Bolger et al., 1996). On 
the other hand, products of its counterpart, the human PDE4A gene, are poor- 
understood. A full length human PDE4 species has been characterised as PDE46 
(HSPDE4A4B) (Bolger et ah, 1993), together with a splice variant, called 2EL 
(HSPDE4A8), which unlike PDE46 exhibits no apparent PDE activity (Horton et 
al., 1995). PDE46 provides a distinct PDE4A splice variant which is expressed 
natively in cells (Torphy et al., 1995). In this study PDE4A transcripts were 
detected in untreated Jurkat T-cells using generic primers. However, probing 
RNA preparations from 9 h forskolin-treated cell for PDE4A transcripts (Figure
3.21) consistently yielded signals of considerably lower intensity than those 
obtained using preparations from untreated cells. Equivalent intensities of the p~ 
actin-specific bands were seen in control versus treated cell, confirming successful 
normalisation of the mRNA (Figures 3.21 and 3.33). This suggests that levels of 
PDE4A were actually decreased upon elevation of intracellular cAMP. To
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characterise this further, I assessed the ability of a PDE4A-specific antiserum to 
immunoprecipitate PDE activity from solubilised Jurkat T-cells (section 2.2.11).
In such experiments, cell extracts from control and from 9 h forskolin-treated cells 
were incubated with an anti-PDE4A polyclonal antibody and absorbed to 
Pansorbin. PDE4 activity was indeed immunoprecipitated from control cells, 
yielding a specific activity of 5.1±0.2 pmol/min per mg of protein (mean ± SD; n -  
3 experiments; units expressed relative to T-cell homogenate PDE activity). This 
fraction of activity was very similar to the rolipram-inhibited PDE component 
determined using Jurkat T-cell homogenates (4.9±0.5 pmol/min per mg of protein;
« = 3) suggesting that, in control cells, PDE4 activity provides the major, if not the
sole, PDE4 activity. However, in cells treated with forskolin, the
immunoprecipitated PDE4A activity recorded was some 3.1±0.3 pmol/min per mg
of protein (mean ±  SD; n = 3 separate experiments using different cell
preparations; units expressed relative to T-cell homogenate PDE activity), implying
a decrease in PDE4A expression of ^  40 %. In each instance >96 % of the
immuno-absorbed activity was inhibited upon addition of 1 0  pM rolipram, i
indicating that this was indeed exclusively PDE4 activity. Such a reduction in the
amount of presumed PDE4A activity seen in forskolin-treated cells was consistent
with the decreased signal seen by RT-PCR transcript analysis (Figure 3.21).
Western blot analyses of PDE4A immunoreactivity was carried out using a specific 
monoclonal antibody. Using this technique, a single band (118+2 kDa) of 
immunoreactivity was detected (Figure 3.26). However, after 9 h of treatment 
with forskolin a band of considerably diminished intensity was seen (45±6 %;n =
3 experiments) (Figure 3.26). This immunoreactive species migrated considerably 
faster on SDS/PAGE than did the PDE46 (Huston et al., 1996, Verghese et al.,
1995) product of the human PDE4A gene which migrated as an 125 kDa species 
(Figure 3.27). It could be thought that such a difference was due to proteolysis.
However, a single species of reproducible size was obtained in all our PDE4A 
immunoblot studies done with Jurkat T-cells. This was also apparent when cells
.0 4
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were boiled directly in SDS/PAGE sample buffer so I believe it unlikely that this is 
a proteolysed species and suggest that it may be a novel splice variant. To try and 
test this I used PCR primers designed to detect specifically the extreme 5’ region of 
PDE46 which should be unique to this species. However, I failed to obtain a 
signal in extracts from Jurkat T-cells (Figure 3.27) but did for control using 
PDE46 expressed in COS7 cells. A further indication that this species may be a 
novel splice variant is that the IC50  value for inhibition of tliis species by rolipram 
is about 50-fold lower than that seen h6.1 (HSPDE4A4C) (Sullivan et al., 1994, 
Wilson et al., 1994) and PDE46 (Huston et al., 1996), indicating a particularly 
potent action of this selective inhibitor on the T-cell PDE4A isoform.
The pattern of expression of multiple variants from the rat (Monaco et al., 1994, 
Sette et al., 1994b) and human (Bolger et al., 1997) PDE4D gene has shown that 
the heterogeneity of the different mRNA lies in the 5' region. At least five 
different, active splice variants have been identified to date. In rats, three different 
transcripts from this gene (Bolger et al., 1994, Swinnen et al., 1989b): PDE4D1, 
PDE4D2 and PDE4D3, and in human five splice variants have been reported: 
PDE4D1 to PDE4D5 (see chapter 4 for more details) (Bolger et al., 1993, Bolger 
et al., 1997, Nemoz et al., 1996). Analysis of the products of this gene by RT- 
PCR, using a set of generic primer pairs, allowed me to detect a weak signal in 
RNA preparations from untreated Jurkat cells (Table 3.4 and Figure 3.22). 
However, using 9 h forskolin-treated cells I consistently obtained a very much 
stronger signal (Figure 3.22). This implied an increase in the level of PDE4D 
transcripts upon chronic elevation of intracellular cAMP concentrations. Using 
sets of primers able to detect each of these reported variants I failed to detect any 
signal for PDE4D3 (Figure 3.28), PDE4D4 (Figure 3.29) and PDE4D5 (Figure 
3.30) species in either untreated or forskolin-treated cells. However, I was able to 
obtain a signal for PDE4D1 in RNA extracts from control cells, although this was 
rather weak (Table 3.4; Figure 3.31). I also detected transcripts for PDE4D2 in
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forskolin treated cells but not in untreated cells (Table 3.4; Figure 3.32). In all 
these experiments similar signals were obtained using primers designed to amplify 
up a region of the cytoskeletal protein actin (Figure 3.32), showing that similar 
levels of mRNA were present in all experiments. These experiments were all done 
using at least three different RNA preparations.
To determine whether the increase in PDE4D mRNA resulted in an increase in 
PDE4D protein content, Jurkat T-cell extracts were subjected to Western blot 
analysis. Using monoclonal antisera able to recognise PDE4D species, I failed to 
identify any signal in extracts from untreated cells (Figure 3.33). This suggests 
that the expression of PDE4D species in untreated cells is minimal and is consistent 
with the notion obtained from immunoprécipitation of PDE4 activity using anti 
PDE4A antisera that the predominant component of PDE4 activity in resting cell is 
due to a PDE4A isoform. However, in forskolin-treated cells I obtained a very 
clear, strong signal for a 67±2 kDa species (Figure 3.33) which co-migrated with 
PDE4D1 expressed in transfected COS7 cells. This is consistent with my RT- 
PCR analyses which implied that cAMP mediated the induction of the PDE4D1 
splice variant. Immunoblot studies, however, also identified a species, with an 
apparent size 65±2 kDa, which consistently migrated just below that identified as 
PDE4D1 (Figure 3.33). This species seems most likely to be PDE4D2, as it is 
highly related to PDE4D1 but has a small internal deletion of 8 6  bp in its 5'
alternatively spliced region which would make the encoded protein product slightly 
smaller than PDE4D1. Consistent with this I was able to identify transcripts for 
PDE4D2 in extracts from forskolin-treated cells (Figure 3.33). I also routinely 
detected a weakly staining species at 75±3 kDa in PDE4D immunoblot studies 
done on forskolin-treated Jurkat T-cells (Figure 3.33). Whether this reflects an as 
yet unreported PDE4D splice variants has yet to be seen.
i';.
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3 . 3 .  Conclusions and Discussion
The pharmacological examination of human Jurkat T-cells indicated that cGMP- 
inhibited PDE3 and cAMP-specific PDE4 families provide the majority of PDE 
activity (Table 3.1). Chronic elevation of cAMP levels in this cell line caused a 
profound, time-dependent, increase in overall cellular PDE activity (Figure 3.8). 
This effect was predominantly achieved through regulation of the expression of 
PDE3 and PDE4 isoforms (Figures 3.13-14), although a transient activation of 
PDE3 was also noted (Figure 3.12). Moreover, increasing intracellular cAMP 
levels by other mechanisms using cholera toxin or 8 -bromo-cAMP also mimicked 
this induction (Table 3.2). The delayed "up-regulation" of PDE3 and PDE4 
activities were blocked by actinomycin D, therefore indicating that RNA synthesis 
is necessary for the rise in these PDE activities (Table 3.3). The immediate 
increase in PDE3 activity was not blocked by actinomycin D, indicating that this 
fast "up-regulation" may involve the protein kinase A-mediated phosphorylation of 
the enzyme. Indeed, the rapid phosphorylation of PDE3 in response to PKA 
activation has been shown in adipocytes and hepatocytes (Degerman et al., 1990, 
Manganiello et al., 1995b). The PDE4 isoforms appear to be of major importance 
in regulating bulk Jurkat T-cell intracellular cAMP levels. This is demonstrated by 
the findings that the PDE4 selective inhibitor rolipram is consistently more 
effective than the PDE3 inhibitor cilostimide at increasing cAMP levels in response 
to forskolin in Jurkat T-cells (Table 3.3). This may have relevance to the design of 
therapeutic agents aimed at inhibiting T-cell functions. Certainly PDE4, but not 
PDE3 inhibitors appears to be most effective (Marcoz et al., 1993b).
RT-PCR analyses with generic primers (Figure 3.20) specific for distinct human 
PDE4 subtypes demonstrated that mRNA for PDE4A and PDE4D subtypes (Table 
3.4; Figures 3.21-22) were present but neither PDE4B nor PDE4C transcripts 
were detectable in control Jurkat T-cells (Table 3.4; Figures 3.23-24). The
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absence of the three known forms (PDE4B1, PDE4B2 and PDE4B3) (Bolger et 
ah, 1993, McLaughlin et a l ,  1993, Huston et a l ,  1997) in both control and 
forskolin-treated cells was also confirmed using isotype specific primers (Figure 
3.25). These observations contrast with studies done on various monocyte cell 
lines (Manning et a l, 1996, Torphy et al., 1995, Verghese et a l ,  1995) and in 
Sertoli cells (Swinnen et a l ,  1991b), where elevation of cAMP levels induced 
PDE4B expression. Time-course studies done with Mono Mac 6  monoyctes 
showed that the induction of PDE4B was transient, with maximal induction 
occurring -  5 h after elevated of cAMP levels (Verghese et a l ,  1995). However, 
even when I studied cell extracts for transcripts and immunoreactive species at Ih 
intervals over 9 h, I failed to observe any expression of PDE4B isoforms.
Performing Western blotting analyses for PDE4A forms identified a single -118 
kDa protein band which migrated considerably faster than the PDE46 (125 kDa) 
species (Figure 3.26). Moreover, when carrying out RT-PCR with primers 
specific for the N-terminal end of PDE46,2EL and h6 .1 the lack of signal showed 
that this was not any known form of PDE4A (Figure 3.27). Indeed, the IC50  
value for inhibition of this species by rolipram was -  50-fold lower than that seen 
for h6.1 and PDE46. This suggests that the active PDE4A isoform in Jurkat T- 
cells may be a novel PDE4A gene product.
The effect of chronic elevation of cAMP levels with forskolin exposure, on PDE4 
expression were apparently exclusively targeted to actions on genes encoding 
PDE4A and PDE4D. Intriguingly, despite a profound increase in PDE4 activity, I 
observed a marked reduction in the expression of the single PDE4A isoform which 
appeared to supply the majority, if not all, of the PDE4 activity in untreated Jurkat 
T-cells. This decrease in the expression of PDE4A in Jurkat T-cells contrasts with 
the effect of chronically elevated cAMP levels on monocyte cell lines (Manning et 
a l, 1996, Torphy et a l, 1995, Verghese et a l, 1995) where increased expression
1 0 8
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of a PDE4A species was seen. However, in those cell lines the PDE4A splice 
variant expressed appeared to reflect PDE46 (Manning et al., 1996, Verghese et 
al., 1995). Interestingly, Engels et. al. (1994) observed that treating another 
Jurkat T-cell line (JKE6-1) with dibutyryl-cAMP led to 2-fold increase in PDE4A 
species. This may reflect differences between various Jurkat cell lines. The 
decrease of PDE4A protein and mRNA in forskolin-treated Jurkat T-cells seen here 
leads to speculation that this subtype could be down-regulated by cAMP. Indeed, 
in a study (Zeng, L. & Houslay, MD. unpublished work) done on rat hepatocyte 
P9 cells, challenging with forskolin for 6 h demonstrated decreased PDE4A mRNA 
and protein levels. Such data may thus signal differences in the control of 
expression of splice variants in various cell types in response to elevation of 
intracellular cAMP concentrations. The down-regulation of the expression of the 
novel PDE4A isoform was more than compensated for, however, by the profound 
induction of the PDE4D forms over long term challenge with forskolin. Western 
blotting showed that increased [cAMP] led to PDE4D protein levels being 
increased following such a treatment (Figure 3.33). This change in PDE4D 
protein synthesis was confirmed by their expression at mRNA levels (Figure
3.22). Five distinct protein variants (Bolger et al., 1993, Bolger et al., 1997, 
Nemoz et al., 1996) arc derived from the PDE4D gene. PDE4D1 is a short protein 
with an amino terminus different from the long forms (PDE4D3, D4 and D5) and 
the PDE4D2 is derived from an internal deletion of the unique N-terminal region of 
PDE4D1 which, again, results from alternative mRNA splicing (Bolger et al., 
1997, Sette et al., 1994b). Whilst profound induction of the PDE4D1 (67±2 kDa) 
and a much smaller level of induction of the PDE4D2 (65±2 kDa) isoforms were 
detectable in forskolin-challenged Jurkat T-cell extracts, neither PDE4D1 nor 
PDE4D2 proteins were detectable in the control cells extracts (Figure 3.33). This 
induction of PDE4D isoforms is similar to that reported in Seitoli cells (Sette et al., 
1994b), where elevation of cAMP levels caused a profound induction of both 
PDE4D1 and PDE4D2 isoforms. Increased PDE4D1 levels were also noted in
.ft
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Mono Mac 6  monocytes in response to chronic elevation of cAMP concentrations 
(Verghese et a l, 1995). A weakly staining protein at 75+3 kDa was also routinely 
detected in PDE4D immunoblot studies done on forskolin-treated Jurkat T-cells 
(Figure 3.33). Further work is needed to characterise whether this species reflects 
an as yet unreported PDE4D splice variants of 4D. Induction of PDE4D1 and 
PDE4D2 gives additional support to the notion (Conti et al., 1995b) that cAMP- 
response elements (CREB) determine the expression of specific PDE4D splice 
variants, as well as demonstrating that inhibitory effects can be exerted on PDE4A 
gene expression.
The functional significance of changes in the expression of specific PDE4 splice 
variants remains to be ascertained. However, the observations that PDE'4 isoforms 
appear to exhibit marked differences in their activity, intracellular targeting (Bolger 
et al., 1996, McPhee et al., 1995, Shakur et al., 1995), protein-protein interaction 
(O'Connell et al., 1996) and regulation by covalent modification (Conti et al., 
1995b) might mean that there are specific functional consequences resulting from 
these changes. This might explain why the pattern of changes in PDE4 isoform 
expression in response to elevated intracellular cAMP levels appears to have cell- 
specific attributes. Thus, such induction of PDE isoforms is likely to reflect a cell- 
specific adaptive mechanism. This may have implications for the use of 
therapeutic regimens which lead to elevated intracellular cAMP levels, and also for 
disease states which involve adenylate cyclase activation.
In conclusion, this study demonstrate that the cAMP-specific PDE can be activated 
by the long-term incubation with cAMP elevating agents through a cAMP- 
dependent protein kinase cascade. In Jurkat T-cells where the PDE4D1 and 
PDE4D2 are induced at the same time as activated PDE3, both enzymes are 
activated upon the increase in cAMP levels. Phosphorylation of PDE3 may 
contribute to the short-term activation seen with cAMP elevating agents.
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T ab le  3.1. A ssessm ent of cAM P phosphod ieste rase  activ ities in 
J u rk a t  T-cells
P h o sp h o d ie ste ra se E ffec to rs pm ol/m in/m g protein
Total PDE none 19.2+1.5
PDEl Ca2/CaM
(50pM/20ng/ml)
3.5+1.0
PDE2 EHNA (lOpM) 1 .0 ±0 .2
PDE2 EHNA + cGMP 
(lOpM/lOpM)
3.5+0.5
PDE3 cGMP (lOpM) 10.8+0.4
PDE3 Cilositimide (lOpM) 11.3+0.6
PDE4 Rolipram (lOpM) 4.8+0.4
PDE7 IBMX (lOOpM) 3.2±0.3
PDE isoforms were assayed in the presence of 1 pM cAMP as substrate to yield 
the respective conù'ol activity with Jurkat T-cell homogenates. PDEl activity was 
determined in the presence of Ca^+ /  CaM. Inhibition by EHNA indicates the 
presence of PDE2 activity. PDE2 activity was also deteimined in the presence of a 
stimulatory concentration o f 10 pM cyclic GMP, which will maximally activate 
this enzyme if present and so allow amplification of any action of EHNA. 
Cilostimide and high level of cGMP inhibition indicates PDE3 activity. Inhibition 
by rolipram indicates PDE4 activity and IBMX indicates PDE7 activity. Data are 
mean ± SD for at least 3 to 8  separate experiments employing different cell 
preparations. In each experiment tiiplicate PDE assays were performed and an 
average value taken.
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T able 3.2. The effect of actinom ycin D on the increase in J u rk a t T- 
celi PDE3 and  PDE4 activities induced upon activation of adenylate 
cyclase by forskolin and  cholera toxin
PDE3 increase (%) PDE4 increase (%)
forskolin 131+11 215±19
forskolin + Act-D -38+12 11±16
Act-D - 1 2 ± 8 -18±14
cholera toxin 104±14 218±49
cholera toxin + Act-D 18±12 23±15
8 -Bromo-cAMP 69+7 58+7
Jurkat T-cells were treated for 9 h with 100 pM forskolin, 6 h with 1 pg/ml 
cholera toxin and 9 h with 100 pM 8 -Bromo-cAMP. In some experiments 
actinomycin D (100 ng/ml) was added to incubations. After indicated times, the 
cells were harvested and homogenate prepared for assay of PDE activity using 1 
pM cAMP as substrate. PDE3 activity was gauged as that fraction of the total PDE 
activity which was inhibited by 10 pM cilostimide. PDE4 activity was gauged as 
that fraction of the total PDE activity which was inhibited by 10 pM rolipram. The 
data represent mean ± SD of three to five separate assays, performed in triplicate, 
using different cell preparations. The change in PDE activities is given as a 
percentage of the activity. Act-D is actinomycin D.
112
T able 3.3. The enhancem ent of forskolin-stim nlated cAM P 
accum ulation in Ju rk a t T-cells by PDE inhibitors
lig an d s [cAMP] (pmol/10^ 
cells)
fold change
none (control) 1.6±0.4
forskolin 29±3 (1)
forskolin + rolipram 154+8 5.3
forskolin + Act-D 70+5 2.4
forskolin + Act-D + 
rolipram
158+9 5.4
forskolin + cilostimide 44.2+4 1.5
forskolin + IBMX 148+12 5.1
Jurkat T-cells were cultured for 9 h in the presence of indicated ligands. These 
were either no added ligand (control) or the indicated combinations of 100 pM 
forskolin, 10 pM rolipram, 10 pM  cilostimide, 100 pM IBMX and 100 ng/ml 
actinomycin D. After this time cells were harvested and the intracellular 
concentration of cyclic AMP was determined as described in section 2.2.9. These 
are shown as pmol/10^ cells. Data are mean ±  SD for n = 3 separate experiments 
using different cell preparations and each carried out in triplicate. The fold change 
indicated the fold potentiation of the forskolin-induced elevation of intracellular 
cAMP levels. Act-D is actinomycin D.
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Table 3,4. Summary of forskolin mediated induction of PDE4 splice 
variants
untreated forskolin-treated
PDE4A (generic) ++++ H—H
PDB4B (generic)
PDE4B1
PDE4B2
PDE4C (generic)
PDE4D (generic) +H“ -f-+++
PDE4D1 + + 4 —1—h
PDE4D2 4 * 4 ”
PDE4D3
PDE4D4
PDE4D5 CM
This summarises the occurrence of PDE4 splicing RNA transcripts after treating 
Jurkat T- cells with 100 pM forskolin for 9 h.
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PDEl 601 bp
—  1078 bp
—  872 bp
—  603 bp
310 bp
Figure 3.1. RT-PCR analysis of P D E l 'generic' transcripts in 
Jurkat T-cells
Total RNA was isolated from cultured Jurkat T-cells and reverse transcribed into 
cDNA (section 2.2.15-16). PCR was then performed (section 2.2.17) using a set 
of primers designed to detect 601 bp fragment found in all PDEl A and PDE IB 
transcripts. The primers were: GR18 sense 5 -RYCTYATCARCCGYTTYAAG- 
ATTCC-3' and GR19 antisense 5 -RAAYTCYTCCATKAGGGGCCWTGG, as 
described previously (Spence et al., 1995). (In these primers, R=A/G, Y=C/T, 
K=G/T and W=A/T). PCR reaction employed 1 min at 95 °C, 80 s at 50 °C and 
70 s at 72 °C for 40 cycles. The products were electrophoresed on 2 % agarose 
gel and visualised with ethidium bromide under UV light. The results are 
representative of three experiments using RNA from different extractions.
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Figure 3.2. A lignm ent o f P D E l tran sc rip t R T-PC R  products from  
hum an Ju rk a t T-cells
The sequence of Jurkat T-cell PDE IB (GenBank accession number U40584) from 
PCR products was aligned together with sequences for the equivalent region of 
published data for C. hamster (U40585), human PDEl A (U40371) and human 
PDEICI (U40370) sequences for comparison. Alignment was carried out with a 
PDEl consensus sequence [a degenerate consensus of the three full-length PDE IB 
sequences; mouse PDEIB form (M94538), rat PDE IB form (M94537), bovine 
PDEIB form (M94867), where M = A/C, R = A/G, W = A/T, S = C/G, Y = T/C, 
K = G/T]. Matches to the consensus are printed within the boxed area.
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Figure 3.3. Identification of PDE3 activity in Jurkat T cells: 
Inhibition by cGMP
Homogenates of Jurkat T-cells were assayed for PDE activity using 1 cAMP 
as substrate as described in section 2.2.7. The dose-dependent changes in Jurkat 
T-cell PDE activity elicited by cGMP are shown. The data reflect mean ± SD for 
triplicate assays done in a single experiment. These data are typical of experiments 
done three times for which IC50  values were calculated and are given in the text. 
PDE activity is expressed in pmol cAMP hydrolysed/min/mg protein.
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Figure 3.4. Identification of PDE3 activity in Jurkat T cells: 
Inhibition by cilostimide
Homogenates of Jurkat T-cells were assayed for PDE activity using 1 |iM  cAMP 
as substrate as described in section 2.2.7. The dose-dependent changes in Jurkat 
T-cell PDE activity elicited by the PDE3 selective inhibitor cilostimide are shown. 
The data reflect mean ± SD for triplicate assays done in a single experiment. 
These data are typical of experiments done three times for which IC50  values were 
calculated and are given in the text. PDE activity is expressed in pmol cAMP 
hydrolysed/min/mg protein.
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Figure 3.5. Identification of PDE2 activity in Jurkat T cells: 
Inhibition by EHNA
Homogenates of Jurkat T-cells were assayed for PDE activity using 1 jiM cAMP 
as substrate as described in section 2.2,7. The dose dependent inhibition of PDE 
activity by EHNA is shown for assays done in the presence of stimulatory 
concentrations (10 pM) of cyclic GMP. The data reflect mean ± SD for triplicate 
assays done in a single experiment. These data are typical of experiments done 
three times for which IC50 values were calculated and are given in the text. PDE 
activity is expressed in pmol cAMP hydrolysed/min/mg protein.
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Figure 3.6. Identification of PDE4 activity in J u r k a t  T cells: 
Inhibition by rolipram
Homogenates of Jurkat T-cells were assayed for PDE activity using 1 |iM cAMP 
as substrate as described in section 2.2.7. The dose-dependent changes in Jurkat 
T-cell PDE activity elicited by the PDE4 selective inhibitor rolipram are shown. 
The data reflect mean ± SD for triplicate assays done in a single experiment. 
These data are typical of experiments done three times for which IC5 0  values were 
calculated and are given in the text. PDE activity is expressed in pmol cAMP 
hydrolysed/min/mg protein.
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Figure 3.7. The effect of forskolin on the accum ulation of 
intracellular cAMP concentrations in Jurkat T-cells
Jurkat T-cells were incubated at 37 °C for the indicated times with and without 100 
|uM forskolin. The reaction was terminated at the indicated times by the addition 
of cold 4 % perchloric acid (PCA). cAMP was measured as indicated in section 
2.2.9. Values represent the mean ± SD of triplicate determinations. Data 
presented are from a representative experiment that was repeated three times with 
similar results.
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Figure 3.8. Time course of total PDE activity in the presence of 
forskolin
Jurkat T-cells were grown in suspension in medium with 5 % serum . They were 
then incubated for the indicated times up to 24 h in the absence (regarded as 
controls) or presence of 100 pM forskolin. At the end of the incubations, cells 
were washed twice with semm free medium, harvested and homogenised (section 
2,2.1.2). The total PDE activity was determined using the cell homogenates with 
1 pM cAMP as substrate. Each point represents the mean ± SD for triplicate 
assays done in a single experiment. These data are typical of experiments done 
three times.
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F ig u re  3.9, T im e course of cho lera  toxin ac tiv a ted  to ta l PDE 
ac tiv ity
Jurkat T-cells were incubated for different times up to 12 h in the absence (control) 
or presence of 1 p-g/ml cholera toxin. At the end of the incubation, cells were 
rinsed twice, harvested and homogenised as described in section 2.2.1.2. Total 
PDE activity was observed in the presence of 1 pM cAMP as substrate. Each 
point represents the mean ± SD of at least three different experiments, each carried 
out in triplicate".
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Figure 3.10. Time course of forskolin activated PD E l activity
Jurkat T-cells were incubated for the indicated times either in the absence (0.1 % 
DMSO, control) or presence of 100 jiM forskolin. At the end of the incubation, 
cells were washed twice with serum free RPMI-1640 medium, harvested and 
counted then homogenised as described in section 2.2.1.2. Changes in PDEl 
activity were assessed by determining the incremental increase in PDE activity 
achieved by the addition of Ca^+ /  CaM (50 p,M; 20 ng/ml) to assays. Activity in 
the absence of Ca^+ / CaM indicates basal PDE activities. Assays employed with 1 
|0.M cAMP as substrate. Each point represents the mean ± SD of three different 
experiments, each carried out in triplicate.
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Figure 3.11. Time course of forskolin activated PDE2 activity
Jurkat T-cells were incubated for the indicated times either in the absence (0.1 % 
DMSO) or presence of 100 jiM forskolin. At the end of the incubation, cells were 
washed twice with serum free RPMI-1640 medium, harvested and counted then 
homogenised as described in section 2.2.1.2. Changes in PDE2 activity were 
calculated by determining the incremental inhibition of cAMP-PDE activity 
achieved by the selective inhibitor EHNA for assays done in the presence of 10 
|J.M cGMP, which would be expected to activate maximally any PDE2. Assays 
employed with 1 jiM cAMP as substrate. Each point represents the mean ± SD of 
three different experiments, each carried out in triplicate.
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Figure 3.12. Time course of forskolin activated PDE3 activity over 
first two hours
Jurkat T-cells were incubated for the indicated times up to 2 h either in the absence 
(0.1% DMSO control) or presence of 100 p-M forskolin. At the end of the 
incubations, cells were washed twice with serum free RPMI-1640 medium, 
harvested and homogenised as described in section 2.2.1.2. The PDE activity was 
determined at the time indicated, in the presence of 10 pM final concentration of 
cilostimide (regarded as PDE3 activity) using the cell homogenates. Assays 
employed with 1 pM cAMP as substrate. Each point represents the mean ± SD of 
at least three different experiments, each carried out in triplicate.
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Figure 3.13. Time course of forskolin activated PDE3 activity
Jurkat T-cells were incubated for the indicated times either in the absence (0.1 % 
DMSO control) or presence of 100 jJ.M forskolin. At the end of the incubations, 
cells were washed twice with serum free RPMI-1640 medium, harvested and 
homogenised as described in section 2.2.1.2, The PDE activity was determined at 
the time indicated, in the presence of 10 pM final concentration of cilostimide 
(regarded as PDE3 activity) using the cell homogenates. Assays employed with 1 
pM cAMP as substrate. Each point represents the mean ± SD of at least three 
different experiments, each carried out in triplicate.
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F igure 3.14. Tim e course of forskolin activated PDE4 activity.
Jurkat T-cells were incubated for the indicated times either in the absence (0.1 % 
DMSO control) or presence of 100 fiM forskolin. At the end of the incubations, 
cells were washed twice with serum free RPMI-1640 medium, harvested and 
homogenised as described in section 2.2.1.2. The PDE activity was determined at 
the time indicated, in the presence of 10 pM final concentration of rolipram 
(regarded as PDE4 activity) using the cell homogenates. Assays employed with 1 
pM cAMP as substrate. Each point represents the mean ± SD of at least four 
different experiments, each carried out in triplicate.
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F igure 3.15. Time course of cholera toxin activated PDE3 activity 
Jurkat T-cells were incubated for different times up to 2 h in the absence (control) 
or presence of 1 p-g/ml cholera toxin. At the end of the incubation, cells were 
rinsed twice, harvested and homogenised (see section 2.2,1,2). The PDE3 
activity was determined at the time indicated, in the presence of 10 p,M final 
concentration of cilostimide using the cell homogenates. Assays employed with 1 
fiM cAMP as substrate. Each point represents the mean ± SD of at least three 
different experiments, each carried out in triplicate.
I
129
-e—  control + cholera toxin
12 r
10
c
s
128 1064
Time (li.)
F igure 3.16. Tim e course of cholera toxin activated PDE4 activity 
Jurkat T-cells were incubated for different times up to 12 h in the absence (control) 
or presence of 1 pg/ml cholera toxin. At the end of the incubation, cells were 
rinsed twice, harvested and homogenised as described in section 2.2.1.2. The 
PDE4 activity was detennined at the time indicated, in the presence of 10 }iM final 
concentration of rolipram using the cell homogenates. Assays employed 1 fiM 
cAMP as substrate. Each point represents the mean ± SD of at least three different 
experiments, each carried out in triplicate.
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Figure 3.17. Total PDE activity in the Jurkat T-ceîi line upon 
stimulation with anti-CD3 antibodies
Jurkat T-cells were stimulated with anti-CD3 monoclonal antibodies (1 jig/ml) for 
different times up to 24 h. Then cells were extensively washed with serum-free 
medium, harvested and homogenised (section 2.2.1.2). Changes in the total PDE 
activity were assessed with 1 pM cAMP as substrate. The data reflect mean ±  SD 
for triplicate assays and are representative values of three experiments.
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Figure 3.18. Time course of total PDE and PDE4 activities in the 
presence of PHA
Jurkat T-cells were challenged with PHA (1 jig/ml) for different times up to 24 h. 
Then cells were washed with serum-free medium, harvested and homogenised 
(section 2.2.1.2). Changes in the total PDE activity were assessed with 1 pM 
cAMP as substrate. The PDE4 activity was measured at the time indicated in the 
presence of rolipram (10 pM) using the cell homogenates. The data reflect mean ± 
SD for triplicate assays and are representative values of three experiments.
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Figure 3.19. Time course of total PDE and PD E l activities in the 
presence of PMA
Jurkat T-cells were challenged with PMA (1 pM) for different times up to 24 h. 
Then cells were washed with serum-free medium, harvested and homogenised 
(section 2.2.1.2). Changes in PD El activity were assessed by determining the 
incremental increase in PDE activity achieved by the addition of Ca2+ / CaM (50 
pM; 20 ng/ml) to assays; activity in the absence of Ca2+ /  CaM indicates basal 
PDE activities. Assays employed 1 pM cAMP as substrate. The data reflect mean 
± SD for triplicate assays and are representative values of three experiments.
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Figure 3.20. Schematic representation of primers used to analyse 
human PDE4 transcripts by RT-PCR
The primers used in this study for RT-PCR analyses of human cAMP-specific 
PDE4 transcripts are shown schematically. The PDE4 products of the four genes 
are shown with (•) splice junctions indicated and the names of the established
active splice variants are given. Open arrows indicate the relative positions of the 
generic primer pairs used to identify the presence of transcripts encoding active 
members of a PDE4 isoforms. Filled arrows indicate the relative positions of 
primer pairs used to identify the presence of specific splice variants. These are 
given for the sense (left to right) and antisense (right to left) directions. The 
PDE4A schematic shows the two identified active species. These are PDE46 
(Bolger et al., 1993), which is analogous to the rat PDE4 isoform RPDE6 and 
truncated species h6.1 which is closely related to hPDE-1 (Livi et al., 1990). The 
fragment amplified using the generic primers represents nucleotides 857-1362 in 
PDE46 and 407-912 in h6.1. The fragment amplified with the PDE46-specific 
primers represents nucleotides 101-917. The PDE4B schematic shows the three 
splice variants PDE4B1 (Bolger et al., 1993), PDE4B2 (McLaughlin et al., 1993) 
and PDE4B3 (Huston et al., 1997). Specific primers amplified a product which 
reflected bases 505-1373 in PDE4B1, bases 322-1190 in PDE4B3 and bases 805- 
1484 in PDE4B2. Generic primers amplified an identical sequence found in 
transcripts of both products which reflected nucleotides 2311-2478 and 2422-2589 
in PDE4B1 and PDE4B2 respectively. The PDE4C schematic shows the single 
reported full length PDE4C4 foim identified to date (Obernolte et al., 1997). The 
generic primers used were designed to amplify a fragment which represents 
nucleotides 2279-2373 in PDE4C4. The PDE4D schematic shows the human 
splice variants identified to date (Bolger et al., 1993, Bolger et al., 1997, Conti et 
al., 1995b, Nemoz et al., 1996), which show analogy with the rat forms (Conti et 
al., 1995b). Generic primers were designed to amplify a 3' fragment found in all 
human PDE4D species reported so far which encode an enzymically active protein: 
PDE4D1 (nucleotides 586-847), PDE4D2 (nucleotides 500-761), PDE4D3 
(nucleotides 978-1239), PDE4D4 (nucleotides 1674-1935) and PDE4D5 
(nucleotides 1180-1441). Specific primers amplified fragments for PDE4D1 
(nucleotides 64-432), PDE4D1+PDE4D2 (nucleotides 7-432 and nucleotides 7- 
346 respectively), PDE4D3 (nucleotides 25-824), PDE4D4 (nucleotides 757- 
1520) and PDE4D5 (nucleotides 226-1026). The single asterisk indicates the 
position of the sense primer used to detect PDE4D1 specifically. This is placed 
with the 86 bp sequence which is deleted from PDE4D2 (Nemoz et al., 1996). 
The double asterisk indicates the position of the sense primer used to detect 
PDE4D1 andPDE4D2.
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F igure 3.20. Schematic representation of primers used to analyse human PDE4 
transcripts by RT-PCR
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Figure 3.21. RT-PCR analysis of hormone effects on PDE4A  
'generic' transcripts in Jurkat T-cells
Jurkat T-cells were untreated or exposed to 100 |iM forskolin for 9 h. After the 
treatment period, RNA was extracted and reverse transcribed into cDNA (sections
2.2.15-16). PGR was then performed (section 2.2.17) using the degenerate 
primers designed to detect transcripts selectively for PDE4A isoforms. These 
primers were: sense-2067, ATGCAGACCTATCGCTCTGTCAGC and antisense- 
2071, ACCATCGTGTCCACAGGGATGC, defining a 506 bp fragment. 
Oligonucleotides were designed to amplify a 3' fragment found in all PDE4A 
species reported so far that encode an enzymically active protein. PCR reaction 
employed 1 min at 95 °C, 2 min at 57 °C and 3 min at 72 °C for 35 cycles. The 
products were electrophoresed on 1.5 % agarose gel and visualised with ethidium 
bromide under UV light. The results are representative of three experiments using 
RNA from different extractions. F: forskolin treated, U: untreated, M: marker.
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Figure 3.22. RT-PCR analysis of hormone effects on PDE4D  
'generic' transcripts in Jurkat T-cells
Jurkat T-cells were untreated or exposed to 100 pM forskolin for 9 h. After the 
treatment period, RNA was extracted and reverse transcribed into cDNA (sections
2.2.15-16). PCR was then performed (section 2.2.17) using the degenerate 
primers designed to detect transcripts selectively for PDE4D isoforms. These 
oligonucleotide primers were: sense-GR34, CCCTTGACTGTTATCATGCACA- 
CC and antisense-GR35, GATCTACATCATGTATTGCACTGGC defining a 262 
bp PCR product. PCR reaction employed 1 min at 95 °C, 2 min at 55.3 °C and 3 
min at 72 °C for 40 cycles. The products were electrophoresed on 1.5 % agarose 
gel and visualised with ethidium bromide under UV light. The results are 
representative of three experiments using RNA from different extractions. F: 
forskolin treated, U: untreated, M: marker.
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Figure 3.23. RT-PCR analysis o f hormone effects on PDE4B 
'generic' transcripts in Jurkat T-cells
Jurkat T-cells were untreated or exposed to 100 pM forskolin for 9 h. After the 
treatment period, RNA was extracted and reverse transcribed into cDNA (sections
2.2.15-6). PCR was then performed (section 2.2.17) using the degenerate 
primers designed to amplify a fragment characteristic of the two reported human 
PDE4B species (PDE4B1, PDE4B2 and PDE4B3). These oligonucleotides were: 
sense-SE5, GACATTGCAACAGAAGACAAGTCCCC and antisense-SE6 
ACTCAAGTAACTGAAAGGCCAGGTGG, defining a 168 bp product. PCR 
reaction employed 1 min at 95 °C, 90 s at 57 °C and 2 min at 72 °C for 35 cycles. 
The products were electrophoresed on 1.8 % agarose gel and visualised with 
ethidium bromide under UV light. The results are representative of three 
experiments using RNA from different extractions. (+): positive control, M: 
marker, U: untreated, F: forskolin treated.
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Figure 3.24. RT-PCR analysis of hormone effects on PDE4C 
'generic' transcripts in Jurkat T-cells
Jurkat T-cells were untreated or exposed to 100 pM forskolin for 9 h. After the 
treatment period, RNA was extracted and reverse transcribed into cDNA (sections
2.2.15-16). PCR was then performed (section 2.2.17) using the degenerate 
primers designed to detect transcripts selectively for PDE4C isoforms. These 
oligonucleotides were: sense-SE7, ATGGATGGTAAAGCCCTTTGGCTCTTGG 
and antisense-SE8, GTCTCCCTAAATGGGTGGGAAAGTGAAG, defining a 95 
bp product. PCR reaction employed 1 min at 95 °C, 2 min at 58 °C and 3 min at 
72 °C for 35 cycles. The products were electrophoresed on 2 % agarose gel and 
visualised with ethidium bromide under UV light. The results are representative of 
three experiments using RNA from different extractions. (+): positive control, U: 
untreated, F: forskolin treated, M: marker.
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Figure 3.25. RT-PCR analysis of Jurkat T-cells using PDE4B1, 
PDE4B2 and PDE4B3 specific primers
Jurkat T-cells were untreated or exposed to 100 pM forskolin for 9 h. After the 
treatment period, RNA was extracted and reverse transcribed into cDNA (sections
2.2.15-16). PCR was then performed (section 2.2.17) using primers specific for 
PDE4B2. These primers were: sense-hBl, AGCGGTGGTAGCGGTGACTC 
and antisense-hB2-601, GCTGCGTGCAGGCTGTTGTG, defining a 680 bp 
fragment. PCR reaction employed here was: 1 min at 95 °C, 2 min at 59 °C and 3 
min at 72 °C for 35 cycles. RT-PCR was also employed for PDE4B1 and 
PDE4B3 using sense-SE14, ACCTTTCCTGGGCACAGCCAG and antisense- 
hB2-601. The reaction conditions used were as described above. The products 
were electrophoresed on 1.5 % agarose gel and visualised with ethidium bromide 
under UV light. The results are representative of three experiments using RNA 
from different extractions. (+): positive control, U: untreated, F: forskolin treated, 
M: marker.
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Figure 3.26. Immunoblot analysis of PDE4A immunoreactivity in 
Jurkat T-cells
Jurkat T-cells were either untreated or exposed to 100 pM forskolin for 9 h. After 
the treatment period cells were washed and homogenised. Identical amounts of 
protein (100 pg of protein) and COS7 cells transfected with PDE46, h6.1 or no 
proteins (as positive and negative controls) respectively were run on SDS- 
polyacrylamide gel electrophoresis (section 2.2.3) and then transferred to 
nitrocellulose membranes (section 2.2.4). The blot was probed with antiserum 
specific for C-terminus of PDE4A. The figure shown is typical of experiments 
performed at least three times using proteins from different homogenates.
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Figure 3.27. RT-PCR analysis of Jurkat T-cells using PDE46 
specific primers
Jurkat T-cells were untreated or exposed to 100 pM forskolin for 9 h. After the 
treatment period, RNA was extracted and reverse transcribed into cDNA (sections
2.2.15-16). PCR was then performed (section 2.2.17) using primers specific for 
the established human PDE4A splice variant PDE46. These primers were: Sense- 
2260, GTGGGGGCCGGATCCATGGAACCCCCGACC and antisense-2261, 
GGTTCAACAGATATCTGAACTTGTGCGAGG, defining a 817 bp fragment. 
PCR reaction employed here was: 1 min at 95 °C, 1 min at 59 °C and 90 s at 72 °C 
for 35 cycles. The products were electrophoresed on 1.5 % agarose gel and 
visualised with ethidium bromide under UV light. The results are representative of 
three experiments using RNA from different extractions. (+): positive control, U: 
untreated, F: forskolin treated, M: marker.
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Figure 3.28. RT-PCR analysis of Jurkat T-cells using PDE4D3 
specific primers
Jurkat T-cells were untreated or exposed to 100 pM forskolin for 9 h. After the 
treatment period, RNA was extracted and reverse transcribed into cDNA (sections
2.2.15-16). PCR was then performed (section 2.2.17) using primers specific for 
PDE4D3. These oligonucleotides were: Sense PDE43-SE11, ATTGCCCACGA- 
TAGCTGCTC and antisense COM-D SE 13, GACTCCACTGATCTGAGAC- 
ATTG. PCR reaction employed: 1 min at 95 °C, 70 s at 55 °C and 100 s at 72 °C 
for 35 cycles. This allowed the detection of a 800 bp fragment found specifically 
in PDE4D3. The products were electrophoresed on 1.5 % agarose gel and 
visualised with ethidium bromide under UV light. The results are representative of 
three experiments using RNA from different extractions. (+) positive control, U: 
untreated, F: forskolin treated, M: marker.
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Figure 3.29. RT-PCR analysis of Jurkat T-cells using PDE4D4 
specific primers
Jurkat T-cells were untreated or exposed to 100 pM forskolin for 9 h. After the 
treatment period, RNA was extracted and reverse transcribed into cDNA (sections
2.2.15-16). APCR was then performed (section 2.2.17) using primers specific 
for PDE4D4. These oligonucleotides were: sense PDE39-SE10, 
AGCGCTACCTGTACTGTCG and antisense COM-D SE13, GACTCCACTGAT 
CTGAGACATTG. PCR reaction employed: 1 min at 95 °C, 70 s at 55 °C and 
100 s at 72 °C for 35 cycles. This allowed the detection of a 764 bp fragment 
found specifically in PDE4D4 representing nucleotides 757-1520. The products 
were electrophoresed on 1.5 % agarose gel and visualised with ethidium bromide 
under UV light. The results are representative of three experiments using RNA 
from different extractions. (+) positive control, F: forskolin treated, U: untreated, 
M: marker.
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Figure 3.30. RT-PCR analysis of Jurkat T cells using PDE4D5 
specific primers
Jurkat T-cells were untreated or exposed to 100 pM forskolin for 9 h. After the 
treatment period, RNA was extracted and reverse transcribed into cDNA (sections
2.2.15-16). PCR was then performed (section 2.2.17) section using primers 
specific for PDE4D5. These oligonucleotides were: Sense PDE79-SE10, 
CTGTTGCAGCATGAGAAGTCC, antisense COM-D SE13, GACTCCACTGA- 
TCTGAGACATTG. PCR reaction employed: 1 min at 95 °C, 70 s at 55 °C and 
100 s at 72 °C for 35 cycles. This allowed the detection of a 801 bp fragment 
found specifically in PDE4D5 representing nucleotides 226-1026. The products 
were electrophoresed on 1.5 % agarose gel and visualised with ethidium bromide 
under UV light. The results are representative of three experiments using RNA 
from different extractions. (+): positive control, U: untreated, F: forskolin treated, 
M: marker.
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Figure 3.31. RT-PCR analysis of Jurkat T-cells using PDE4D1 
specific primers
Jurkat T-cells were untreated or exposed to 100 pM forskolin for 9 h. After the 
treatment period, RNA was extracted and reverse transcribed into cDNA (sections
2.2.15-16). PCR was then performed (section 2.2.17) using primers specific for 
the established human PDE4D splice variant PDE4D1. These oligonucleotide 
primers were: sense PDE4D1-SE9, ATGGCCCCCTTTGAACTCGC and 
antisense-COM-D SE13, GACTCCACTGATCTGAGACATTG, defining a 369 
bp product. PCR reaction employed: 1 min at 95 °C, 70 s at 55 °C and 100 s at 72 
°C for 35 cycles of each condition utilised. The products were electrophoresed on 
1.8 % agarose gel and visualised with ethidium bromide under UV light. The 
results are representative of three experiments using RNA from different 
extractions. F: forskolin treated, U: untreated, M: marker.
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Figure 3.32. RT-PCR analysis of Jurkat T-cells using PDE4D1/2 
specific primers
Jurkat T-cells were untreated or exposed to 100 pM forskolin for 9 h. After the 
treatment period, RNA was extracted and reverse transcribed into cDNA (sections
2.2.15-16). PCR was then performed (section 2.2.17) using primers specific for 
the established human PDE4D splice variants PDE4D1/2. These oligonucleotide 
primers were: sense PDE4D1/2-SE16, AAGGAGCAGCCATCATGTGC and 
antisense-COM-D SE13, GACTCCACTGATCTGAGACATTG. This allowed 
the detection of a 426 bp fragment found in hPDE4D 1 and was also capable of 
detecting a 340 bp fragment in hPDE4D2. PCR reaction was 1 min at 95 °C, 70 s 
at 55 °C and 72 °C at 100 s for 35 cycles. The products were electrophoresed on 
1.5% agarose gel and visualised with ethidium bromide under UV light. The 
results are representative of three experiments using RNA from different 
extractions. 6-U: beta actin untreated, 6-F: beta actin forskolin treated, F: 
forskolin treated, U: untreated, M: marker.
146
 , *;-■<
75 kDa 
67 kDa 
65 kDa
lïieay»''. - t  >
r r -  ': "
214 kDa
kDa
74 kDa
■45 kDa
U Dl
Figure 3.33. Immunoblot analysis of PDE4D immunoreactivity in 
Jurkat T-cells
Jurkat T-cells were either untreated or exposed to 100 pM forskolin for 9 h. After 
the treatment period cells were washed and homogenised. Identical amounts of 
protein (100 pg of protein) and COS7 cells transfected with PDE4D1 (D l) or no 
proteins (as positive and negative controls, respectively) were run on SDS- 
polyacrylamide gel electrophoresis (section 2.2.3) and then transferred to 
nitrocellulose membranes (section 2.2.4). The blot was probed with antiserum 
specific for the C-terminus of PDE4Ds. Figure shown is typical of experiments 
performed four times using proteins from different homogenates. F: forskolin 
treated, U: untreated control, Dl: positive control.
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CHAPTER 4
CHARACTERISATION OF FIVE HUMAN FDE4D
ISOFORMS
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4 .1 . Introduction
shown to encode the putative catalytic region (Jin et ah, 1992). The other two 
blocks of strong sequence homology which were located in the N-terminal regions 
of the proteins were called UCR l and UCR2, Upstream Conserved Region 1 and 
2 (Figure 4.1), (Bolger, 1994). PDE4D1 and PDE4D2 lack the UCR l region and
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The PDE4 cAMP-specific phosphodiesterases are a large family of enzymes that 
are characterised by a high specificity and affinity for cAMP, their inhibition by the 
antidepressant rolipram (Beavo et al., 1994, DiSanto & Heaslip, 1995) and 
insensitivity to both cyclic GMP and Ca^+/ CaM (Livi et al., 1990, Shakur et al., 
1995, Wilson et al., 1994) (Table 1.1). The human PDE4s are highly 
homologous to the Drosophila melanogaster 'dunce' gene (Chen et al., 1986) in 
terms of DNA and protein sequences, similar kinetics and genomic structure
(Monaco et al., 1994) (Figure 1.4). The first PDE4 cDNA to be isolated was for 
the Drosophila dunce enzyme (Chen et al., 1986). This cDNA was used to probe 
mammalian cDNA libraries so as to isolate cDNAs encoding PDE4 isoforms from 
rat (Conti & Swinnen, 1990, Davis, 1990, Swinnen et al., 1989a) and human 
(Baecker et al., 1994, Bolger et al., 1993, Livi et al., 1990, Mchala et al., 1990).
Analysis of cDNA clones derived from human (Baecker et al., 1994, Beavo et al., 
1994, Conti et al., 1995b) and rat (Davis et al., 1989, Swinnen et al., 1989a) have 
indicated that four gene families (PDE4A, 4B, 4C and 4D) encoding closely related 
proteins are present. Three of these genes (PDE4A, 4B and 4D) encode multiple 
PDE isoforms, due to different alternatively spliced mRNA transcripts. These 
PDE isoforms have identified two conserved splice junctions (Bolger, 1994, Conti 
et al., 1995b). The first splice point occurs where the PDE4D3, 4D4 and 4D5 
mRNAs converge. A second splice junction occurs where the PDE4D1 and 4D2 
mRNAs diverge from the consensus sequence (Figure 4.1). In the PDE4D 
sequences there are three distinct homologous regions. One of these regions was
I
they represent the so-called 'short' form PDE isoforms. PDE4D3, PDE4D4 and 
PDE4D5 have both conserved regions and are so-called 'long' form PDE 
isoforms. U CR l and UCR2 regions appears to be distinct and they lack 
homology to each other. Additionally, these regions of human and Drosophila 
melanogaster, respectively show more homology to each other than to any other 
sequences in the GenBank or EMBL data bases (Bolger, 1994), although the 
functional significance of these regions is not known. However, that they are 
conserved in long form products of the various PDE4 isoforms suggests that they 
may have an essential function (Bolger, 1994).
The PDE4D gene (Bolger, 1994, Sette et al., 1994b) encodes a number of mRNA 
variants that differ in the 5'-domain. In rats, four different transcripts from this 
gene have been demonstrated (Bolger et al., 1994, Sette & Conti, 1996, Swinnen 
et al., 1989b), these are: rat PDE4D1, rat PDE4D2, rat PDE4D3 (formerly known 
as ratPDE3.1, ratPDE3.2 and ratPDE3.3, respectively) and PDE4D4 (Vicini and 
Conti, unpublished data). The human counterparts of PDE4D1 and PDE4D2 (the 
4D2 transcript is missing one or more exon(s) (86 bp) (Figure 4.1) that are present 
within the 5' region of 4D1 (Nemoz et al., 1996), PDE4D3 and PDE4D4 (Bolger 
et al., 1993) isoforms) have been reported. The novel human PDE4D splice 
variant PDE4D5 has recently been cloned by Bolger et al. (1997) (Figures 4.1).
Alignment of the rat and human PDE4D1, PDE4D2 and PDE4D3 amino acid 
sequences shows highly conservative features. Each of the human proteins is 
nearly identical in length to its rat counterpart and has greater than 90 % amino acid 
identity. However, recent data suggest that each of the various isoforms has a 
distinct function. For example, they differ in their ability to be induced by changes 
in cAMP levels (Erdogan & Houslay, 1997, Sette et a l ,  1994a, Verghese et ah,
1995) and protein-protein interaction (O'Connell & Houslay, unpublished data).
The rat PDE4D1, PDE4D2 and PDE4D3 proteins vary in their enzymologic
I
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properties and in their regulation by phosphorylation (Sette & Conti, 1996, Sette et 
ah, 1994a).
4 . 1 . 1 .  Aim of the study
In this chapter, different cDNA clones (isolated by Dr. Bolger, Utah/USA) derived 
from different mRNA transcripts of the human PDE4D  gene were transiently 
expressed in COS7 cells and their ability to hydrolyse cAMP, subcellular 
localisation of their encoded proteins, biochemical and pharmacologic properties 
were analysed.
4 . 2 ,  R esults  
4 . 2 . 1 .  Expression and subcellular distribution of human PDE4D1, 
PDE4D2, PDE4D3, PDE4D4 and PDE4DS cDNAs in COS7 cells
In order to characterise the five different PDE enzymes encoded by the pPDE39, 
pPDE43, pPDE79, pPDE82 and pDun411 cDNAs (PDE4D4, PDE4D3, PDE4D5, 
PDE4D2 and PDE4D1 respectively) these were engineered into expression 
plasmids (pcDNA3) under the control of the cytomegalovirus (CMV) inteimediate 
early gene promoter which allowed transcript expression in COS7 cells (section 
2.2.12.1). The clones have been identified with their isoforms and their GenBank 
accession numbers are given in the table 4.1.
Homogenates of transfected COS7 cells were subjected to centrifugation in order 
to isolate a low-speed pellet (PI), a high-speed pellet (P2: particulate fraction) and 
a high-speed supernatant (S: cytosol) (see section 2.2.12.3). The PDE activities 
were measured in these fractions using 1 p.M cAMP as substrate (2.2.5). The 
average PDE activity in the mock transfection with the parent plasmid was 10±4 
pmol/min/mg of protein (« = 4 separate experiments). Transfection with the parent
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plasmid had no effect (<3 %) on either the total endogenous C0S7 cell PDE 
activity or rolipram inhibited fractions.
Typically, cytosolic fractions (S) of the 'short' form of the PDB4D1 and PDE4D2 
exhibited PDE activities of 298±21 and 160±13 pmol/min/mg of protein, 
respectively (n = 4 experiments using different transfections). This increased 
homogenate PDE activity was completely inhibited (>96 %) by the addition of 
rolipram (10 |liM). However, no observable increase in the PDE activities of the 
PI and P2 fractions (<2 » 3 % change; n -  4) were detected. This demonstrates 
that PDE4D1 and PDE4D2 proteins were located exclusively in the cytosol fraction 
(Table 4.2).
The three 'long' forms of human PDE4D isofoims were distributed between both 
particulate and cytosol compartments (Table 4.2). The cytosolic fractions of 
PDE4D3, PDE4D4 and PDE4D5 activities were considerably greater, with specific 
activities of 351±21, 410±25 and 379±18 pmol/min/mg of protein, respectively (« 
~ 4 experiments using different transfections). All of this increased PDE activity 
(>95 %) was inhibited by rolipram (10 jj.M). The majority of PDE4D4 activity 
was in the particulate fraction (60 %), whereas, about 30 % of PDE4D3 and 
PDE4D5 activities were associated with the membrane fraction with the major 
fraction occuring in the cytosol (Table 4.2). In addition, the three species differed 
in their distribution between PI and P2, with PDE4D5 present in a higher relative 
amount in P I, compared to PDE4D3 and PDE4D4 (Table 4.2).
4 . 2 . 2 .  Im m unological detection of human PDE4D1, FDE4D2, 
PDE4D3, PDE4D4 and PDE4D5 cDNAs expressed in COST cells
The human PDE4D gene products share sequence homology in their carboxyl- 
terminal regions (Figure 4.1). A monoclonal antibody generated against the C-
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terminal region found in common with all of the known human PDE4D proteins 
was used for the detection of PDE protein. To characterise whether the different 
mRNA variants were translated into different protein products, the five cDNAs 
were expressed in COS7 cells. The signals generated with the antibody in Western 
blots were linear over a wide range of amounts of protein loaded on the 
immunoblot (Figures 4.2 and 4.3). Each of the five recombinant proteins migrated 
as single, distinct species with the exception of the PDE4D4 and PDE4D5 
isoforms (see below for figure numbers), where an additional band of much 
weaker intensity (~5 %) was present. These additional bands migrated near 
PDE4D3 in both cases and may represent initiation of translation at a second 
downstream start codon. The PDE4D1 and PDE4D2 variants were found as 
soluble immunoreactive species of about 68 kDa with no immunoreactivity 
associated with the pellet fractions (Figures 4.4 and 4.5 respectively). Thus both 
the immunoblot data and activity data were consistent and showed that PDE4D1 
and PDE4D2 isoforms were evident solely in the cytosol fraction. In contrast 
PDE4D3, PDE4D4 and PDE4D5 isoforms (molecular mass of 95±2 kDa, 119+2 
kDa and 105±2 kDa respectively) were found in both paiticulate-associated and 
soluble forms (Figures 4.6, 7 and 8 respectively). This indicated that the 'long' 
forms contain information in their N-terminal extention regions that allows 
anchoring to paiticulate/membrane fraction.
All five PDE4D variants migi*ated on SDS-PAGE gel slower (re. larger apparent 
size) than their predicted amino acid sequence (Table 4.3). This may reflect 
particular conformational properties, or the anomalous binding to SDS of these 
proteins in SDS-PAGE. Similar anomalous results on SDS-PAGE has been 
observed for recombinant rat and human PDE4A proteins (Bolger et al., 1996, 
Huston et al., 1996).
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4 .2 .3 .  S o lu b ilisa tio n  o f p a r t ic u la te  f ra c tio n s  of th e  h u m an  
PDE4D3, PDE4D4 and  PDE4D5 by T riton  X-100 and  NaCl
The rat PDE4A1 protein RDI has been shown to be released from the particulate 
fraction by the detergent Triton X-100 (Shakur et al., 1995), whereas the human 
PDE4A4B (Huston et al., 1996), rat PDE4A5 (McPhee et al., 1995) and rat 
PDE4A8 (Bolger et al., 1996) proteins were not able to be eluted from the 
particulate fraction by either detergent or high salt concentrations. Therefore, I set 
out to see whether the human PDE4D particulate-associated proteins could be 
released from the particulate fraction by detergent and high salt treatments. C0S7 
cell high-speed pellets expressing either PDE4D3, PDE4D4 or PDE4D5 were 
either solubilised with the non-ionic detergent Triton X-100 (5 %) or high salt 
(NaCl) concentration (1 M) or both. The resulting high-speed pellet and 
supernatant were then analysed by immunoblotting (Table 4.4). The PDE4D5 
protein could be released, at least in part, from the particulate fraction by either of 
these treatments and was completely released by a combination of the two (Figure 
4.9). PDE4D3 could be partly solubilised by Triton X-100 alone and was 
completely released by a combination of the two (Figure 4.10). PDE4D4 was 
resistant to either treatment alone, but could be solubilised by a combination of 
both (Figure 4.11). Detergent treatment was used to solubilise integral proteins 
and high salt to release peripheral proteins. Of course release of these PDEs might 
reflect the liberation of the PDE4D species together with anchoring protein.
4 .2 .4 .  K inetics of cA M P h y d ro ly sis  by five h um an  PDE4D 
iso fo rm s
To examine the biochemical properties of these enzymes PDE4D1, PDE4D2,
PDE4D3, PDE4D4 and PDE4D5 were transiently expressed in COS7 cells.
Soluble (S; cytosol) and particulate (P2; membrane) fractions were isolated from
■|
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COS7 cells expressing the indicated isoforms, values were determined 
(section 2.2.6) over a cAMP range of 0.25 jiiM - 25 p-M at seven different 
concentrations. The values were obtained for both soluble PDE4D1, 4D2.
4D3,4D4 and 4D5 (Figures 4.12, 13,14, 15 and 16 respectively) and particulate- 
associated fractions of PDE4D3, 4D4 and 4D5 (Figures 4.17, 18 and 19 
respectively) by non-linear fitting of data to the Michaelis equation. The soluble 
and particulate fractions exhibited similar (0.7 p-M - 1.3 pM  cAMP) low 
values for cAMP hydrolysis (Table 4.5). These values reflect those reported for 
other PDE4 enzymes (Bolger, 1994, Conti et al., 1995b, Conti et al., 1992, A
Engels et al., 1995, Huston et al., 1996, Michaeli et al., 1993). yf
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The relative amounts of PDE4D protein in the isolated cytosolic and particulate 
fractions was obtained by immunoblotting. Vmax values were then obtained from 
double-reciprocal (Lineweaver-Burk) plots (Figures 4.2 and 4.3). From these data
the relative Fmax values of these isoforms were determined so as to see if the five 
different PDE4Ds had different maximal activities. The relative Fmax values for
the cytosolic forms were compared relative to that of the PDE4D1 enzyme, which 
was determined as 1.0 (Table 4.6). The cytosolic forms of PDE4D2, PDE4D3 
and PDE4D5 showed relatively similar Fmax values, whereas PDE4D4 had a 
relative Fmax 2- to 3-fold higher than that of the other four cytosolic enzymes 
(p<0.001). The ratios of paiticulate to cytosolic relative Fmax of both PDE4D4 
and PDE4D5 were 2.5- to 3.3-fold higher (p<0.001), respectively, implying that 
the activity of the particulate forms were higher. The Fmax of the particulate form
of PDE4D3 was the same of that of the cytosolic form and 2- to 3-fold lower than 
that of both PDE4D4 and PDE4D5. I
1I
156
4 .2 .5 .  In h ib itio n  of p a rtic u la te  and  cytosolic fo rm s of the  five 
hum an PDE4D enzymes by ro lipram
Rolipram caused the dose-dependent inhibition of both cytosolic and particulate 
PDE4D isoforms. The values were typical for members of the PDE4 family 
(Bolger et al., 1996, Huston et al,, 1996, McPhee et al., 1995). High 
concentrations of rolipram almost completely abolished detectable PDE activity in 
the extracts of D l, D2, D3, D4 and D5 (Figures 4.20, 21, 22, 23 and 24 
respectively) and of particulate fractions (Figures 4.25, 26 and 27 respectively). 
The concentration of rolipram needed for 50 % inhibition of enzyme activity (IC50) 
of the various cytosolic forms was similar (Table 4.7). However, particulate 
fractions of PDE4D3 and PDE4D5 were 2- to 7-fold less sensitive to rolipram 
inhibition than those of their respective cytosolic forms (p<0 .0 1  and p<0 .0 0 1 , 
respectively).
All the PDE4D isoforms, with the exception of PDE4D3, deviated from the simple %
Michaelian kinetics. The inhibitor curves for the cytosolic forms of the five 
proteins were quite similar, except PDE4D3, which had a much steeper slope (for 
figures see above, Table 4.8). Similarly, the dose-effect curves for the particulate 
forms of PDE4D3 and PDE4D5 had a steeper slope than that of the particulate 
form of PDE4D4. The association of PDE4D3, PDE4D4 and PDE4D5 with 
membranes produced a modest (less than 2-fold) difference in slope (Table 4.8), 
despite the changes in IC50 for PDE4D3 and PDE4D5. The data demonstrate that 
only the cytosolic and particulate forms of PDE4D3 showed simple Michaelian 
kinetics, with a Hill coefficient approaching unity and that the other forms i
demonstrated apparent negative co-operativity.
I
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4 .3 . Conclusion and Discussion
It has been shown that multiple PDE isoforms can be derived by different 
transcription initiation sites, alternative mRNA splicing and RNA editing. The five 
human PDE4D cDNA clones described in this chapter were generated by 
alternative mRNA splicing. Comparison of the nucleotide sequences of PDE4D4 
and PDE4D5 cDNAs to those encoding three other human PDE4D proteins 
(PDE4D1, PDE4D2 and PDE4D3), demonstrated that each corresponding mRNA 
transcript has a unique region of sequence at or near its 5' end (Figure 4.1). Three 
of the five cDNAs encoded proteins (PDE4D3, PDE4D4 and PDE4D5) which 
contained UCR l and UCR2 as well as the catalytic region, whereas the two other 
cDNAs encoded proteins (PDE4D1 and PDE4D2) which lack UCR l, but contain 
at least a portion UCR2 and the complete catalytic region. For these five different 
cAMP-PDE isoforms, all encoded by the human PDE4D gene, their enzymatic 
properties and subcellular localisation were compared subsequent to U'ansient 
expression in COS7 cells. It is believed that the five human cDNA clones do not 
represent artefacts of cloning for two reasons. First, each of the five cDNAs 
generated a protein very similar in size to PDE4D species occurring naturally. 
Secondly, all of the proteins appear to have homologs in the rat. cDNAs encoding 
rat homologs of PDE4D1, PDE4D2 and PDE4D3 have been reported previously 
(Bolger et al., 1993, Monaco et al., 1994, Sette & Conti, 1996, Swinnen et al., 
1989b). Bolger et al. (1997) has shown that homologs of the all human PDE4D 
proteins exist in rat brain.
The 'short' forms, PDE4D1 and PDE4D2, were present only in cytosol whereas 
'long' forms (PDE4D3, PDE4D4 and PDE4D5) also exist in the particulate 
fraction (Figures 4.4, 5, 6, 7 and 8 respectively) expressed in COS7 cells. 
Treatment with either Triton X-100 or high concentrations of NaCl or both were 
shown to solubilise the PDE4D3, PDE4D4 and PDE4D5 membrane forms
157
(Figures 4.10, 11 and 9 respectively). This complexity may reflect the binding of 
these PDE4D species to anchor proteins. Thus release of the PDE4D forms may 
occur due to disruption of their interaction with the anchor protein(s) or the 
solubilisation of the anchor proteins. Solubilisation data (Table 4.4) suggest that 
considerable differences occur between the long' forms in their ability to be 
dissociated from the particulate fraction. This may reflect differences in the anchor 
proteins for the various species and suggests that the variant N-terminal regions are 
important for the specificity of subcellular localisation of these isoforms. Indeed, 
Huston et al. (1996) showed that the 'long' form of human hPDE46 
(HSPDE4A4B) was associated with the particulate fraction, whereas h6.1 
(HSPDE4A4C) which lacks the N-terminal extention seen in PDE46, was 
completely cytosolic. Three rat PDE4A species were demonstrated to have 
identical catalytic regions but contained unique N-terminal regions. However, 
amino-terminal domains of these species apparently regulate activity and the 
propensity to interact with other specific proteins (McPhee et al., 1995, Scotland & 
Houslay, 1995, Shakur et al., 1993, Shakur et al., 1995). This data suggests that 
the UCR l region may be involved or, alternatively, that other parts of the amino- 
terminal regions of PDE4 proteins have either a prime role for membrane-binding 
or interaction with specific proteins or regulation of the enzyme.
Comparison of the values o f five different PDE4Ds showed that each form 
hydrolysed cAMP with high affinity (Figures 4.12, 13, 14, 15, 16, 17, 18 and 
19). The analysis of the values calculated for each enzyme form, 
demonstrated that the values were not significantly different between either 'long' 
and 'short' forms or cytosolic and particulate fractions (Table 4.5). The five 
PDE4Ds all share an identical core catalytic region which would explain the 
observed similarity in the Xm values. To determine if  there were any differences 
in the Umax values for each of the reported enzymes in this present study an 
antibody against the C-terminus of PDE4D isoforms was used. The PDE4D
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antiserum was used to immunoblot equal amounts of PDE protein from each of the 
COS7 cell extracts. This enabled the use of equal amounts of protein in activity 
assays by determination of the density on the immunoblot. I was able to define the 
relative Umax values of these isoforms and determine any differences between 
isoforms. The cytosolic form of PDE4D4 protein was shown to have a Umax that 
was 2- to 3 “fold higher than that of the other four cytosolic isoforms (Table 4,6), 
which were very similar. This suggests that the amino-terminal regions of these 
proteins affect the conformation of the protein in a highly specific way, by 
attenuating the Umax, but not ifm- The Umax o f  the particulate forms of both 
PDE4D4 and PDE4D5 were 2.5- to 3.3-fold higher than that of the cytosolic 
fractions (Table 4.6). The Umax of the particulate form of PDE4D3 was the same 
of that of the cytosolic form and 2- to 3-fold lower than that of both PDE4D4 and 
PDE4D5. This suggests that the extreme amino-terminal regions of PDE4D4 and 
PDE4D5 may contain specific information for regulation of the catalytic activity of 
particulate enzymes.
IC50  values were calculated from the dose-response curves to rolipram for each of 
the enzyme forms (Figures 4.20, -21, 22, 23, 24, 25, 26 and 27). Rolipram 
caused the dose-dependent inhibition of both particulate and soluble forms of the 
five different human PDE4D isoforms expressed in C0S7 cells. The inhibitor 
sensitivity of the five cytosolic forms were found to be quite similar (Table 4.7). 
However, particulate forms of PDE4D3 and PDE4D5 were approximately 2- to 7- 
fold less sensitive to inhibition by rolipram than that of cytosolic forms. On the 
other hand, cytosolic and particulate forms of PDE4D4 were equally sensitive to 
rolipram inhibition (Table 4.7).
Five different human PDE4D isoforms were analysed by expression in COS7 
cells. It is possible that the recombinant proteins may be processed differently in 
COS7 cells or tissues or that overexpression of the proteins in COS7 cells may
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affect their intracellular distribution. However, it is considered that data obtained 
by expressing PDE4 cDNAs in COS7 cells is likely to provide a good 
representation of the native enzyme. This is based on previous studies (Bolger et 
al., 1996, McPhee et al., 1995, Shakur et al., 1995) which yielded similar 
subcellular localisation data for the rat PDE4A1 and PDE4A5 proteins, as 
expressed in COS7 cells, compared to the corresponding native proteins in the 
brain.
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There may be other ways in which the 'long' PDE4D variants differ from the 
'short' ones. Whilst the human and rat PDE4D1 and PDE4D2 isoforms are 
differentially regulated by cAMP at the level of transcription and/or de novo 
synthesis in various cells (Erdogan & Houslay, 1997, Sette et ah, 1994a, Sette et 
ah, 1994b, Swinnen et ah, 1989b, Swinnen et ah, 1991b). Whereas the rat 
PDE4D3 is phosphorylated by a cAMP-dependent protein kinase (Sette & Conti,
1996). The serine residue shown to be required for the phosphorylation of the rat 
PDE4D3 protein, which corresponds to serine^'^ in human PDE4D3, is shared by 
all the human PDE4D3, PDE4D4 and PDE4D5 isoforms. The proline rich amino- 
terminal regions of the rat PDE4A5 (O'Connell et ah, 1996) and the human 
PDE4D4 but not PDE4D1 or PDE4D2 (O'Connell & Houslay, unpublished data) 
isoforms interact with SH3 domains on other proteins. This suggests that the 
regulation of 'long' forms differ from 'short' forms due to their amino-terminal 
regions.
I
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T ab le  4.1. cDNA clones co rre sp o n d in g  to tra n s c r ip ts  from  the 
hum an  PDE4D isoform s
P lasm id  nam e Isoform  nam e Accession num ber
pDun411 PDE4D1 U50157*, U79371
pPDE82 PDE4D2 U50158*, 8:1059275
pPDE43 PDE4D3 L20970
pPDE39 PDE4D4 L20969
pPDE79 PDE4D5 8:1059276
The clones are identified with their isoform names and GenBank accession 
numbers. Accession numbers with an asterisk (*) correspond to the clones of 
Nemoz, et al. (1996). All other accession numbers are from Bolger, et al. (1993) 
or Bolger, et al. (1997).
I
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Table 4.2. Subcellular distribution of human PDE4D activities, as
expressed in COST cells
P I P2 Supernatant P1/P2 ratio Particulate
(%) (%) (%) -(M (%)
PDE4D1 4±2 3±1 93±3 n/a 7
PDE4D2 2±2 4±2 94+6 n/a 6
PDE4D3 11±3 20±2 69±6 0.55 31
PDE4D4 20±4 40±7 40+3 0.5 60
PDE4D5 18±3 15+1 67+9 1.2 33
Homogenates from COS7 cells expressing plasmids encoding various isoforms 
were fractionated into a low speed pellet (PI), a high speed pellet (P2) and high 
speed supernatant, as described in section 2.2.12.3. PDE activity assays were 
performed in the presence of a final concentration of 10 pM rolipram using 1 pM 
cAMP as substrate (section 2.2.5) in the assay. Each value represents the mean ± 
SD of at least three different experiments, each using separate transfections and 
were carried out in triplicate, n/a: not applicable
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Table 4.3. Properties of human PDE4D proteins expressed in
COST cells
Iso fo rm Amino acids Predicted size (kDa) O bserved size (kDa)
PDE4D1 586 66.5 68±1
PDE4D2 508 57.8 68+1
PDE4D3 673 76.5 95db2
PDE4D4 810 91.1 119+2
PDE4D5 746 84.4 105+2
The predicted and experimentally determined sizes of the five human PDE4D 
proteins are shown in the table. In order to deteimine the size of the proteins, 
homogenates from COST cells expressing (section 2.2.12.3) the five plasmids 
were immunoblotted and the relative sizes of the recombinant proteins were 
determined.
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Table 4.4. Solubilisation of m em brane-associated human PDE4D  
proteins by detergents or high salt concentrations
. Amount solubilised 1'%'»
Buffer only IM  NaCl S %  Triton X-100 [IM NaCI + 
5% Triton X-100]
PDE4D3 5±3 13+6 39+8 93+6
PDE4D4 6±4 9±7 12±9 86+11
PDE4D5 2±3 42±7 47±8 94+5
The high speed membranes (P2 pellets) were isolated from COS7 cells expressing 
the indicated isoforms and treated with high concentrations of the salt NaCl, non­
ionic detergent Triton X-100 or both. After the incubation and centrifugation, as 
described in section 2.2.12.4, the residual pellet and supernatant fractions were 
subjected to SDS/PAGE and Western blotting (sections 2.2.3 - 4) with anti- 
PDE4D antibody. The resultant ECL/autoradiographs were scanned and 
absorbance changes quantified. Wash buffer (KHEM) was used as a negative 
control. Values are expressed as mean ±  SD for 3 seperate experiments.
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Table 4.5. K m  values for cAMP for human PDE4D isoforms
transfected in COST cells
cytosol m em branes
PDE4D1 1.2+0.3 n/d
PDE4D2 1.310.2 n/d
PDE4D3 1.210.3 0.710.2
PDE4D4 1.110.1 0.810.1
PDE4D5 1.010,2 0.810.2
The human PDE4D cDNAs were transfected into COS7 cells and then cytosolic (S; 
supernatant) and membrane (P2; high speed pellet) fractions were isolated as 
described in section 2.2.12.3. K m  values (in pM) were determined over a 
substrate range of 0.25 to 25 pM cAMP (7 different concentrations) and were 
obtained by non-linear fitting of data to the Michaelis equation. Values are given 
as mean ± SD for three independent experiments, each using separate 
transfections, n/d = not determined.
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Table 4.6. Umax values for cAMP for human PDE4D isoforms
transfected in COST cells
cytosol 
relative to PDE4D1
Umax particu late/cytosol 
activity ratio
PDE4D1 (1) n/a
PDE4D2 1.110.2 n/a
PDE4D3 1.210.3 0.9110.2
PDE4D4 2.910.3 2.510.1
PDE4D5 1.510.2 3.310.1
The relative Umax values were determined from Lineweaver-Burk plots, with 
enzyme amounts quantitated by immunoblotting. Umax values for the cytosolic 
activities are given relative to those of the PDE4D1 protein, which is set as 1.0. 
Values are given as mean ± SD, for three independent experiments, each using 
separate transfections, n/a: not applicable
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Table 4,7, Inhibition of human PDE4D Isoforms from COST
transfected cells by rolipram
cytosol m em branes m em brane/cytosolic
ratio
PDE4D1 0.0510.01 n/a n/a
PDE4D2 0.0510.01 n/a n/a
PDE4D3 0.1410.01 0.3210.05 2.310.3
PDE4D4 0.0610.05 0.0510.02 0.811.1
PDE4D5 0.0810.01 0.5910.05 7.410.5
The human PDE4D cDNAs were transfected into C0S7 cells and then cytosolic (S; 
supernatant) and membrane (P2; high speed pellet) fractions were isolated as 
described in section 2.2.12.3. PDE assays were performed in the presence of 
IpM  cyclic AMP as substrate with 7 different concentrations of the inhibitor 
rolipram. The values are given (in pM) as mean ± SD for three independent 
experiments, each using different transfections. IC50  was the concentration which 
resulted in 50 % inhibition, n/a = not applicable.
167
Table 4.8. Hill coefficients for the inhibition of human PDE4D
isoforms by rolipram
Iso fo rm cytosol particulate
PDE4D1 0.4710.12 n/a
PDE4D2 0.6110.05 n/a
PDE4D3 0.9310.08 0.9410.03
PDE4D4 0.5010.05 0.3510.08
PDE4D5 0.5410.05 0.7510.09
The data is calculated using by the KaleidaGraph computer programme.
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Figure 4.1. Alignment of the amino acid sequences of the human
PDE4D isoforms
The five human PDE4D amino acid sequences have been aligned. •  denoted an 
identical amino acid residue. Horizontal lines indicate the positions of U CR l, 
UCR2 and the catalytic region of the proteins. ■i
■i
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Figure 4.1. Alignment of the amino acid sequences of the 
human PDE4D enzymes
PDE4D1PDE4D2PDE4D3PDE4D4PDE4D5
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F igu re  4.2. L in e a rity  of d e tec tio n  of v a rio u s  cy tosolic  PDE4D 
p ro te in s
This data shows that with increasing concentrations of cytosolic (supernatant) 
protein (2.5 pg to 10 pg) from COS7 cells (transfected with indicated PDE4D 
isoforms), a linear relationship between intensity and applied protein was 
observed. The proteins were immunoblotted by monoclonal antibody and the blots 
were scanned. The intensity of the signal is plotted for each plasmid. Such 
analyses were used to determine the relative amounts of PDE4Ds for the 
determination of relative Vmax values in table 4.6.
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F igu re  4.3. L in ea rity  of de tec tion  of various m em b ran e  PDE4D 
p ro te in s
This data shows that with increasing concentrations of membrane (P2 pellet) 
protein (2.5 fig to 10 pg) from COS? cells (transfected with indicated PDE4D 
isoforms), a linear relationship between intensity and applied protein was 
observed. The proteins were immunoblotted by monoclonal antibody and the blots 
were scanned. The intensity of the signal is plotted for each plasmid. Such 
analyses were used to determine the relative amounts of PDE4Ds for the 
determination of relative Vmax values in table 4.6.
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Figure 4.4. Immunoblotting of COST cells transfected with the 
cDNA for human PDE4D1
PDE4D1 plasmid was transfected into COS7 cells. After 72 h the cells were 
harvested, disrupted, and extracts were then subjected to differential centrifugation 
in order to give low-speed pellet (PI), high-speed pellet (P2) and 
cyctosol/supernatant (S) fractions (section 2.2.12.3). Samples were then 
subjected to SDS/PAGE followed by Western blotting with the C-terminus 
monoclonal antiserum. Results are from a typical experiment which was 
performed at least three times with different transfections.
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Figure 4.5. Immunoblotting of COS7 cells transfected with the 
cDNA for human PDE4D2
PDE4D2 plasmid was transfected into COS7 cells. After 72 h the cells were 
harvested, disrupted, and extracts were then subjected to differential centrifugation 
in order to give low-speed pellet (P I), high-speed pellet (P2) and 
cyctosol/supernatant (S) fractions (section 2.2.12.3). Samples were then 
subjected to SDS/PAGE followed by Western blotting with the C-terminus 
monoclonal antiserum. Results are from a typical experiment which was 
performed at least three times with different transfections.
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Figure 4.6. Immunoblotting of COST cells transfected with the 
cDNA for human PDE4D3
PDE4D3 plasmid was transfected into COS7 cells. After 72 h the cells were 
harvested, disrupted, and extracts were then subjected to differential centrifugation 
in order to give low-speed pellet (P I), high-speed pellet (P2) and 
cyctosol/supernatant (S) fractions (section 2.2.12.3). Samples were then 
subjected to SDS/PAGE followed by Western blotting with the C-terminus 
monoclonal antiserum. Results are from a typical experiment which was 
performed at least three times with different transfections.
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Figure 4.7. Immunoblotting of COS7 cells transfected with the 
cDNA for human PDE4D4
PDE4D4 plasmid was transfected into COS7 cells. After 72 h the cells were 
harvested, disrupted, and extracts were then subjected to differential centrifugation 
in order to give low-speed pellet (P I), high-speed pellet (P2) and 
cyctosol/supernatant (S) fractions (section 2.2.12.3). Samples were then 
subjected to SDS/PAGE followed by Western blotting with the C-terminus 
monoclonal antiserum. Results are from a typical experiment which was 
performed at least three times with different transfections.
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Figure 4.8. Immunoblotting of COST cells transfected with the 
cDNA for human PDE4D5
PDE4D5 plasmid was transfected into COS7 cells. After 72 h the cells were 
harvested, disrupted, and extracts were then subjected to differential centrifugation 
in order to give low-speed pellet (P I), high-speed pellet (P2) and 
cyctosol/supernatant (S) fractions (section 2.2.12.3). Samples were then 
subjected to SDS/PAGE followed by Western blotting with the C-terminus 
monoclonal antiserum. Results are from a typical experiment which was 
performed at least three times with different transfections.
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PDE4D5
Figure 4.9. So lu b ilisa tion  o f human PDE4D5 protein from  
membranes using high salt and non-ionic detergent treatments
The high speed membranes (P2 pellets) were isolated from COS7 cells expressing 
the indicated PDE isoforms and treated with IM NaCl, 5% Triton X-100 or both. 
After incubation and centrifugation, as described section 2.2.12.4 - 5, the residual 
pellet and supernatant fractions were subjected to SDS/PAGE and Western blotting 
with anti-PDE4D antibody. The resultant ECL/autoradiographs were scanned and 
absorbance changes quantified (Table 4.4). These data are from a typical 
experiment which was performed at least three times with different membranes. 
Residual supernatants; 1: buffer only, 2: 1 M NaCl, 3: 5 % Triton X-100, 4: 1 M 
NaCl + 5 % Triton X-100. Residual pellets; 5: buffer only, 6: 1 M NaCl, 1:5 % 
Triton X-100, 8: 1 M NaCl + 5 %  Triton X-100.
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PDE4D3
Figure 4.10. Solubilisation of human PDE4D3 protein from  
membranes using high salt and non-ionic detergent treatments
The high speed membranes (P2 pellets) were isolated from COS7 cells expressing 
the indicated PDE isoforms and treated with IM NaCl, 5% Triton X-100 or both. 
After incubation and centrifugation, as described sections 2.2.12.4-5, the residual 
pellet and supernatant fractions were subjected to SDS/PAGE and Western blotting 
with anti-PDE4D antibody. The resultant ECL/autoradiographs were scanned and 
absorbance changes quantified (Table 4.4). These data are from a typical 
experiment which was performed at least three times with different membranes. 
Residual supernatants; 1: buffer only, 2: 1 M NaCl, 3: 5 % Triton X-100, 4: 1 M 
NaCl + 5 % Triton X-100. Residual pellets; 5: buffer only, 6: 1 M NaCl, 7: 5 % 
Triton X-100, 8: 1 M NaCl + 5 % Triton X-100.
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Figure 4.11. Solubilisation of human PDE4D4 protein from  
membranes using high salt and non-ionic detergent treatments
The high speed membranes (P2 pellets) were isolated from COST cells expressing 
the indicated PDE isoforms and treated with IM NaCl, 5% Triton X-100 or both. 
After incubation and centrifugation, as described section 2.2.12.4-5, the residual 
pellet and supernatant fractions were subjected to SDS/PAGE and Western blotting 
with anti-PDE4D antibody. The resultant ECL/autoradiographs were scanned and 
absorbance changes quantified (Table 4.4). These data are from a typical 
experiment which was performed at least three times with different membranes. 
Residual supernatants; 1: buffer only, 2: 1 M NaCl, 3: 5 % Triton X-100, 4: 1 M 
NaCl + 5 % Triton X-100. Residual pellets; 5: buffer only, 6: 1 M NaCl, 1:5 % 
Triton X-100, 8: 1 M NaCl + 5%  Triton X-100.
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Figure 4.12. Effect of cAMP concentration on the velocity of 
soluble hPD E4D l activity
Cytosolic extracts were isolated from COS7 cells expressing hPDE4Dl. 
values were determined over a substrate range of 0.25 to 25 jiM cAMP (7 different 
concentrations). Activity is given in pmoles of cAMP hydrolysed/min/mg of 
protein. The data shown is typical of three independent experiments with details of 
values given in table 4.5.
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F ig u re  4.13. E ffect o f cAM P co n cen tra tio n  on the  velocity  o f 
soluble hPDE4D2 activity
Cytosolic extracts were isolated from C0S7 cells expressing hPDE4D2. K^i 
values were determined over a substrate range of 0.25 to 25 |iM cAMP (7 different 
concentrations). Activity is given in pmoles of cAMP hydrolysed/min/mg of 
protein. The data shown is typical of three independent experiments with details of 
values given in table 4.5.
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F ig u re  4.14. E ffect of cA M P co n cen tra tio n  on th e  velocity o f 
soluble hPDE4D3 activity
Cytosolic extracts were isolated from COST cells expressing hPDE4D3. X’jn 
values were determined over a substrate range of 0.25 to 25 jiM cAMP (7 different 
concentrations). Activity is given in pmoles of cAMP hydrolysed/min/mg of 
protein. The data shown is typical of three independent experiments with details of 
values given in table 4.5.
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Figure 4.15. Effect of cAMP concentration on the velocity of 
soluble hPDE4D4 activity
Cytosolic extracts were isolated from COS7 cells expressing hPDE4D4. 
values were determined over a substrate range of 0.25 to 25 fiM cAMP (7 different 
concentrations). Activity is given in pmoles of cAMP hydrolysed/min/mg of 
protein. The data shown is typical of three independent experiments with details of 
values given in table 4.5.
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Figure 4.16. Effect of cAMP concentration on the velocity of 
soluble hPDE4D5 activity
Cytosolic extracts were isolated from COS7 cells expressing hPDE4D5. 
values were determined over a substrate range of 0.25 to 25 jiM cAMP (7 different 
concentrations). Activity is given in pmoles of cAMP hydrolysed/min/mg of 
protein. The data shown is typical of three independent experiments with details of 
values given in table 4.5.
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F ig u re  4.17. E ffect o f cA M P co n cen tra tio n  on th e  velocity of 
pa rticu la te  hPDE4D3 activity
Particulate (P2) extracts were isolated from COS? cells expressing hPDE4D3. 
values were determined over a substrate range of 0.25 to 25 |iM cAMP (7 different 
concentrations). Activity is given in pmoles of cAMP hydrolysed/min/mg of 
protein. The data shown is typical of three independent experiments with details of 
values given in table 4.5.
185
■ I
■I
g  0 . 9 -AbO _a 0 . 8 -
>  0 . 5 -
^  0 . 4 -
Qa 0.3-
S 0 .2 -
20 2 510 1 50 5
I
[cAMP] (|IM)
F ig u re  4.18. E ffect o f cA M P co n cen tra tio n  on th e  velocity of 
p a rticu la te  IiPDE4D4 activity
Particulate (P2) extracts were isolated from C0S7 cells expressing hPDE4D4. 
values were determined over a substrate range of 0.25 to 25 }iM cAMP (7 different 
concentrations). Activity is given in pmoles of cAMP hydrolysed/min/mg of 
protein. The data shown is typical of three independent experiments with details of 
values given in table 4.5.
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Figure 4.19. Effect o f cAMP concentration on the velocity of 
particulate hPDE4D5 activity
Particulate (P2) extracts were isolated from COST cells expressing hPDE4D5. 
values were determined over a substrate range of 0.25 to 25 p.M cAMP (7 different 
concentrations). Activity is given in pmoles of cAMP hydrolysed/min/mg of 
protein. The data shown is typical of three independent experiments with details of 
values given in table 4.5.
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F ig u re  4 ,20. D o se-d ep en d en t in h ib itio n  of so lu b le  tiP D E 4D l 
activity by ro lip ram
The activity of the soluble forms of hPDE4Dl was determined in the presence of 1 
jiM cAMP as substrate with the indicated increasing concentrations of rolipram. 
100 % activity is denoted as that observed in the absence of inhibitor. The data 
shown is typical of an experiment done three times in triplicate, each using separate 
transfections. Resultant IC5 0  values are given in table 4.7.
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F ig u re  4.21. D o se-d ep en d en t in h ib itio n  of so lub le  hPD E 4D 2 
activity  by ro lip ram
The activity of the soluble forms of hPDE4D2 was determined in the presence of 1 
|iM cAMP as substrate with the indicated increasing concentrations of rolipram. 
100 % activity is denoted as that observed in the absence of inhibitor. The data 
shown is typical of an experiment done tliree times in triplicate, each using separate 
transfections. Resultant IC50 values are given in table 4.7.
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Figure 4.22. D ose-response curve for the inhibition of soluble 
hPDE4D3 activity by rolipram
The activity of the soluble forms of hPDE4D3 was determined in the presence of 1 
pM cAMP as substrate with the indicated increasing concentrations of rolipram. 
100 % activity is denoted as that observed in the absence of inhibitor. The data 
shown is typical of an experiment done three times in triplicate, each using separate 
transfections. Resultant IC50 values are given in table 4.7.
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F ig u re  4.23. D ose-response cu rv e  fo r the in h ib itio n  of soluble 
hPDE4D4 activity  by ro lip ram
The activity of the soluble forms of hPDE4D4 was determined in the presence of 1 
pM cAMP as substrate with the indicated increasing concentrations of rolipram. 
100 % activity is denoted as that observed in the absence of inhibitor. The data 
shown is typical of an experiment done tliree times in tilplicate, each using separate 
transfections. Resultant IC50 values are given in table 4.7.
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F ig u re  4.24. D ose-response cu rve  fo r the in h ib itio n  of soluble 
hPDE4D5 activity  by ro lip ram
The activity of the soluble forms of hPDE4D5 was determined in the presence of 1 
|iM cAMP as substrate with the indicated increasing concentrations of rolipram. 
100 % activity is denoted as that observed in the absence of inhibitor. The data 
shown is typical of an experiment done three times in triplicate, each using separate 
transfections. Resultant IC50 values are given in table 4.7.
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Figure 4.25. Dose-response curve for the inhibition of particulate 
hPDE4D3 activity by rolipram
The activity of the particulate (P2) forms of hPDE4D3 was determined in the 
presence of 1 pM cAMP as substrate with the indicated increasing concentrations 
of rolipram. 100 % activity is denoted as that observed in the absence of inhibitor. 
The data shown is typical of an experiment done three times in triplicate, each 
using separate transfections. Resultant IC50 values are given in table 4.7.
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Figure 4.26. Dose-response curve for the inhibition of particulate 
hPDE4D4 activity by rolipram
The activity of the particulate (P2) forms of hPDE4D4 was determined in the 
presence of 1 [iM cAMP as substrate with the indicated increasing concentrations 
of rolipram. 1 0 0  % activity is denoted as that observed in the absence of inhibitor. 
The data shown is typical of an experiment done three times in triplicate, each 
using separate ti-ansfections. Resultant IC50  values are given in table 4.7.
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Figure 4.27. Dose-response curve for the inhibition of particulate 
IiPDE4D5 activity by rolipram
The activity of the particulate (P2) forms of hPDE4D5 was determined in the 
presence of 1 pM cAMP as substrate with the indicated increasing concentrations 
of rolipram. 1 0 0  % activity is denoted as that observed in the absence of inhibitor. 
The data shown is typical of an experiment done three times in triplicate, each 
using separate transfections. Resultant IC50 values are given in table 4.7.
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5 .1 . Introduction
The human cAMP-specific PDE4 family comprises a series of enzymes encoded 
by four distinct genes located on three different chromosomes. The gene for 
human PDE4A and PDE4C isoforms is localised on chromosome 19, but evidence 
suggest that they might be located on different regions (Horton et al., 1995, 
Milatovich et al., 1994, Sullivan et al., unpublished data). They are both distinct 
from PDB4B and PDE4D, which are found on chromosomes 1 and 5 respectively 
(Milatovich et al., 1994, Szpirer et al., 1995). Analysis of the catalytic 'core' 
domain shows that, whilst members of any one PDE class show 60 - 90 % 
homology in the catalytic region, those belonging to different classes are much less 
homologous (-30 %) (Bolger, 1994). The 'core' region of PDE4 can be identified 
by homology with other PDE species and is conserved throughout the PDE4 class 
(Jin et al., 1992). However, the N- and C-terminal region of PDE4A-D isoforms 
differ widely (Bolger et al., 1993). The complex family of isoforms produced by 
PDE genes results from alternative splicing, which predominantly takes the form 
of 5' domain swaps, leading to isoforms having distinct N-terminal regions 
(Figures 5.1 - 5.2). In contrast the C-terminal region of each particular PDE4 gene 
family is unique and is thus common to all active isoforms produced from a 
particular PDE4 gene (Bolger, 1994, Conti et al., 1995b).
It has been identified that the human PDE4A gene family consists of at least three 
catalytically active and two catalytically inactive isoforms. Catalytically active 
forms are; PDE46 (Bolger et al., 1993), hPDE-IVA-h6.1 (h6.1) (Sullivan et al.,
1994) and hPDE-IVA-Livi (hPDE-1) (Livi et al., 1990). Catalytically inactive 
products are; 2EL (Horton et al., 1995) and TM73 (Bolger et al., 1993) (Table 
5.1 and Figure 5.2). GeneBank accession numbers are given in table 5.1. It is 
possible that more PDE4A isoforms will be isolated in the future. Indeed, this 
study has shown that an active human PDE4A species exists in human Jurkat T-
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cells (see chapter 3) which is distinct from PDE46 with differences in molecular 
weight, sensitivity to rolipram and in its extreme N-terminal region. The 
characteristics of PDE4A family enzymes, like other members of the PDE4 family 
is that they are potently inhibited by low-concentrations of rolipram and Ro 17- 
2074, that they have a high specificity for cAMP and that they are insensitive to 
cGMP and Ca^+ /  CaM (Beavo et al., 1994, Conti et al., 1995b, Huston et al., 
1996).
The PDE46 and h6.1 isoforms have been biochemically and pharmacologically 
characterised. When transiently expressed in transfected COS7 cells human 
PDE46 was localised to both particulate and cytosol compartments, whereas h6.1 
was found only in the soluble fraction (Huston et al., 1996). The amino acid 
alignment shows that h6.1 and hPDE-1 are highly related proteins but differ with 
respect to five amino acids contained within, or adjacent to, the putative catalytic 
domain (Sullivan et ah, 1994). They both are N-terminally truncated forms of 
PDE46. It is possible that hPDE-1, the first human PDE4A to be cloned may 
reflect an artefact of cloning and, based upon h6.1 analyses may suffer from eiTors 
in sequencing (Bolger, 1994). Wilson et al. (1994) have shown that rolipram 
served as a simple competitive inhibitor of h6.1, whereas Livi et ah (1990) 
showed that rolipram inhibited hPDE-1 in a more complex fashion. The different 
inhibitory kinetic mechanisms for the action of rolipram on these two isoforms 
suggests that they may be conformationally and functionally distinct forms.
A catalytically inactive PDE4A splice vaiiant, called 2EL, was cloned from resting 
human Jurkat T-cell library (Horton et ah, 1995), which was screened with a PDE 
specific probe (Sullivan et ah, 1994). Neither the functional significance of 
producing such a protein, nor the molecular basis for lack of catalytic function is 
known. 2EL is a 323 residue protein which differs markedly from PDE46 or h6.1 
in two regions. In 2EL, the catalytic 'core' region is truncated at both its N- and
198
199
C-terminal ends (Horton et a l, 1995), leaving a portion of the 'core' region which 
reflects residues 365 and 643 in PDE46 (Bolger et al., 1993). It is believed that 
2EL represents the catalytic domain of PDE46 located within the region 
encompassed by residues 335 - 658 on the basis of homology between other PDE 
species and the cAMP binding subunit of protein kinase A (Bolger, 1994, Bolger 
et al., 1993). Therefore 2EL does contain the 'core' catalytic region common in 
other PDE4 species albeit somewhat truncated at both its C- and N-termini. 
Sequence analysis of the putative catalytic proteins by 2EL, h6.1 or PDE46 shows 
that 2EL has a sequence of 30 novel amino acids at the N-terminal sequence 
(Figure 5.1). After this region, their identity extends over a further 278 amino 
acids. At the end of the identical region, there is 34 bp insertion, within the 
catalytic region, where premature termination of 2EL occurs as a result of the 
frameshift of the 2EL open reading frame (ORE). Thus 2EL has a unique 
sequence of 15 amino acids which forms its novel C-terminal region (Horton et 
al., 1995). It is possible that loss of either or both the N- and C-terminal regions 
found in active PDE46 and h6.1 might account for 2EL being catalytically inactive. 
To investigate the function o f the unique N- and C-terminal regions of 2EL, 
H Y B l, HYB2 and D elta-1 isoforms were constructed (Dr. Sullivan, Astra 
Charnwood/U.K). H YBl was generated by replacing the unique C-terminal 
regions of the putative catalytic domain of 2EL with one reflecting that seen in the 
active PDE4A forms PDE46, h6.1 and hPDE-1. However, the chimera still has 
the unique N-terminal splice region found in 2EL togetlier with a foreshortened N- 
terminal end of the putative 'core' catalytic region (Figure 5.2). Delta-1 was 
constructed by truncation of the N-terminal region of PDE46 which lacks the 
corresponding unique 30 amino acids region of 2EL. Therefore, Delta-1 does not 
contain unique the C-terminal 15 amino acids found in 2EL (Figure 5.2). The 
HYB2 chimeric species was created by exchanging the N-terminal region of 2EL 
with the corresponding region of h6.1 to asses the effect of the N-terminal region 
of 2EL on catalytic activity (Figure 5.2). To examine the effect of the structural
I
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5 .2 .  R esu lts
5 .2 ,1 .  Sequence alignm ents of 2EL, H Y B l, H YB2, D elta-1, 
PDE46 and h6.1
corresponding unique region of 2EL. Therefore Delta-1 is similar with 2EL i.e. 
HYBl without the unique N-terminal region of 2EL.
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modification of the truncated enzymes, H YBl, HYB2 and Delta-1, were studied 
assaying the kinetics of cAMP hydrolysis, the effect of rolipram inhibition and the 
relative P^ax values (if the constructs were catalytically active).
5 .1 .2 .  Aim of the study
The purpose of this study was to investigate the role of N- and C-terminal regions 
of the inactive 2EL enzyme. For this reason. Dr. M. Sullivan generated three 
chimeras, called H Y Bl, HYB2 and Delta-1, by replacing the unique N- or C- 
teiminal regions of 2EL with the corresponding region of the active form of h6.1. 
These constructs were transiently transfected into C0S7 cells to investigate the 
effects on catalysis, rolipram sensitivity and substrate specificity. In addition, 
transcription analyses were done on these transfected cells using RT-PCR 
techniques.
The human PDE4A species, truncated form and hybrids are shown schematically 
in Figure 5.2. The amino acid sequences of the chimeric species, 2EL and h6.1 
are all aligned to the sequence of PDE46 (Figure 5.1). HYBl was generated by 
replacing the unique C-terminal regions of 2EL with that of PDE46, h6.1. HYB2
was constructed by exchanging the unique N-terminal region of 2EL with that of 
h6.1. Delta-1 was truncated in the N-terminal region of h6.1, which lacks the
experiments, activities of 1.1 ± 0.1 nmol/min/mg of protein {n ~ 3) were seen after
5 .2 ,2 .  Expression and subcellular distribution of H YBl, HYB2,
Delta-1 cDNAs in COS7 cells
H Y B l, HYB2, Delta-1, h6.1 and PDE46 plasmids (pSV.SPORT-hybl, ~hyb2, 
-delta 1, -h6.1 and -pde46 respectively), as well as native vector (pSV.SPORT) 
alone were transfected (section 2.2.12.1) into COS7 cells to express the indicated 
PDEs. HYBl was also stably expressed in a strain of Saccharomyces cerivisiae 
(Wilson, 1996). Cell homogenates were subjected to centrifugation for 1 h at 100 
000 gav at 4 “C in order to gain a high-speed pellet (P2; particulate) and supernatant 
(S; cytosolic) fraction (Section 2.2.12.3). Then, fractions were either 
immunoblotted or assayed for PDE activity at a substrate concentration of 1 pM 
cAMP. Transfection of COS7 cells with HYB1 cDNA led to an increase in the 
PDE activity of these cells of 230 ± 11 pmol/min/mg of protein in the cytosol 
fraction (mean ± SD; n -  4 different transfections). In a parallel set of
transfection to express h6.1 protein and 1.05 ± 0.2 nmol/min/mg of protein (« = 3)
:after transfection to express PDE46 cytosolic proteins. The novel PDE4 activity 
seen in pSV.SPORT-hyb 1 transfected COS7 cells was, as with h6.1 (Sullivan et 
al., 1994), found exclusively in the cytosol fraction of these cells with <5 % of the 
total activity seen in the pellet fraction. Mock transfection with the parent plasmid 
had no effect (<3 %) on either the total endogenous COS7 cell PDE activity or the
rolipram inhibited cytosol fraction.
S. cerivisiae was transfected so as to express the H Y Bl and YMS6 (h6.1) 
isoforms with the activity of soluble extracts being some 1.4±0.3 and 5-9 
pmol/min/mg of protein, respectively (Wilson, 1995, Wilson et al., 1994). This 
evidence suggests that HYB 1 is an active, chimeric novel PDE enzyme. Indeed, 
the increase in PDE activity seen in pSV.SPORT-hyb 1 transfected COS7 cells was 
unaffected (<5 % change; « = 3) by the addition of either Ca^+ /  CaM (50 pM/20
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ng/ml); which would stimulate any PDEl activity, or by 1 pM  cGMP (<5 % 
change; n -  3); which would alter either PDE2 or PDE3 activities (Kilgour et al., 
1989, Wilson et al., 1994). However, the increased PDE activity seen in these 
H YBl expressing transfected cells was inhibited by >95 % upon addition of 10 
pM  rolipram (1 pM cAMP as substrate). Such observations are consistent with 
HYBl behaving as a PDE of the PDE4 isoform class.
5 .2 .3 .  Immunological detection of H Y Bl and Delta-1
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IHowever, neither pSV.SPORT-hyb2 nor pSV.SPORT-deltal transfected COS7 
cells extracts expressed measurable PDE activity (<1 % change; n - 3 ,  different 
proteins preparations). Delta-1 was generated by the truncation of the N-terminal 
region of h6.1 which lacks the corresponding unique 30 amino acid region of 2EL. 
HYB2 chimera was constructed by exchanging the unique N-terminal region of 
2EL with the corresponding region of h6.1 (Figure 5.2). This suggests that
deletions of unique N-terminal region amino acids prevents the production of
■catalytically activity enzyme by expression of chimeric H Y Bl. Premature 
truncation at the C-terminal end of 2EL may prevent the correct assembly of a 
functional catalytic centre for the hydrolysis of cAMP by 2EL.
.3>
The alignment of PDE46 and h6.1 sequences shows that C-terminal amino acids 
are identical (Figure 5.2). Using the polyclonal antibody, raised against the C- 
terminal end of human PDE4A-GST fusion protein (section 2.2.2), allowed the 
detection of a single 82 ± 2  kDa immunoreactive species in the cytosolic fraction of 
HYBl expressing COS7 cells (Figure 5.3). However this was not observed in 
those cells which had been transfected with a control vector. From such 
immunoblot and activity studies (see section 5.2.2) it was evident that HYBl PDE 
was localised in cytosol but not in the membrane. This species was, as might be 
predicted (Figure 5.1) smaller than that of h6.1, which migrated as a 102 ± 2 kDa
.g
#
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species and PDE46 which migrated as a 127 ± 1 kDa species (means ± SD; « = 3) 
(Figure 5.3). The catalytically inactive form, truncated PDE46 specie Delta-1 was 
also expressed in COS7 cells to allow immunoblot analysis. It was found that this 
species was expressed solely in the cytosolic fraction with molecular mass of 80 ± 
2 kDa (Figure 5.3).
5 .2 .4 .  Transcriptional analysis of H Y B l and HYB2 chimeras
H Y B l, HBY2, 2EL and h6.1 plasmids were transfected into C0S7 cells as 
detailed in section 2.2.12. Then, after ~72 h, RNAs were isolated (section 2.2.15) 
from each of the transfected COS7 cell lines, transcribed into cDNA and PCR was 
performed. The sense-2069 and antisense-Pharmacia primers were designed to 
amplify a fragment unique to the 5'-end of 2EL and H Y Bl chimera which 
represent nucleotides 333 - 726 in 2EL. This allowed the detection of a 393 bp 
fragment (Figure 5.4). In order to examine h6.1 and HYB2 transcripts, sense- 
2726 and antisense-2728 primers were used to amplify a 576 bp fragment. The 
fragment amplified represents nucleotides 64 - 639 in h6.1 (Figure 5.5). The 
primer pairs and PCR conditions ate given in the appropriate figure legends. 2EL 
and HYBl specific primers yielded signals with similar intensity (changes <5 %) 
(Figure 5.4). h6.1 and HYB2 specific primers amplified to produce a higher 
intensity signal for HYB2 than h6.1.
5 .2 .5 .  Kinetics of cyclic AMP hydrolysis by H Y B l
The Km value for the hydrolysis of cAMP by the cytosol fraction of COS7 cell 
expressing HYB 1 was determined. The data was obtained from the PDE activity 
assay using 8 different cAMP concentrations (0.5 jiM to 30 jxM cAMP) as 
substrate. This was then analysed by computer fitting to the hyperbolic form of 
the Michaelis-Menten equation using the Ultrafit graphical package (section 2.2.6).
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The 'robust weighting' facility was used and the 'goodness of fit' index was no 
less than 0.99 with the estimation, 1 being a perfect fit (Figure 5.6). This analysis 
yielded a Km value of 2.7 ± 0.3 pM (« ~ 4 ) for HYBl which is similar to that 
found for this enzyme expressed in S, cerivisiae (Table 5.2). These values were, 
however, about half those seen for h6.1 but were similar to those seen for PDE46 
(Table 5.2)
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In order to determine relative V m a x  values, increasing concentrations of proteins 
(10 pM  to 30 pM) from the cytosolic fraction of transfected COS7 cells were 
immunoblotted. The anti-human PDE4A antisera (section 2.2.2) was used to 
detect the specific PDE proteins and then the labelled bands were visualised using 
the ECL procedure according to the manufacturers instructions (section 2,2.4).
The appropriate signal absorbance (A) versus amount of protein (pg) were plotted 
(Figure 5.7). Relative concentrations of PDE protein were calculated from this 
plot. For the Vmax determination, equal amounts of COS7 cell extracts (PDE 
protein) were taken for PDE assay. Then, the relative Vmax values were calculated 
using the Michaelis-Menten equation and the experimentally derived Km. values. It 
was demonstrated that HYBl was -70  % more active than the full length species 
PDE46 but much less active than h6.1 (Table 5.2).
%
5 .2 .6 .  Dose-dependent inhibition of H Y B l by rolipram
HYB 1 activity was potently inhibited in a dose-dependent fashion by the selective 
inhibitor rolipram, yielding IC50  values of -2.1 pM (« = 3) (Figure 5.8 and Table
5.2). In the inhibition studies, 3 pM cAMP concentration was used as substrate 
which reflects that of the Km value. Rolipram was used in the concentration range 
of 0.001 pM  - 100 pM. IC50  values (concentration of inhibitor which produced 
50 % reduction in substrate hydrolysis) were then calculated from the dose- 
response curve using the KaleidaGraph computer programme.
■I
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5 . 3 .  Conclusion and Discussion
Both human and rat PDE4 genes appear to produce multiple transcripts involving 
5'-domain swopping (Beavo, 1995, Conti et ah, 1995b) to yield alternative splice 
forms with different N-terminal domains. Catalytically active human PDE4A 
forms PDE46 (Bolger et al., 1993), h6.1 (Sullivan et al., 1994) and hPDE-1 (Livi 
et al., 1990) yield protein products that have identical catalytic sites and C-terminal 
regions but show highly different N-terminal domains. However, two catalytically 
inactive isoforms, 2EL (Horton et al., 1995) and TM3 (Bolger et al., 1993), also 
exhibits unique C-terminal regions as well as unique N-terminal regions. This 
suggests that these unique N- and C-terminal regions may perform specific 
functions, such as, affecting catalytic activity and interaction with other proteins. 
2EL is an enzymatically inactive PDE4A isoform by virtue of the premature 
truncation within the putative catalytic region of the enzyme (Horton et al., 1995). 
This property of 2EL could not be examined by expression in a cell system. 
Therefore the molecular basis and their functional significance are unknown. 
However, it is a possibility that 2EL and TM3 perhaps represent the products of a 
mechanism to control the level of mRNAs for functional PDEs (Horton et al.,
1995). In this study, PDE4A isoform 2EL was shown to be inactive, however, it 
was unknown as to whether this was due to the presence of 30 novel amino acids 
in the N-terminal end or an inhibitory 34 bp insert in the C-terminal end. In order 
to investigate the unique 5'- end and 3'-end roles, two constructs and one 
truncated PDE46 form (made by Dr. Sullivan) were analysed in this study. HYBl 
chimeric species was generated by replacing the C-terminal region of the inactive 
2EL with one equivalent to that seen in active splice variants PDE46 and h6.1. 
HYB2 chimera was constmcted by swopping the N-terminal unique 30 amino acid 
region of 2EL with the corresponding region of h6.1. The truncated form Delta-1 
was generated by deletion of the N-terminus of PDE46 at residues 1 - 365. These
■a
hybrids and truncated form are shown diagramatically in Figure 5.2 and theii' 
amino acid sequences are given in the alignment in Figure 5.1.
Transient transfection with HYB2 and Delta-1 cDNAs showed that they lack PDE 
activity. However, the HYBl chimera expressed cAMP-specific PDE4 activity 
indicating that it is the foreshortened C-terminal region which renders 2EL 
catalytically inactive. Deletion of the unique 30 amino acid region on HYB2 and 
Delta-1 constructs showed that this region plays an important role in rendering 
HYBl chimera catalytically active. The inhibition by low-concentrations of 
rolipram, insensitivity to Ca3+/ CaM and cGMP and specificity to cAMP suggest 
that the pSV.SPORT-hyb 1 cDNA encodes a PDE4. HYBl PDE activity was only 
seen in the cytosol fraction when expressed in COS7 cells. This was similar to 
h6.1 expressed in COSl and COS7 cells (Huston et al., 1996, Sullivan et al., 
1994). Immunoblotting studies also showed that HYBl was solely localised to the 
soluble fraction, where a novel -82  kDa immunoreactive species was seen (Figure
5.3). This species was smaller than that of h6.1 and PDE46 (Figure 5.1). Similar 
study also demonstrated that inactive construct. Delta-1, was 80 kDa protein 
(Figure 5.3).
Comparison of the Km values calculated for HYBl expressed in COS7 cells and 
S. cerevisiae (Wilson, 1995) were similar (Table 5.2). These values were, 
however, about half those exhibited by h6.1 (Sullivan et al., 1994) but were 
similar to those seen for PDE46 (Huston et al., 1996) (Table 5.2). This may 
imply that a role exists for the unique N-terminal 30 amino acid region of HYBl in 
catalysis. The relative Vmax values were determined from equalised PDE protein 
by immunoblotting (section 2.2.8). From this study, HY Bl chimera was 
demonstrated to be -70  % more active than the full length species PDE46 but much 
less active than h6.1 (Table 5.2). This was as shown by (Huston et al., 1996), 
that h6.1, which lacks the N-terminal extention of PDE46, was about 11-fold more
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active than PDE46, It has also been shown that the extended N-terminal region of 
rat PDE4A enzyme RD I was less active than the N-terminally tmncated species 
met^bRDl (Shakur et al., 1995). From these studies HYBl would be expected to 
be much more active than PDE46. This would be explained by either, the unique 
30 amino acids at the N-terminal end of HYBl having an inhibitory effect on the 
catalytic activity compared to that seen in h6 .1 , or this could be due to the 131 
amino acid extension of the N-terminus of h6 .1 enhancing the catalytic activity.
The PDE4 specific inhibitor rolipram caused dose-dependent inhibition of soluble 
H YBl activity (Figure 5.8). The calculated IC50  value for HYBl was -2 .4  fiM 
when expressed in COS7 cells and this was similar when expressed in S. 
cerevisiae (Wilson, 1995) (Table 5.2). Again these values were distinct from h6.1 
but similar to that seen for PDE46 (Huston et al., 1996) (Table 5.2). This 
obseivation indicates that the N-terminus of h6.1 must contain specific mfoimation 
for inhibitor interaction. Indeed, Wilson (1995) has demonstrated that deletion of 
either C-terminus only (608 - 692 in yeast) or the N- and C-terminus (1 - 172 and 
608 - 692 in yeast) of h6.1 PDE together, have similarly less sensitivity to 
rolipram inhibition. These findings supports that the N-terminal region of h6.1 
has a role for interaction with inhibitor and for catalytic activity.
The enzymatically active HYBl chimeric PDE demonstrated that premature 
truncation of the putative catalytic domain prevents the correct assembly of a 
functional catalytic centre for the hydrolysis of cAMP by 2EL. In addition, the 
inactive Delta-1 truncated form showed that the unique N-terminal region of 2EL 
has a functional role in rendering HYBl PDE catalytically active. Thus the splice 
variant 2EL is catalytically inactive because of the premature truncation occurring at 
the C-terminus. This region provides the basis for lack of PDE activity in 2EL.
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Table 5.1. The human PDE4A splice variants
Isoform  nam e S hort nam e Accession No Active (A) / 
Inactive (I)
HSPDE4A4B PDE46 L20965 A
HSPDE4A4C h6.1 U18087 A
HSPDE4A4A hPDE-1 M37744 A
HSPDE4A5? TM73 L20967 I
HSPDE4A8 2EL U18088 I
The table shows the isoforms of human PDE4A family with their catalytic activity 
(A) and inactivity (I). The isoforms are identified with their GenBank accession 
numbers from the references PDE46 and TM73 (Bolger et aL, 1993), h6.1 
(Sullivan et a l ,  1994), hPDE-1 (Livi et al., 1990) and 2EL (Horton et a l, 1995).
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T able 5.2, P roperties of the chim eric PDE4A species H Y B l
PD E species Cell system Km iC so
ro lip ram
R elative
Vmax
HYBl S. cerevisiae 2.4+0.2 ^ 2.010.2 #
HYBl COS7 2.910.4 2.110.5 1.710.3
h6.1 S. cerevisiae 6±2# 0.610.1 ^
h6.1 COS7 6+21! 0.610.2 H 9.610 .9
PDE46 COS7 2.310.4 H 3.510.5 (1)
Data is give for the enzymes expressed in the indicated transfected cells. Values of 
the apparent Æm (in jiM) and Vmax were determined over a wide range of cAMP 
substrate concentrations (0.5 - 30 |xM, 8 different concentrations) by fitting data to 
the Michaelis-Menten equation (section 2.2.6). Relative Vmax values were derived 
from such data upon assessment of the relative levels of expression of these 
PDE4A forms in transfected COS7 cells (2.2.8). IC50  values (in pM) for rolipram 
were derived in assays done at 3 pM cAMP as substrate. Each value is the mean ± 
SD of three independent experiments each using seperate transfections (triplicate 
determinations of each experiment). ^Data were taken from Wilson et al., 1994, 
tension  et al., 1996.
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F igure  5.1. A lignm ent o f the am ino acid sequences of the PDE46, 
h6.1, 2EL, H Y B l, HYB2 and  Delta-1
Amino acid alignments were made using the Gene Jockey programme and were 
aligned to the sequence of PDE46. ® denoted an identical amino acid residue in 
both sequences.
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F igure 5.1, A lignm ent of the am ino acid sequences of the 
PDE46, h6.1, 2EL, H Y B l, HYB2 and Delta-1
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QNEVEIPSPTMKEREKQQAPRPRPSQPPPPPVPHLQPMSQITGLKKLMH
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------------------------------------------LHQELENLNKWGLNIFCVSDYAGGRSLT
— — ----------------------------------------- LENLNKWGLNIFCVSDYAGGRSLT
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SNSLNNSNIPRFGVKTDQEELLAQELENLNKWGLNIFCVSDYAGGRSLT
SNSLNNSNIPRFGVKTDQEELLAQELENLNKWGLNIFCVSDYAGGRSLT
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2EL CIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADV
D e lta -1  CIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADV
h 6 .1  CIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADV
HYB 1 CIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADV
HYB 2 CIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYHADVAYHNSLHAADV
PDE 4 6 CIMYMIFQERDLLKKFRIPVDTMVTYMLTLEDHYPIADVAYHNSLHAADV
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ELALMYNDESVLENHHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVID
ELALMYNDESVLENHHLAVGFKLLQEDNCDIFQNLSKRQRQSLRKMVID
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F ig u re  5.2. Schem atic  rep re sen ta tio n  of hum an  PD E4A  form s, 
H Y B l and  HYB2 chim eras an d  Delta-1 trunca ted  form s 
This figure diagramatically shows the structural features of human PDE4A forms 
discussed in this study.
:
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Figure 5.2. Schematic representation of human PDE4A forms, HYBl and HYB2 
chimeras and Delta-1 truncated forms
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Figure 5.3. Immunoblot of H Y Bl and Delta-1 expressed in COS? 
cells
The plasmids encoding h6.1, H YBl, PDE46 and Delta-1 were transfected into 
COS7 cells and the cytosol (S) fractions were yielded by high-speed centrifugation 
(2.2.12.3). Samples were then subjected to SDS/PAGE followed by Western 
blotting using the C-terminus human PDE4A specific antiserum. Data is typical of 
experiments done three times using separate transfections.
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Figure 5.4. Transcriptional analysis of HYBl chimera by RT-PCR
Total RNA was extracted from COS7 cells transfected with HYBl and 2EL 
plasmids. RT-PCR was performed as described in sections 2.2.16-17. Primers 
were used to amplify a 393 bp fragment. These primers were: sense-2069 
ATGGTGCTTCCTTCAGACCAAGG and antisense-Pharmacia CGGCGAGAA- 
TCTCCAGGTCC. PCR reaction employed 1 min at 95 °C, 70 s at 58 °C and 100 
s at 72 °C for 35 cycles. The products were then electrophoresed on 1.5 % 
agarose gel and visualised with ethidium bromide under UV light. These results 
are representative of three experiments using RNA from different isolations.
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Figure 5.5. Transcriptional analysis of HYB2 chimera by RT-PCR
Total RNA was extracted from COS7 cells transfected with HYB2 and h6.1 
plasmids. RT-PCR performed as described in sections 2.2.16-17. Primers were 
used to amplify a 576 bp fragment. These primers were: sense-2726 AAGGC 
CACGCTGTCA and antisense-2728 GATGCGGAATTTCTTCA. PCR reaction 
employed 1 min at 95 °C, 70 s at 57 °C and 100 s at 72 °C for 35 cycles. The 
products were then electrophoresed on 1.5 % agarose gel and visualised with 
ethidium bromide under UV light. These results are representative of three 
experiments using RNA from different isolations.
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Figure 5,6. Determination of K m  for the cytosolic H Y Bl fraction
Cytosolic HYBl extracts were isolated from COS7 cells transfected with the 
HYB 1 plasmid. Æm values were deteimined over a substrate range 0.5 to 30 pM 
cAMP. Km values were calculated using the Ultrafit programme as described in 
section 2.2.6 and the data is shown in table 5.2. This experiment is representative 
of one earned out three times.
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Figure 5.7. Linearity of detection of various concentrations of 
cytosolic I1 6 .I  and H Y B l
This data shows that using increasing concentrations of cytosolic protein (5 - 10 
pg) from COS7 cells transfected with indicated cDNAs, a linear relationship 
between intensity and applied protein was observed. The proteins were 
immunoblotted with human PDE4A antibody and the blots were scanned. The 
intensity of the resultant signal is plotted for each plasmid. Such analyses were 
used to determine the relative amounts of indicated PDEs for the determination of 
relative Vmax values in table 5.2.
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F igu re  5.8. D ose-response cu rve  fo r the in h ib itio n  of cytosolic 
H Y B l activity by ro lip ram
The activity of the soluble forms of HYB 1 was determined in the presence of 3 pM 
cAMP as substi'ate with the indicated concentrations of rolipram. 100 % activity is 
denoted as that observed in the absence of inhibitor. The data shown is typical of 
an experiment done three times in triplicate, each using separate transfections. 
Resultant IC50 values are given in table 5.2.
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6 . 1 .  FINAL DISCUSSION
Homeostasis of intracellular cAMP levels is critical to the regulation of many 
cellular responses to extracellular stimuli such as hoimones and neurotransmitters. 
This is achieved through the regulation of both cAMP synthesis by adenylate 
cyclases and its degi'adation by cyclic nucleotide phosphodiesterases (PDEs). This 
system is also dependent upon protein kinase A which after activation subsequent 
to increase cAMP levels phosphoiylates serine/threonine residues of target proteins 
either in the nucleus or in the cytoplasm. Thus the cAMP signalling system 
provides on part of the core machinery needed for the integi'ation of signalling 
within the cell.
PDE isoform expression is tissue specific and can be differentially regulated by 
hormones. That individual PDE enzymes are regulated in both positive and 
negative manners has highlighted their pivotal role in mediating cross-talk between 
second messenger pathways. It has also provided a conceptual basis for 
understanding many of the distinctive, cell type-specific differences in the 
amplitude and duration of cAMP signals produced in response to stimulation of 
adenylate cyclase.
Increased cAMP has been associated with inhibition of the function of various 
types of cells including immune and inflammatory cells. The mechanisms by 
which cAMP modulates cell function are not completely understood. However, it 
appears to depend on the activation of PKA and subsequent phosphorylation of its 
target proteins which are expressed in a cell-specific fashion. A study in T-cells 
has been shown that activated PKA down-regulates c-Jun N-terminal kinase 
(INK) activity (Hsueh & Lai, 1995, Tamir et al., 1996) which then blocks T-cell 
activation including IL-2 secretion (Su et ah, 1994).
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It has been demonstrated that PDE4 enzymes play a predominant role for cAMP 
hydrolysing activity in lymphocytes, monocytes, eosinophils, leukocytes,
In this study I have shown that the up-regulation of PDE4 activity can occur in
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basophils and mast cells (Erdogan & Houslay, 1997, Manning et al., 1996,
Teixeira et al., 1996, Torphy & Undem, 1991, Toiphy et al., 1995). These cells 
have been implicated in various diseases such as arthritis, asthma and multiple 
sclerosis, for instance where elevated cAMP levels attenuate their functioning and 
thus inflammatory responses. Currently, therefore, members of the PDE4 family 
provide molecular targets for the design of novel therapeutic agents caried at 
treating these diseases.
response to either chronic stimulation of adenylate cyclase or a cAMP elevating
agent. This led to the production of novel PDE4D transcripts and increased 
.expression of specific PDE4D isoforms in Jurkat T-cells. In addition to this, the 
PDE3 activity was also increased in two distinct phases. Namely, rapid transient 
one followed by a delayed phase in response to cAMP elevating agents. The 
profound 'up-regulation' of both PDE3 and PDE4 activities were blocked by the
■
■I
transcriptional inhibitor factor actinomycin D, suggesting that RNA synthesis was 
necessary for the rise in these PDE activities. To define the roles of individual 
PDEs on the hydrolysis of cAMP, selective PDE inhibitors were added to Jurkat 
T-cells together with the adenylate cyclase activator, forskolin. The PDE4 
selective inhibitor rolipram enhanced the forskolin-induced elevation of 
intracellular cAMP concentrations to levels which were similar to those seen with 
IBMX which is non-selective PDE inhibitor. This suggests that bulk cAMP levels 
are determined almost exclusively by PDE4 enzymes. Indeed, whilst PDE3 
activity predominated in unstimulated Jurkat T-cells, the PDE3 selective inhibitor 
cilostimide was only weakly capable of enhancing forskolin stimulated cAMP 
accumulation. Indeed, a similar situation has been seen for thymocytes (Marcoz et
i
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al., 1993b). Thus PDE4 activity appears to play a major role in controlling 
intracellular cAMP levels in Jurkat T-cells.
Using transcript analysis, immunoprécipitation and immunoblotting I demonstrated 
that unstimulated Jurkat T-cell PDE4 activity was solely due to a 118 kDa PDE4A 
isoform. The size of this species does not coiTelate with any known PDE4A form 
and RT-PCR analysis suggested that this was a novel long PDE4A form. 
Intriguingly, PDE4A activity appeared to decrease -50  % after forskolin exposure. 
The down-regulation of PDE4A protein and mRNA levels in Jurkat T-cells 
contrasts with the effect of chronically elevated cAMP levels in monocytic cell lines 
(M anning et al,, 1996, Torphy et al., 1995, Verghese et al., 1995) where 
increased PDE4A expression was seen. However, the PDE4A splice variant 
expressed in those cells appears to reflect the 125 kDa PDE46 species (Manning et 
al., 1996, Verghese et al., 1995). Similar to these results, Engels et al. (1994) 
have reported that elevated intracellular cAMP levels led to an increase in PDE4A 
species in another Jurkat T-cell line (JKE6-1). This may indicate differences 
between various Jurkat T-cell lines. However, in a similar fashion to the Jurkat T- 
cell studied here, elevation of cAMP levels down-regulated PDE4A mRNA and 
protein levels in rat hepatocyte P9 cells chronically exposed to forskolin (Zeng, L. 
& Houslay, MD., unpublished data). Thus cell-type-specific changes in PDE4 
splice variants expression can occur in response to elevation of cAMP levels.
Neither PDE4B nor PDE4C transcripts were detected in either untreated or 
prolonged forskolin treated Jurkat T-cells. However, unlike Jurkat T-cells, long- 
tenn elevation of cAMP has been shown to increase PDE4B transcripts in human 
monocytes and a human monocytic cell line (U937) (Manning et al., 1996, Torphy 
et al., 1995) and rat Sertoli cells (Swinnen et al., 1991b). This suggests that the 
expression of various PDE4 splice variants may be very different and this may 
relate to their cell-specific functions.
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It has been shown that challenge of various cells with either hormones or cAMP 
elevating agents induces the 'short' forms (PDE4D1 and PDE4D2) of the PDE4D 
enzyme family. Studies with follicle-stimulating (FSH), thyroid-stimulating
hormones (TSH) and dibutyryl cAMP indicated that the 'short' forms, PDE4D1
and PDE4D2, were induced by the elevation of intracellular cAMP levels in rat 
Sertoli cells (Sette et al., 1994b, Swinnen et al., 1991b). Similar results have 
demonstrated using human monocytes and human monocytic cell lines (Mono Mac 
6 ), namely that chronic elevation of intracellular cAMP levels cause the up- 
regulation of PDE4DI and PDE4D2 (Verghese et al., 1995). In this study I 
showed that chronic exposure of Jurkat T-cells to the adenylate cyclase activator 
forskolin led to induction of the 'short' forms of PDE4D enzymes (Erdogan & 
Houslay, 1997). Whilst RT-PCR analysis implied a large increase in transcripts 
for PDE4D1 and PDE4D2, the induction of PDE4D protein expression appeared to 
be completely dominated by PDE4D1. None of the 'long' forms of PDE4D 
(PDE4D3, PDE4D4 and PDE4D5) enzymes were present in quiescent Jurkat T- 
cells, nor was their expression detectable after chronic exposure to forskolin.
'::S
The situation described above differs from  that described by (Sette et al., 1994a) 
where PKA has been demonstrated to mediate the expression of 'short' forms of 
PDE4D1 and PDE4D2, whilst increasing activity of PDE4D3 by phosphorylation
in response to TSH in FRTL-5 thyroid cells. TSH causes a transient elevation of 
intracellular cAMP levels and this led to rapid increase in PDE4D3 activity which 
can be seen within 3 min of TSH application and which returns to basal levels after 
15 min. Unlike the 'short' forms the PDE4D3 isoform can be phosphorylated 
through the action of protein kinase A. This has also been shown for the 
recombinant enzyme expressed in MA-10 cells and insect Sf9 cells (Sette & Conti, 
1996, Sette et al., 1994a, Sette et al., 1994b). The target phosphoiylation site has 
been shown to be serine54 residue, which is located in the U CRl region of
PDE4D3. This variety in the regulation of the various 'short' and 'long' PDE4D
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forms suggests that splice variants from the same locus may have specific 
functional roles.
It is appears currently that the PDE4D gene produces more isoforms than any other 
cAMP-specific PDE4s. Four cloned active human PDE4D isoforms, namely 
PDE4D1, 4D2, 4D3 and 4D4 (Bolger et al., 1993, Bolger et al., 1997, Nemoz et 
al., 1996) and three rat PDE4D isoforms (PDE4D1, 4D2 and 4D3) (Bolger et al., 
1994, Jin et al., 1992, Sette et al., 1994b, Swinnen et al., 1989a) have been 
reported. In addition to human splice variants a novel PDE4D5 has recently been 
cloned from HeLa cells (Bolger et al., 1997). Although five members of the 
human PDE4D isoforms have been cloned, no study has been done to compare 
their characteristics.
The PDE4D1 species and PDE4D2 form which lack UCRl are the so called ’short’ 
PDE4D forms. These were first isolated from rat by (Swinnen et al., 1989a) who 
suggested that PDE4D1 was found in both cyctosolic and low-speed particulate 
(PI) fraction of COS7 cell transfected cells. However, whilst <20 % of the PDE 
activity was found in PI fraction it was unclear as to how much of this was due to 
either the presence of unbroken cells or to residual cytosol as the pellet fraction had 
not been subjected to any washing procedures. Five human PDE4D isoforms 
were characterised and expressed in C0S7 cells in this study (chapter 4) (Bolger et 
al., 1997). Fractionation studies demonstrated that the two 'short' fomi activities 
were found exclusively in the cytosol (>94 %) whereas, the three 'long' forms 
were found in the both cytosol and the pellet fractions. PDE4D3 and PDE4D5 
were located ~35 % in the combined particulate fractions (PI and P2) and this 
value rose to -60  % for PDE4D4. Whilst the molecular basis of such differences 
has yet to be ascertained it is very clear that its basis must lie in the very different 
nature of the N-terminal alternatively spliced regions. Indeed, the 'short' rat 
PDE4A species RDI was found exclusively associated with the membrane (P2)
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fraction (Scotland & Houslay, 1995, Shakur et al., 1993). However, the mutant 
met^^-RDl, which was engineered by the deletion of unique N-terminus first 25 
amino acids of RD I, proved to be a solely cytosolic PDE (Shakur et al., 1993). It 
is thus suggested that a membrane targeting domain is found within the extreme N- 
terminal domain of RDI.
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ÎSolubilisation of various PDE proteins from membrane/particulate fractions has indicated that attachment could also be effected in rather different ways. In 
contrast to the PDE4A forms (rPDE6 , PDE39, PDE46) (Bolger et al., 1996, 
Huston et al., 1996, McPhee et al., 1995) and PDE4B form (PDE4B3) (Huston et
al., 1997) which were not solubilised by detergent added together with high 
[NaCl], PDE4B1/2 (Huston et al., 1997), all three 'long' forms of PDE4D (in 
chapter 4) proteins were completely released by such a treatment. In contrast, 
detergent alone served only to partially release PDE4D3 and PDE4D5 and did not 
release PDE4D4 at all. High [NaCl] alone partially solubilised PDE4D5 but had 
little effect on PDE4D3 and PDE4D4. This suggests that the differences in the 
mode of anchorage of these PDE isoforms is likely to be attributable to distinct 
properties of their extreme N-terminal domains and distinct interacting species.
Selective PDE4 inhibitor rolipram caused dose-dependent inhibition of both 
cyctosolic and particulate forms of the five PDE4D enzymes expressed in COS7 
cells. These inhibitions were similar to other known human PDE4 isoforms (0.05- 
6  |iM) (McPhee et al., 1995, Huston et al., 1997, Owens et al., 1997).
However, the IC50  values of the particulate forms of PDE4D3 and PDE4D5 were
2- to 7-fold higher than those of their respective cytosolic fomis. This suggest that 
the membrane-association of these enzymes can influence the sensitivity of 
components to inhibition by rolipram (Wilson et al., 1994, Bolger et al., 1996,
McPhee et al., 1995).
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The iCfn values for cAMP utilisation of all PDE4D isoforms were in the range of
0-7 - 13 |xM. These values were similar to the other PDE4 enzmes, with values 
within the range of 1 - 5 jiM (Huston et ah, 1997, Huston et al., 1996, McPhee et 
ah, 1995, Wang et al., 1997). The value of cytosolic PDE4D4 was 2-3-fold 
higher than that of the other four cytosolic enzymes indicating an isoform specific 
difference. Analysis of the particulate forms shown that the catalytic activity of 
PDE4D4 and PDE4D5 was -3-fold higher than that of their respective cytosolic 
PDE forms. In contrast to this the cytosolic and particulate forms of PDE4D3 
were very similar. Although all members of the PDE4D family share identical core 
catalytic domains, the properties of these enzymes were rather different. This 
provides evidence that the N-terminal regions of the PDE4D proteins can regulate 
their biochemical properties.
I
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The human PDE4A splice vaiiant 2EL was cloned from resting Jurkat T-cells 
(Horton et al., 1995). 2EL exhibits both a 5' domain swap together with an 
insertion toward the 3' end which results in a frameshift inducing premature 
truncation witliin the putative catalytic region of the enzyme. Transfection into the 
either COS 1 or COS7 cells or S. cerevisiae demonstrated that 2EL exhibits no 
detectable catalytic PDE activity (Horton et al., 1995, Sullivan et al., 1997, 
Wilson, 1995). This species consists of a segment of 278 residues found within 
the catalytic core together with small and unique N- and C-terminal regions of 30 
and 15 residues, respectively. The lack of activity of 2EL suggests that sequences 
outwith this central segment are essential to maintain functional integrity of the 
catalytic unit.
To investigate the functional role of N- and C-terminal regions the chimeras and 
truncated form were studied. Replacing the unique C-terminal domain (HYB1 
chimera) reconstituted activity whilst replacing the N-terminal domain did not 
(HYB2 chimera) (Figure 5.2). The catalytically active HYBl chimera showed
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similar rolipram sensitivity, insensitivity to cGMP and Ca^+ /  calmodulin and 
subcellular distribution with an active PDE4A form called h6.1. However, HYBl
exhibited a Km value for cAMP which was about half of exhibited by h6.1, but 
was similar to that seen for a full length PDE4A species PDE46. The HYB 1 
chimera was enzymatically as active as PDE46 but was less active than h6.1. 
These variations may suggest that unique N-terminal 30 amino acid region of 
HYBl can influence the functioning of catalytic unit. Indeed, in support of this, 
the truncation of the N-terminal region of 1 - 365 residues of the active PDE46 
(Delta-1 mutant), which lacks the corresponding unique 30 amino acids region of 
2EL, was catalytically inactive. This not only demonstrates that 2EL is 
catalytically inactive by virtue of C-terminal truncation alone but also suggests that, 
again, the unique 30 amino acid residues found in N-terminal region of 2EL can 
affect the structure (folding ?) (Houslay, 1996) of the catalytic unit and will in fact 
maintain its activity.
The physiological function of both inactive human PDE4A splice variants 2EL 
(Horton et al., 1995) and TM3 (Bolger et al., 1993) is not understood at present. 
One suggestion is that the mRNAs of these non-functional splice variants may 
control the level of mRNA for functional PDEs. Alternatively they may be 
expressed as proteins which form complexes with the functional species and serve 
to modulate theh activity.
The control of cAMP PDEs appears to play as an important role in regulating the
metabolism of cAMP as adenylate cyclase. In this regard it will be critical to 
determine which PDE isoforms are expressed and regulated by the immune and *
inflammatory cells as well as other cell systems concerning with different 
pathogenetic states. A consistent finding of many laboratories has been shown that 
inhibition of PDE4 enzymes causes suppression of inflammation. Thus, 
individual PDE4s are likely to be good targets for therapeutic intervention of
diseases which are related to changes in cAMP levels. However, despite 
development of many PDE4 inhibitors, they appear to have some side effects such 
as emesis. Sub-family specific therapeutic agents may avoid such an unwanted 
effect and provide a specific cure for diseases involving inflammation.
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